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Sarcomas are a group of rare and heterogeneous mesenchymal neoplasms. In contrast to other 
malignancies, sarcomas can arise in patients of any age and occur at almost any anatomic 
site. Sarcomas also display a wide spectrum of behaviour and variable clinical outcomes. 
Tumours are typically grouped into two broad categories; soft tissue sarcomas (STS) and 
bone sarcomas. Traditional morphological evaluation,  immunohistochemical tests and 
molecular genetic assays have now enabled characterisation of more than one hundred 
distinct histological subtypes.
1
 This thesis will principally focus on the larger group of 
patients with STS, although patients with bone sarcomas will also be considered where 
relevant. 
Soft tissue sarcomas account for less than 1% of all cancer diagnoses in adults, however, 
occur relatively more frequently in adolescents and young adults (6-8%) and children (8-
12%).
2–4
 The European incidence of STS is estimated to be around 5.6 per 100000 per year, 
although this figure is likely to underestimate the true incidence as national cancer registries 
are often incomplete.
5–7
 The aetiology is often unknown, however recognised risk factors 
include older age, von Recklinghausen’s disease, Li-Fraumeni syndrome, previous radiation, 
HIV infection and exposure to certain chemicals.
2,8,9
 Patients with rare cancers such as STS 
encounter many challenges including delay in diagnosis, difficulty accessing specialists 





Treatment guidelines recommend a multidisciplinary approach to the management of all 
patients, and studies have consistently demonstrated the importance of expert management at 
a specialist (reference) centre.
9,11–14
 Localised tumours are generally treated with wide 
surgical excision and (neo)adjuvant radiotherapy for high risk patients; high grade, deep, 
>5cm, positive surgical margins. Approximately half of patients with initially localised (high 
grade) sarcomas will develop metastatic disease; most commonly haematogenous 
dissemination resulting in pulmonary metastases.
15
  Systemic chemotherapy is the mainstay 
of treatment for patients with advanced or metastatic disease, although localised approaches 
such as metastastectomy can be considered in patients with indolent, oligometastatic disease. 




Outcomes for patients with metastatic STS are poor (12-18 months) although there are a 
minority of long term survivors (five year survival rate 5-8%).
16,17
  
Personalised medicine: where is the focus? 
In the current era of personalised medicine, cancer prevention and treatment strategies are 
increasingly tailored to the individual characteristics of patients. Although there is no 
universally accepted definition, European Union Health Ministers have published the 
following description of personalised medicine: “A medical model using characterisation of 
individuals’ phenotypes and genotypes (e.g. molecular profiling, medical imaging, lifestyle 
data) for tailoring the right therapeutic strategy for the right person at the right time, and/or to 
determine the predisposition to disease and/or to deliver timely and targeted prevention.”
18
 
Improvements in diagnostic techniques, development of targeted drugs and immune-based 
therapies have revolutionised outcomes for patients with many cancers. Gastro-intestinal 
stromal tumours (GIST) are the most notable example in the field of sarcomas, where KIT 
and PDGFRA signalling have been successfully targeted with tyrosine kinase inhibitors such 
as imatinib.
19
 Immunotherapy trials in STS have been disappointing to date; attributed to the 
comparatively low mutational burden of most STS subtypes.
20
 The ultimate goal is to provide 
a personalised approach for each individual, which not only considers the aforementioned 
approaches, but also takes into account characteristics such as patient age, beliefs, values, 
preferences and their social context.  
Patient-reported outcomes and personalised care 
There is increasing recognition of the importance of patient-reported outcomes (PROs) in 
providing a patient-centered, personalised approach to treatment. Patient-reported outcomes 
(PROs) are “any report of the status of a patient’s health condition that comes directly from 
the patient, without interpretation of the patient’s response by a clinician or anyone else.”
21
  
Health-related quality of life (HRQoL) is the most commonly used PRO and is a 
multidimensional concept that integrates the patient’s perception of the impact of the disease 
and its treatment on physical, psychological, and social functioning.
22
  
Monitoring of PROs can enable timely detection of symptoms and facilitate early response to 
problems. This has been shown to improve symptom control and satisfaction with care, 
reduce hospital admissions, enable patients to remain on treatment for longer and may confer 






 PRO data can also be combined with clinical data to provide more 
comprehensive evidence of the net clinical benefit of a treatment.
25
 Regulatory authorities, 
including the United States Food and Drug Administration (FDA) and European Medicines 
Agency (EMEA), now incorporate PRO assessments in the evaluation and labelling of 
medicinal products.
22,25–27
 PRO data can also enhance patient-centred decision-making 
through tailored information provision and can empower patients to become more involved in 
their care.
28
 Although it is widely acknowledged that evaluation of new treatments should 
consider impact on both length- and quality of life, PROs are not routinely included as 
endpoints in clinical trial. Furthermore where PROs are included in randomised clinical trials 
for patients undergoing cancer treatments, the data are frequently under-reported and subject 
to delay in publication.
29–35
  
Patient-reported outcomes in sarcoma research 
It is well recognised that patients with STS often experience significant physical and 
psychological symptoms with an adverse influence on HRQoL.
36,37
 Although PRO research 
is a rapidly evolving field, data in patients with advanced STS are lacking. Existing studies 
have focused on specific groups of patients, principally survivors of localised extremity STS, 
or subgroups of patients with advanced STS.
37–40
 Several drugs have been approved for 
advanced and metastatic STS over recent years, however data on the short- and long-term 
impact of these treatments on HRQoL have not been systematically measured in clinical 
trials. The PALETTE (Pazopanib for Metastatic Soft Tissue Sarcoma) trial was one of the 
few recent sarcoma trials to include HRQoL as an exploratory endpoint.
41
 In this study for 
advanced STS patients, pazopanib (2
nd
 line treatment or beyond) improved progression-free 
survival compared with placebo without relevant deterioration in HRQoL.
41
 This exemplifies 
how HRQoL and clinical data can be combined to determine the overall benefit of treatment 
and may augment treatment discussions with patients. 
Aims and organisation of thesis 
This thesis will be subdivided into two sections. The first section of this thesis will address 
HRQoL, preferences and expectations of patients with advanced or metastatic STS treated 
with palliative chemotherapy, and consider how these data can be used to enhance 
personalised care. The second section will address age-specific clinical outcomes of patients 




with advanced STS, and age-specific experiences of patients with sarcomas (STS and bone 
sarcomas).  
Part 1: Health-related quality of life 
Patients with advanced STS have a poor prognosis and often experience a substantial burden 
of symptoms. Palliative chemotherapy is the principal treatment modality and anthracyclines 
have been standard first-line treatment since the 1970s. Several recent randomised phase 3 
clinical trials have failed to demonstrate any survival benefit with doxorubicin combination 
therapies compared to single-agent doxorubicin.
44–47
 The efficacy of anti-cancer treatments 
has historically been assessed through objective measures such as radiologic response, 
progression-free and overall survival. Physician-reported symptomatic adverse events 
frequently underestimate the frequency and severity of toxicity from the patient’s 
perspective.
48
 Clinical and biochemical measures may not capture what is meaningful to 
patients, whereas assessment of how patients feel and function can provide invaluable, 
additive information. 
In advanced STS, where cure is not possible and survival benefits of systemic treatment are 
limited, improvement of HRQoL is a primary goal of treatment. HRQoL has been shown to 
be of at least equal importance to survival in many patients with advanced cancers.
49
 Despite 
this, the impact of standard chemotherapy and novel therapies on HRQoL has not been 
studied systematically in clinical trials nor consistently measured in clinical practice. Given 
low chemotherapy response rates, lack of validated biomarkers for response and potential 
treatment related adverse events, HRQoL data could enhance discussions surrounding the 
risks and benefits of treatment, and empower patients during treatment decisions. Chapter 2 
of this thesis is based on the ‘HOLISTIC’ study protocol (Health-related quality Of Life In 
patients with Soft TIssue Sarcomas treated with Chemotherapy). The concept for the 
HOLISTIC study was developed in collaboration with patients, families and patient 
advocates who felt that there was a lack of information regarding the impact of chemotherapy 
on HRQoL in order to make well informed decisions. The principal aim of the study is to 
determine trajectories of HRQoL in patients with advanced STS receiving palliative 
chemotherapy; final results are awaited. 
In the setting of advanced STS, patient values and preferences are an important component of 
treatment decisions. Patient values and priorities may be influenced by factors such as life 




experiences, family, friends and current health status.
50
  Furthermore, despite the palliative 
intent of treatment, studies indicate that many patients with advanced cancers consider that 
treatment may be curative and are therefore willing to accept a treatment that may adversely 
impact their quality of life.
51,52
 Although it is acknowledged that patients ‘should’ be involved 
in treatment decisions, current treatment guidelines are focused around providing evidence-




Expectations of palliative chemotherapy, treatment preferences and degree to which patients 
with advanced STS want to be involved in decisions have not previously been studied in 
patients with advanced STS but may help to guide delivery of personalised care. 
Consequently Chapter 3 will explore the preferences and expectations of patients with 
advanced STS starting palliative first-line chemotherapy.   
Part 2: Age-specific considerations  
It is well-established that patient age has a significant influence on cancer biology, treatment 
efficacy, tolerance and outcomes.
42
 Age-appropriate models of care have been shown to 
improve clinical outcomes and satisfaction with care.
43
 This is particularly well-demonstrated 
in setting of paediatric cancers, where multicentre, international trials have led to dramatic 
improvements in survival over the last 50 years. Unfortunately other groups of patients have 
not benefitted in the same way from these structured services. Adolescents and young adults 
(AYA), aged 15-39 years, are a notable example where patients often fall between services 
for paediatrics and adults. This has led to slower progress in survival outcomes. Elderly 
patients, aged 65 years and older, are also a vulnerable group of patients who are frequently 
under-treated based on chronological age and face other challenges such as inadequate social 
support and limited transport options. This thesis will address gaps in the understanding of 
outcomes and experiences of patients with sarcoma in these two age groups, and more 
detailed objectives are discussed below.  
Sarcomas can affect patients of any age, although significant differences are observed in the 
distribution of individual histological subtypes across the age spectrum. Although rare in 
adults, STS are proportionally more common among children, adolescents and young adults. 
Mortality rates are high compared to most other cancers affecting young people (e.g. germ 
cell tumours), contributing to substantial loss of life years. It is acknowledged that STS 




arising in AYA have distinct biological and genomic features compared to children and older 
adults.
54
 AYA are vulnerable to delayed diagnosis as cancer may not be suspected in this age 
group, and face unique psychosocial challenges (e.g. employment and fertility) during this 
phase of transition in their lives.
55
 Young patients often receive intensive treatments with 
potential adverse consequences for long term survivors including infertility, cognitive 
dysfunction, altered mobility and risk of secondary malignancies.
56
 Chapter 4 will evaluate 
treatment patterns and clinical outcomes of young adults with advanced STS treated at a 
specialist sarcoma centre. The aims of this chapter are to provide data to augment discussions 
with patients and their families on potential treatments and possible outcomes, and inform 
strategies for future research studies.   
Owing to increasing life expectancy, elderly patients are the fastest growing section of the 
population, and more than half of all sarcoma diagnoses occur in this age group.
57
 
Chronological age can influence clinical decision-making and elderly patients are often 
undertreated due to (mis)perception of frailty and tolerability.
58,59
 Elderly patients with 
cancer are widely under-represented in clinical trials and therefore a robust evidence base for 
treatment in these patients is lacking. Chapters 5 and 6 will evaluate the clinical outcomes of 
elderly patients (aged >65 years) treated within international randomised clinical trials of 
systemic treatment for advanced STS in order to guide clinical decision-making. Chapter 6 
will also discuss the prevalence of treatment-related adverse events and relevance of these 
data for treatment decisions.  
Part 2 of this thesis will also consider age-specific experiences of patients with sarcomas 
based on results from a national survey of sarcoma patients (STS and bone sarcoma) in 
England. Chapter 7 will address age-specific differences in the diagnostic and treatment 
pathways, information provision, prevalence of symptoms and post-treatment concerns. 
In Chapters 8 and 9 the principal findings of this thesis will be discussed and consideration 
given to the implications for future research and clinical practice. Chapter 8 provides the 
summary in Dutch.  
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Introduction: Chemotherapy is the mainstay of treatment for patients with advanced soft 
tissue sarcomas (STS). Treatment intent is usually palliative, aiming to improve symptoms, 
stabilise or reduce tumour-burden and extend life. Clinical trials have traditionally used 
radiological response, time to progression and survival as measures of treatment efficacy. 
Health-related quality of life (HRQoL) is at least equally important or more important than 
survival for many patients with advanced cancer. Systematically collecting HRQoL data 
during chemotherapy can provide greater insight into treatment efficacy from the patient 
perspective.  
The primary aims of this study are to evaluate HRQoL in patients with advanced STS treated 
with chemotherapy over time, explore the decision-making process and patient reflection 
post-treatment.  
Methods and analysis: This is an observational, international cohort study for 132 patients 
aged 18 years with advanced STS treated at eight centers (three in United Kingdom, five in 
the Netherlands). Patients will be recruited prior to starting first-line or third-line 
chemotherapy and invited to complete questionnaires using the Patient-Reported Outcomes 
Following Initial treatment and Long-term Evaluation of Survivorship registry (PROFILES) 
registry; an established international registry for collection of cancer patient-reported 
outcomes. Online (or paper) questionnaires will be completed at baseline, each cycle of 
chemotherapy and 2-3 monthly during follow-up. The questionnaire package includes the 
Decisional Conflict Scale, Control Preferences Scale, Quality-Quantity Questionnaire, 
treatment expectations, European Organisation for the Research and Treatment of Cancer 
Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30), EORTC financial toxicity items, 
Work Ability Index, Functional Assessment of Cancer Therapy-General (FACT-G) items and 
Decisional Regret Scale. Clinical data will be extracted from patient records and linked with 
questionnaire responses. The primary outcome measure is the change in global HRQoL from 
baseline to after cycle 4 of first-line chemotherapy (based on published data showing that 
patients with advanced STS complete a median number of four cycles of first-line 
chemotherapy).  
Ethics and dissemination: Heath Research Authority and Research Ethics Committee (REC 
17/NI/0197). Results from the Health-related quality Of Life In patients with advanced Soft 
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TIssue sarcomas treated with Chemotherapy (HOLISTIC) study will be published in peer-
reviewed journals and disseminated at local, national and international conferences. We will 
also present our findings at any appropriate patient meetings and involve patients in study-
related publications. 























Soft tissue sarcomas (STS) are a group of rare and heterogeneous tumours, which account for 
approximately 1% of solid malignancies in adults.
1
 Due to the rarity and diverse presentation 
of STS, diagnosis can be delayed and around 10% of patients will present with metastatic 
disease.
2–5
 Furthermore, many STS demonstrate an aggressive phenotype and approximately 
half of patients with high grade localised tumours will develop metastatic disease after initial 
curative treatment.
3,6
 Despite advances in the treatment of many other cancers, the prognosis 




Chemotherapy is the mainstay of treatment for patients with advanced STS. Other options 
include active surveillance for those with indolent or asymptomatic disease, radiotherapy or 
local therapies (e.g. radiofrequency ablation or surgery) for patients with oligometastases, 
and best supportive care for those with end-stage disease and poor performance status.
6
 The 
principal aims of chemotherapy are to ameliorate symptoms, slow or halt tumour growth and 
prolong survival.
9
 Standard first-line treatment, for the majority of STS subtypes, is 
anthracycline-based chemotherapy (usually doxorubicin), administered three-weekly up to a 
maximum of six cycles due to the risk of cumulative cardiotoxicity. The combination of 
doxorubicin with ifosfamide is associated with higher response rates and longer progression-
free survival, however with no improvement in overall survival and at the expense of 
increased toxicity.
10
 Doublet therapy may be considered for certain patients in whom a rapid 
response is clinically desirable, such as those with highly symptomatic chemosensitive 
disease.
10
 Other first-line chemotherapy regimens include weekly paclitaxel for patients with 
angiosarcoma and (rarely) low dose cyclophosphamide +/- prednisolone for frail, often 
elderly patients.
11,12
 A number of systemic agents are available following first-line 
anthracycline-based therapy, including trabectedin, pazopanib, gemcitabine +/- docetaxel, 
dacarbazine and eribulin. 
Radiological response to first-line chemotherapy for advanced STS ranges from 10-50% 
(according to response evaluation criteria in solid tumours (RECIST version.1.1)), and is 
dependent on patient-specific factors, tumour histology and chemotherapy regimen.
6
 
Treatment decisions are often challenging due to modest response rates and potential 
treatment-related adverse side effects. For many patients with advanced cancer, health-related 
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quality of life (HRQoL) is equally important or more important than survival when making 
treatment decisions.
13,14
 HRQoL is a multidimensional concept that represents the patient’s 
perception of a disease and its treatment on physical, psychological and social aspects of their 
life.
15
  Systematically collecting HRQoL data over time may provide greater insight into 
treatment efficacy from the patient perspective and may enable a more detailed assessment of 
the risk-benefit ratio of chemotherapy for each individual patient.
16
 
The efficacy of systemic therapies in patients with cancer has traditionally been evaluated 
with dimensional radiological response, progression-free survival and overall survival. The 
burden of symptoms in patients with advanced STS is high, particularly pain and dyspnoea.
17
 
Despite the high symptom burden and palliative intent of treatment for most patients with 
advanced STS, the degree to which chemotherapy reduces symptoms of disease, improves or 
stabilises daily functioning and impacts health-related quality of life (HRQoL) has rarely 
been measured or incorporated in the main endpoints of clinical trials.
15
 Collecting patient-
reported outcomes (PROs), such as HRQoL, is increasingly recognised to be key to fostering 
patient-centred care and influencing clinical decision-making.
18
 Patients’ perspectives can 
also influence treatment decisions in an era of rising treatment costs and limited resources. 
Collection of PROs during chemotherapy has been well described.
19,20
 Patient self-reporting 
improves symptom detection as clinicians frequently under estimate toxicities associated with 
systemic chemotherapy.
20,21
 Recording electronic PROs in real time can also improve 
HRQoL, patient-provider communication, reduce hospitalisation and improve survival.
22
  
Existing research into the HRQoL of patients with sarcoma has primarily focused on 
survivors of localised extremity STS, or specific subgroups of patients with advanced STS.
23–
26
 For example, the SABINE study evaluated HRQoL among patients with metastatic STS or 
bone sarcoma who had attained a favourable response to chemotherapy.
27
 The PALETTE 
trial of pazopanib versus placebo, as second-line treatment (or greater) for patients with 
advanced STS, evaluated HRQoL as an exploratory endpoint.
28
 Although pazopanib did not 
improve HRQoL, meaningful improvement in progression-free survival was demonstrated 
with no associated impairment of HRQoL.
28
 Hugdens et al analysed HRQoL for patients with 
advanced STS treated within the phase 3 trial of eribulin versus dacarbazine.
29
 This analysis 
demonstrated lower global health status and physical functioning scores, significantly worse 
loss of appetite, nausea and vomiting, and insomnia in patients treated with dacarbazine on 
progression compared with patients in treated with eribulin.
29
 The REGOSARC study of 




metastatic STS patients refractory to doxorubicin, post-hoc quality-adjusted survival benefit 
analysis demonstrated superiority of regorafenib over placebo.
30
 The SARC021 phase 3 trial 
of doxorubicin versus doxorubicin plus evofosfamide reported no difference in HRQoL 
between treatment arms, despite a higher incidence of adverse events in the combination 
treatment arm.
8
 The phase 3 randomised study of trabectedin versus dacarbazine in patients 
with metastatic leiomyosarcoma or liposarcoma after failure of conventional chemotherapy 
used patient-reported symptom scoring.
31
 A variety of HRQoL instruments were used to 
collect data in these studies as no specific HRQoL tool exists for STS - primarily due to the 
heterogeneity of this group of patients.
16,26
  
In order for patients with advanced STS to make a well-informed decision about 
chemotherapy and consider the possible effects on all aspects of their lives, clinicians should 
be able to provide HRQoL data. This will enhance the shared decision-making process 
between clinicians and their patients. To the best of our knowledge this is the first study for 
patients with advanced STS which will evaluate HRQoL across chemotherapy treatment 
lines, consider the decision-making process (expectations and preferences for quantity versus 
quality of life) and explore decisional regret.  
Methods/Design 
The Health-related quality Of Life In patients with advanced Soft TIssue sarcomas treated 
with Chemotherapy (HOLISTIC) study is a longitudinal cohort questionnaire study for 
patients with advanced STS treated at eight sarcoma centers; three in the United Kingdom 
(U.K) and five in the Netherlands (NL). The principal aim of this study is to assess how first-
line chemotherapy affects global HRQoL over time (specified below) in patients with 
advanced STS. This study also aims to assess patient functioning (physical, psychological, 
emotional, social and role) and symptoms, before, during, and after treatment with 
chemotherapy. The study will also explore treatment decision-making (expectations and 
preferences), financial toxicity of treatment and decisional regret after treatment. Detailed 
outcome measures are defined below. The study was approved by the Heath Research 
Authority and Research Ethics Committee of the United Kingdom (REC reference 
17/NI/0197).  
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Patient and Public Involvement 
The study concept was developed in consultation with patient advocates, patients and their 
relatives, who felt that there was a lack of information on HRQoL in patients receiving 
chemotherapy for advanced soft tissue sarcoma in order to make a well-informed decision 
about treatment. Study documents were reviewed by the patients who are members of the 
Royal Marsden Hospital Patient and Public Involvement panel. The panel provided feedback 
on the protocol, questionnaires, patient information sheet and informed consent form, with 
regard to content and readability. All suggestions were considered and changes incorporated 
in the final documents. The questionnaire package was designed to minimise timing burden 
and questionnaire fatigue for patients. Patients will be involved in study-related presentations 
and publications.  
Eligibility criteria and materials 
Inclusion criteria.  
Eligible patients must be aged 18 years with a diagnosis of advanced (not amenable to 
curative surgical resection) or metastatic STS, as confirmed by a sarcoma histopathologist, 
and has decided to start palliative chemotherapy following consultation with their oncologist. 
Patients must be enrolled prior starting first-line chemotherapy or third-line chemotherapy. 
Patients must be able to communicate in English or Dutch and have mental capacity to 
provide informed consent and participate in the study (as determined by their treating 
physician). Patients must be able to complete questionnaires themselves, which is a 
prerequisite for patient-reported outcomes. Participants must be treated at one of the 
participating centres.  
Exclusion criteria.  
Due to significantly different treatment protocols, patients with Ewing sarcoma, 
rhabdomyosarcoma, desmoplastic small round cell tumour and gastrointestinal stromal 
tumour are not eligible for the study.  
 
 





Data collection and online questionnaire administration will be done within the ‘PROFILES’ 
registry (Patient-Reported Outcomes Following Initial treatment and Long-term Evaluation 
of Survivorship; www.profilesregistry.nl). The ‘PROFILES’ registry was established in the 
Netherlands (2009) for the study of the physical and psychosocial impact of cancer and its 
treatment in short and long-term cancer survivors.
32
  Since PROFILES has been established, 
studies have recruited over 30,000 patients, resulting in more than 100 scientific publications. 
Security of the PROFILES server is established in accordance with current European norms 
(NEN-ISO/IEC 27002). Questionnaire data which are collected from participants (UK and 
NL) through the PROFILES registry will be stored on a secure server in the Netherlands. 
This application has been developed to the requirements of the higher education and research 
community using end-to-end encryption. 
Recruitment 
Patients will be identified by a member of the sarcoma team who will check eligibility 
criteria using electronic patient records. Patients will be invited to participate in the outpatient 
clinic, provided with a patient information sheet and given the opportunity to ask any 
questions to a member of research team. Interested patients will be given the option to 
participate online or using paper versions of the questionnaire. Those who prefer online 
participation will receive an email which includes a link to the secure PROFILES website, 
unique username and password. The US Food and Drug Administration have made it clear 
that electronic capture of clinical trial source data is preferred over paper-based data 
collection.
33
 There is now widespread use of electronic patient-reported outcome measures 
(PROMs) within clinical trials, and several reviews and meta-analyses have shown evidence 
of equivalence between electronic and paper administration of PROMs.
34,35
 In order to ensure 
that patients are not excluded if they are unable to use a computer, we have provided the 
option for paper questionnaire completion. Paper copies of the questionnaires will be entered 
using the data entry option of PROFILES, after which a quality control check will take place. 
This online data entry portal minimises the chance of errors as the answer options are 
selected from electronic lists. This also ensures that the paper questionnaire data can be 
extracted in the same format as the online questionnaire data. The PROFILES data manager 
will randomly choose five participants who have completed paper questionnaires and check 
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the data entry for complete accuracy. If any errors are found, then all data will be rechecked 
and corrected where necessary.   
All participants will complete an informed consent form. This can be done electronically 
(using PROFILES personal login details) or on paper if the patient prefers a hard copy. 
Patients are assured that non-participation has no consequences for their treatment or follow-
up care. 
After informed consent, patients will be invited to complete the online (or paper) baseline 
questionnaire. This must be completed before starting first-line chemotherapy or third-line 
chemotherapy (third-line patient cohort). Patients can complete the online questionnaire on 
their own computer, tablet or mobile phone, or using a hospital computer if available. 
Patients who have completed the baseline questionnaire will then receive an email on day 1 
of each cycle of chemotherapy, inviting them to complete a new questionnaire using their 
existing login details (usually every three weeks). Patients who prefer paper versions will be 
handed a hard copy of the questionnaire in the chemotherapy clinic, with the option to return 
this by mail using the prepaid envelopes provided, or hand to the research team in a sealed 
envelope. If chemotherapy is delayed for any reason, patients will be invited to complete the 
questionnaire when treatment has restarted. Baseline questionnaires will take around 20 
minutes to complete and subsequent questionnaires will take around 10-15 minutes. Patients 
will complete a maximum of eight questionnaires during chemotherapy, to reduce 
questionnaire fatigue. Patients have a 2 week period to complete each questionnaire and will 
be sent an electronic or paper reminder after 1 week if they have not completed a 
questionnaire. 
When a participant stops first-line chemotherapy, or third-line chemotherapy (respective 
cohorts), for any reason (e.g. all cycles completed, or disease progression), he/she will be 
invited to complete an ‘end of chemotherapy’ questionnaire. Patients will receive this 
invitation approximately three weeks after the last dose of chemotherapy. Thereafter patients 
who have received first-line chemotherapy will be invited to complete 3 monthly follow-up 
questionnaires, and patients in the third-line chemotherapy cohort will complete 2 monthly 
follow-up questionnaires (due to the shorter prognosis). If a participant starts a new line of 
chemotherapy (e.g. second-line chemotherapy) during the follow-up period, he/she will 
remain on the same follow-up schedule of questionnaires in order to follow the trajectory of 
their HRQoL during second-line treatment and beyond. Due to concern about questionnaire 




fatigue, it was felt that patients who had already completed 3-weekly questionnaires during 
first-line chemotherapy should remain on the three-monthly follow-up schedule, rather than 
receiving questionnaires at the beginning of each Cycle of 2
nd
 line chemotherapy. Due to the 
time frame of the study, we will simultaneously recruit patients beginning third-line treatment 
to explore HRQoL in patients with advanced STS who are further along their treatment 
trajectory. 
Participants will be invited to complete follow-up questionnaires until he/she chooses to stop, 
is too unwell to continue, or death occurs, whichever comes first, and up to a maximum of 
two years after study enrolment. Participants will only be enrolled once; either prior to first-
line chemotherapy or before third-line chemotherapy. Throughout the study, it is the 
responsibility of the local sarcoma team to inform the study coordinator if a participant has 
died or is too unwell to continue.  
Case report forms 
After a patient has provided informed consent, clinical data will be collected from electronic 
patient records by a member of the research team. Data collection and storage will be 
maintained according to ICH-GCP (international good clinical practice) standards. Clinical 
details will be entered into the password protected database (MACRO) and stored using an 
anonymous patient identifier number. Personal identifiable clinical data of the patient will not 
leave the hospital where the patient is treated.  
Case report forms (CRF) will be completed at four time points during the study. The first 
CRF should be completed after patient consent, and includes documentation of eligibility 
criteria, date of diagnosis of sarcoma, histological subtype and chemotherapy treatment 
regimen. The second part of the CRF should be completed when a patient stops first-line 
chemotherapy (or third-line chemotherapy for the third-line cohort). Information gathered at 
this time point includes reason for discontinuation of chemotherapy (e.g. disease 
progression). The third point for CRF completion occurs when a patient stops participation in 
the study (e.g. patient preference) and includes details of all chemotherapy regimens received 
during the study. The final point for CRF data collection is death notification, where 
applicable.  
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At the end of the study, questionnaire data will be linked with the clinical data contained 
within the CRF database using patient study numbers. Data linkage will be done by the study 
statistician at the Royal Marsden Hospital. Data will be recorded and retained in accordance 
with the Data Protection Act 1998. 
Questionnaires 
The baseline questionnaire contains questions on socio-demographic characteristics of the 
participant, such as marital and occupational status. Patients will also be asked a single 




The following internationally validated questionnnaires and published questionnaires in 
studies of cancer patients will be used. These questionnaires have not been specifically 
validated in patients with advanced STS, however no STS-specific questionnaire has been 
developed to date. Permission to use all questionnaires has been obtained from authors. 
Formal licences are not required. Patients were involved in the design and review of the 
questionnaire package. All questionnaires were available in English. The Dutch questionnaire 
package was developed using validated Dutch versions of the questionnaires where possible 
or existing online Dutch translations of the questions. Where existing translations were not 
available, bilingual speakers assisted  with formal foward-backward translation of questions 
and discrepancies resolved by OH (details below). 
EORTC-Quality of Life Questionnaire 
 
The European Organisation for the Research and Treatment of Cancer Quality of Life 
Questionnaire Core 30 (EORTC-QLQ-C30) V.3.0 was developed to assess QoL in patients 
with cancer. It has been translated and validated in over 100 languages, including English and 
Dutch. This questionnaire has 30-items,consisting of five functional scales (physical, role, 
cognitive, emotional and social), a global quality of life scale, three symptom scales (fatigue, 
pain, nausea and vomiting) and single items assessing common symptoms (dyspnoea, loss of 
appetite, sleep disturbance, constipation and diarrhoea) and perceived financial impact of the 
disease.
38
 After linear transformation, all scales and single item measures range in score from 
0-100. A higher score on functional scales and global QoL means better functioning and 
HRQoL, whereas a higher score on the symptom scales means more complaints.
38
 




Financial toxicity  
Financial toxicity questions were selected from the item bank of the EORTC computer 
adaptive testing instrument and are validated in both English and Dutch languages.
39
 In 
combination with the EORTC-QLQ-C30 questionnaire, these questions will maximize 
information surrounding the financial impact of advanced STS and its treatment. This is 
particularly relevant for patients with rare cancers, such as STS, who may need to travel long 
distances to receive care at a specialist centre.
40
  
Functional Assessment of Cancer Therapy – General  
The Functional Assessment of Cancer Therapy-General (FACT-G) is a validated 
questionnaire which has been widely used to measure HRQoL in patients with cancer. The 
FACT-G has been translated and validated in many languages including English and 
Dutch.
41,42
 Patients are asked to rate their response to several statements on a 5-point Likert 
scale from ‘not at all’ to ‘very much.’ 
41
 We have selected two items from the FACT-G 
questionnaire:  ‘I am bothered by side effects of treatment’ and ‘I am able to enjoy life’ as a 
summary measure of the burden of a given set of toxicities.
43
 Single items from the FACT-G 
questionnaire are not validated, however bother of side effects has been shown to be 
associated with patients’ ability to enjoy their lives.
43
  
Control Preferences Scale. 
 
This validated questionnaire is designed to measure patients’ preferred role in decision 
making versus their doctor’s role.
44
 Patients are asked to choose from five options the phrase 
that best describes the role that they have taken in dealing with their cancer diagnosis and 
treatment decisions, and the role that they would have preferred (active/collaborative/passive 
role).
44
 Understanding patient preferences for control in treatment decision-making is crucial 
to improving shared decision-making and providing patient-centred care.
45,46
 Dutch 
translations of the Control Preferences Scale are available and have been used in previous 





The Decisional Conflict Scale measures personal perception of decision making, and 
certainty or uncertainty over their choice.
48
 This includes determining the level of 
150542-Younger_BNW.indd   34 28-04-2021   20:07
THE HOLISTIC STUDY PROTOCOL 
35 
 
information and support to make the choice, whether the decision was in line with patient 
values and how satisfied they are/were with their decision. Items are given a score value of 0 
(no) or 1 (yes). The total score can only be calculated if all four items are answered. The sum 
of the four items will range from 0 (extremely high decisional conflict) to 4 (no decisional 
conflict). A score of  3 indicates decisional conflict.48 This four-item version of the 
Decisional Conflict Scale questionnaire (SURE) has been validated in English and a Dutch 
translation is available (psychometric properties have been partly confirmed in Dutch 
patients).
49
   
Quality-Quantity Questionnaire  
The Quality-Quantity Questionnaire (QQQ) is a validated construct consisting of eight 
questions which measure patient attitudes towards the trade-off between quantity (length) 
versus QoL (four questions for length of life (LoL) and four questions for QoL).
50
 A separate 
score is calculated for LoL and QoL. The total score for all four questions (LoL or QoL) is 
calculated and the minimum score (4) is then subtracted. This answer is then divided by the 
range (20-4) to create a rescaling of 0-100. For example, if a person scores 3 (midpoint 
answer) for all 4 questions, the calculation would be: (12-4)/(20-4) = 0.50 (midpoint overall 
score).
50
 Decision-making in patients with advanced STS is extremely complex. Patient 
preferences for LoL and QoL are of utmost importance when weighing up the benefits and 
risks of treatments such as chemotherapy. Responses to these questions will allow insight 
into the preferences of patients with advanced STS and may help to inform shared treatment 
decisions. The original QQQ was written in the Dutch language (Professor Stiggelbout from 
the Netherlands) and has been translated and validated in English.
50
   
Expectations of treatment.
  
After the decision has been made to receive chemotherapy, patients are asked how likely they 
think that chemotherapy will improve survival, cure their cancer and improve symptoms due 
to cancer.
51
 Studies in patients with other metastatic solid tumours have shown that patients 
often overestimate their life expectancy and many believe that chemotherapy will be 
curative.
51
 Prognostic awareness has been associated with worse HRQoL in patients newly 
diagnosed with incurable (lung or gastrointestinal) cancer.
52
 This question will be used to 
assess expectations of chemotherapy among advanced STS patients. These questions were 




originally written in English and therefore bilingual speakers performed a forward-backward 
translation of the questions into Dutch under the supervision of OH.  
Work ability index 
 
The Work Ability Index (WAI) consists of questions which assess the ability to work, taking 
into account the demands of the work, health status and resources.
53
 There are seven 
questions from which we selected two general questions to inform future patients who are 
receiving chemotherapy on their potential ability to work during and after chemotherapy. 
These two questions are scored 0-10 and 1-6 respectively, and will be described in the 
analysis.
53
  The WAI was developed in Finland and is available in 24 languages, including 
English and Dutch.
54
 The validity and reliability of the WAI has been assessed in correlation 
analyses and used in many international research studies. 
Decisional Regret Scale
 
Patients are asked to think about the decision they have made to receive chemotherapy and 
answer five statements on how strongly they agree/disagree: 1) It was the right decision, 2) I 
regret the choice that I made, 3) I would go for the same choice if I had to do it over again, 4) 
The choice did me a lot of harm, 5) The decision was a wise one.
55
 Items 2 and 4 should be 
reverse-coded so that, for each item, a higher number will indicate more regret. To help 
others interpret the score more readily with other scales ranging from 0 to 100, these scores 
can then be converted to a 0-100 scale by subtracting 1 from each item and then multiplying 
by 25.
55
 To obtain a final score, the items are summed and averaged. A score of 0 means no 
regret; a score of 100 means high regret.
55
 The Decisional Regret Scale can be used to 
measure distress or regret after a health care decision such as the choice to receive 
chemotherapy. Regret about the decision to receive chemotherapy has not been previously 
measured in patients with advanced STS. The Decision Regret Scale is available in English 
and Dutch; Dutch translation by Leiden University Medical Centre under supervision of Prof. 






150542-Younger_BNW.indd   36 28-04-2021   20:07
THE HOLISTIC STUDY PROTOCOL 
37 
 
Table 1: Enrolment and schedule of questionnaires  
TIMEPOINT Enrolment Baseline 
Cycle 1 
Chemotherapy 




Eligibility screen X     
Informed consent X     
QUESTIONNAIRES      










Sociodemographics (15)  
X 
   
Health literacy (1) 
 
X 
   




   













X X X - 
EORTC-QLQ-C30 (30) 
 
X X X X 
Work ability index (3) 
 
X X X X 
EORTC CAT items: 
financial difficulties (5) 
 
X X X X 
FACT-G items (2) 
 
- X* X X 
Decisional Regret Scale 
(5) 
 
- - X X 
Total number of 
questions 
 
71 50 56 45 
*FACT-G: Cycle 1 questionnaire includes the single statement ‘I am able to enjoy life’. 
Cycles 2-8 and follow-up questionnaires include the additional statement ‘I am bothered by 
the side effects of treatment’.  
 
 





Questionnaire A is the baseline questionnaire, which should be completed before starting 
chemotherapy. Patients are invited to complete Questionnaire B on day 1 of Cycle 1 of first-
line chemotherapy or third-line chemotherapy (third-line cohort). Patients are invited to 
complete Questionnaire C on day 1 of every cycle from Cycle 2 onwards and 3 weeks after 
the last cycle of chemotherapy. Questionnaire D is the follow-up questionnaire which is 
completed every 3 months after the end of chemotherapy for first-line chemotherapy patients, 
and every 2 months for the third-line chemotherapy patient cohort. Patients have a 2 week 
period to complete each questionnaire and will be sent a reminder after 1 week if they have 
not completed the questionnaire. Table 1 summarises enrolment, time points, questions 
included in each questionnaire and number of items included in each questionnaire  
Endpoints 
The primary endpoint is change in EORTC-QLQ-C30 global HRQoL score (continuous 
scale) after treatment with first-line chemotherapy. Secondary endpoints are change in 
EORTC-QLQ-C30 physical, cognitive, social, role and emotional functioning scores 
(continuous) after treatment with first-line chemotherapy, and change in EORTC-QLQ-C30 
symptoms (continuous) after treatment with first-line chemotherapy. 
The study will also explore change in EORTC-QLQ-C30 global HRQoL score, EORTC-
QLQ-C30 functioning scales and symptom scores after treatment with third-line 
chemotherapy (third-line patient cohort).  
For all patients we will examine whether there is an association between socio-demographic 
and clinical factors (including age, gender, relationship status, educational level, PS, tumor 
subtype, site of metastases, baseline anaemia (Hb <13g/L male, <11.5g/L female), 
lymphopenia <1x10
9
/L, LDH >250U/L, hypoalbuminaemia <35g/L) and baseline EORTC-
QLQ-C30 global HRQoL and/or change in physical, cognitive, social, role and emotional 
functioning during and after treatment. The study will evaluate whether there is an 
association between HRQoL and radiological response (according to RECIST version 1.1) to 
chemotherapy, and between HRQoL and financial toxicity. 
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The study will explore work-ability in patients with advanced STS treated with 
chemotherapy, patient preferences for collaborative decision-making, decisional conflict 
about treatment, expectations of treatment with chemotherapy, preferences for quantity 
versus quality of life, and retrospective views on their decision to receive chemotherapy. 
Statistical analysis and power calculation.  
Primary Endpoint 
Change in EORTC-QLQ-C30 global HRQoL score will be tested using a paired sample t-test 
from baseline to after four cycles with a two-sided 5% significance level. For patients who do 
not complete four cycles, the last score/observation (post baseline) will be carried forward for 
the analysis. Four cycles was chosen for the analysis based on a study of 488 patients with 
advanced STS treated at the Royal Marsden Hospital, showing that patients completed a 
median number of 4 cycles of chemotherapy (range 1-8).
57
 
A sensitivity analysis will also be performed excluding those patients who do not reach 4 
cycles. If data are not normally distributed, then the Wilcoxon test will be used. 
Secondary endpoints 
Differences in physical, cognitive, social, role, emotional functioning and symptoms from 
baseline measurements over time will be analysed using mixed models, to allow for the 
repeated nature of the data by including subject as a repeated effect, and associations across 
visits (included as a fixed) will be investigated. The baseline score will also be fitted as a 
fixed effect in all models.  
Exploratory endpoints 
HRQoL of patients treated with third-line chemotherapy over time will be presented 
descriptively at each time point. 
The association between sociodemographic and clinical factors (including age, gender, 
relationship status, educational level, PS, tumour subtype, site of metastases, baseline 
laboratory values), financial toxicity and radiological response with global HRQoL, physical, 
cognitive, social, role, emotional functioning and symptoms at each time point will be 




analysed using univariate mixed models as above. Firstly time-invariant variables (e.g. sex, 
race, and age at diagnosis) will be assessed and then time-variant variables to evaluate 
whether time-specific conditions influence a linear trend of HRQoL over time. Interactions 
between factors and time will also be explored to assess whether trajectories of HRQoL over 
time differed by subgroups.  
A multivariate model will be constructed as a function of time, sociodemographic and 
clinical characteristics, and interactions between time and other covariates. Any factors found 
significant (p<0.05) in univariate analysis will be tested in a multivariate mixed-effects 
models to see if factors of QoL are independent of each other. A backward selection method 
will be used (p<0.05) to identify a parsimonious model. 
Patient preference for treatment decision making, decisional conflict, patient expectations, 
preference for LoL versus QoL, and retrospective views on their decision to receive 
chemotherapy will be presented descriptively with mean (SD) or median (IQR) at each time 
point as appropriate.  
Sample Size 
For the primary endpoint, the difference from baseline to 4 cycles will be tested. A mean 
difference of 10 points in EORTC-QLQ C30 global HRQoL score is deemed to be clinically 
relevant with an effect size of 0.3, where the SD of the mean difference is 33.3.
38
  With a 
90% power and a two-sided 5% significance level, a total of 119 patients are required.
38
 To 
allow for drop outs an additional 10% of patients will be recruited, giving a total sample size 
of 132.  
We estimate that there will be approximately thirty patients in the third-line chemotherapy 
cohort within the timeframe of the study. 
Missing data 
Subjects who have completed online questionnaires will not have any missing data unless 
they have not completed the entire questionnaire. The electronic questionnaires have been 
programmed so that participants are not able to proceed to the next question until all of the 
questions on the current page have been answered. If patients have not completed the 
questionnaire they will be sent an electronic reminder to finish the questionnaire within the 
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time period specified. Regarding paper questionnaires we will quantify the extent of missing 
items (i.e. number of unanswered questions per patient) and describe these results in our 
findings. For the EORTC-QLQ-C30 we will follow the EORTC scoring manual guidelines 
for missing data and use imputation where appropriate.
58
 For all other questionnaires, scores 
cannot be calculated unless the patient has answered all of the items. We will categorise these 
responses as missing/not answered in the presentation of the results so that ‘non-responses’ 
are included in the analysis in order to minimise bias in interpretation.  
Ethics and dissemination 
This study was approved by the Heath Research Authority and Research Ethics Committee of 
the United Kingdom (REC reference 17/NI/0197) and in the Netherlands at each participating 
centre (Radboud University Medical Centre and UMCG: 2018-4151, Erasmus medical 
Centre: MEC-2018-1101, Leiden University Medical Centre: P18.179 P1a, Antoni van 
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Background: Palliative chemotherapy is the principal treatment for patients with advanced soft 
tissue sarcomas (STS), however prognosis is limited (median OS 12-19 months). In this setting, 
patient values and priorities are central to treatment decisions.  
Methods: The HOLISTIC study is a prospective cohort study in the UK and the Netherlands 
assessing health-related quality of life in advanced STS patients receiving palliative 
chemotherapy. Participants completed a questionnaire before starting chemotherapy, including 
attitudes towards quality of life (QoL) versus length of life (LoL), decisional control 
preferences, treatment expectations and decisional conflict. Chi-squared and Fisher’s exact tests 
were used to evaluate associations between patient characteristics, preferences and expectations.  
Results: One hundred and thirty-seven patients with advanced STS participated (UK: n=72, 
Netherlands: n=65). Median age was 62 (27-79) years. Preference for extended LoL (n=66, 
48%) was slightly more common than preference for QoL (n=56, 41%); 12 patients (9%) valued 
LoL and QoL equally (missing: n=3). Younger patients (age<40 years) prioritised LoL, whereas 
two thirds of older patients (aged 65 years) felt that QoL was equally- or more important than 
LoL (p=0.020). Decisional conflict was most common in patients who prioritised QoL 
(p=0.024). Most patients preferred an active (n=45, 33%) or collaborative role (n=59, 44%) role 
in treatment decisions. Gender, performance status and country were significantly associated 
with preferred role.  Concordance between preferred and actual roles was high (n=104, 76%). 
The majority (n=121, 88%) considered chemotherapy could prolong life, 92 patients (67%) that 
chemotherapy could improve symptoms and 37 patients (27%) indicated that chemotherapy 
could be curative. Participants from Black, Asian and minority ethnic backgrounds were 
significantly more likely to indicate that cure was possible (n=22; p=0.016).  
Conclusions: Heterogeneous preferences and expectations among advanced STS patients 
support personalised decisions about palliative treatment. Considering cultural and ethnic 
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Soft tissue sarcomas (STS) are a group of rare, heterogeneous neoplasms of mesenchymal 
origin.  Approximately 10% of patients present with synchronous metastases, and around half of 
those with localised high-risk tumours will develop metastases after primary treatment.
1,2
 
Patients with advanced STS often have a substantial burden of physical and psychological 
symptoms, which have a negative impact on health-related quality of life (HRQoL).
3,4
  Quality 
of life (QoL) is a wide concept including ‘non-health’ factors. QoL is defined as “an individual's 
perception of their position in life in the context of the culture and value systems in which 
they live and in relation to their goals, expectations, standards and concerns.”
5
 
In the setting of advanced STS, principal treatment goals are to alleviate disease-related 
symptoms, maintain or improve QoL and to prolong survival (median overall survival 12-19 
months with systemic treatment). Anthracycline-based chemotherapy is standard first-line 
treatment for most histological subtypes, however common side-effects include fatigue, nausea, 
vomiting, myelosuppression and cardiotoxicity.
6,7
 Chemotherapy response rates are low (10-
40%) and there are no validated predictive biomarkers for response to anthracyclines in STS.
8
 
Furthermore, chemotherapy may improve certain symptoms, such as pain and discomfort, but 
may cause (initial) deterioration in other symptoms, such as fatigue, and overall QoL.
9,10
  
Patients with advanced STS are therefore faced with a challenging trade-off between possible 
beneficial outcomes, such as improvement in symptoms, and almost inevitable chemotherapy-
related morbidity.
11
 Consequently, patients may experience decisional conflict, representing 
“personal uncertainty about which course of action to take when choice among competing 
options involves risk, regret, or challenge to personal life values.”
12
 Decisional conflict is 
influenced by personal values, understanding information, degree of support, and perception 
that a decision was poor or ineffective.
12
  
Previous studies have demonstrated that patients’ beliefs and attitudes are strongly influenced 
by their current health status, previous experiences, family, friends, healthcare professionals and 
media.
13
 Treatment preferences in seriously unwell patients are also related to the perceived 
burden of treatment, the likelihood of the outcome and the outcome itself (e.g. survival or 
functional improvement).
14
 Shared decision-making is a method to support patients in treatment 
decisions, and is acknowledged to be a central component of patient-centred care.
15
 Clinicians 
should provide information on the anticipated benefits of treatment, potential adverse effects, 




alternative management approaches (including best supportive care), while considering 
individual values and preferences.
13,16
 Acknowledging clinical uncertainty and encouraging 
patients to discuss their preferences may enhance shared decision-making.
17
 Conversely, not all 
patients want to participate in decision-making, and eliciting preferences for involvement in 
treatment decisions can improve communication, satisfaction and quality of care.
18,19
  The 
Control Preferences Scale is the most widely used tool to assess patient preferences for 
involvement in decisions about medical treatment, measuring the degree of control an 
individual wants to assume during decisions about their health.
20
 Understanding control 
preferences can enhance patient satisfaction and high quality care.
18,19,21
  
While advanced STS is incurable for the majority of patients, there are a minority of longer-term 
survivors with more indolent disease (5 year survival: 8-15%), and cure may be possible for 
those who achieve complete response to anthracycline chemotherapy.
22,23
 Despite the largely 
palliative intent of treatment for most advanced malignancies, a significant proportion of 
patients with advanced cancer consider that treatment may be curative.
24–26
 Inaccurate beliefs 
about treatment goals may compromise the ability of patients to make an informed decision 
that is congruent with personal preferences.
24,27
 Cultural and ethnic differences in 
understanding and preferences for information provision, such as disclosure of prognosis, 
have previously been described.
28,29
    
In order to provide high quality, patient-centred care, clear understanding of patient priorities is 
needed. The primary objectives of this analysis are to explore priorities towards quality versus 
length of life, decisional control preferences, treatment expectations and decisional conflict in 
patients with advanced STS starting first-line palliative chemotherapy in sarcoma reference 
centres in the United Kingdom (UK) and The Netherlands (NL) 
Methods 
The HOLISTIC study (Health-related quality Of Life In patients with advanced Soft TIssue 
sarcomas treated with Chemotherapy) is a prospective cohort study for patients aged 18 years, 
treated with chemotherapy for advanced STS in the UK and the NL (NCT03621332).
30
  Ethical 
approval was obtained in the UK (REC 17/NI/1097) and at all participating sites in the 
Netherlands. Data were collected in the PROFILES registry; an established international 
registry for collection of cancer patient-reported outcomes.
31
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Patients were recruited from two sarcoma reference centres in the UK and five in the 
Netherlands. All patients had a histologically-confirmed diagnosis of soft tissue sarcoma. 
Advanced disease was defined as metastatic disease, or locally-advanced disease not amenable 
to curative surgical resection. Patients with advanced Ewing sarcoma, rhabdomyosarcoma, 
desmoplastic small round cell sarcoma and gastro-intestinal stromal tumours were excluded 
based on their distinct management approaches. After providing informed consent, participants 
completed a baseline questionnaire (online or paper/English or Dutch) before starting first-line 
chemotherapy. Participants then completed a questionnaire after each cycle of chemotherapy 
and three-monthly during follow-up. The primary endpoint of the HOLISTIC study was change 
in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 
C30 (EORTC-QLQ-C30) global QoL score from baseline to post Cycle 4 of chemotherapy 
(mean number of cycles completed); final results are awaited (follow-up two years). Exploratory 
endpoints included baseline attitudes towards quality of life versus length of life, decisional 
control preferences, expectations of treatment and decisional conflict; reported here. Full details 




Participant characteristics  
Socio-demographic characteristics such as age, gender, ethnicity, religious beliefs, relationship 
status and education were assessed in the baseline patient questionnaire. Clinical characteristics 
were collected in case report forms, including disease extent, histological subtype and baseline 
ECOG performance status (PS). 
Questionnaires  
The EORTC-QLQ-C30 was used to measure global QoL.
32
 The Quality-Quantity 
Questionnaire, was used to explore attitudes towards the trade-off between quality or length of 
life.
11
 Four items are related to preference for quality of life (QoL) and four related to 
quantity (length) of life (LoL). Patients are asked how strongly they agree or disagree with 
these items on a five-point Likert scale. Higher total score for QoL or LoL items demonstrates 
inclination towards QoL or LoL respectively.
11
  




The Control Preference Scale is a widely used measure to assess patient preferences for role 
in treatment decisions.
20
 Patients were asked to select from five options, the phrase that best 
describes their preferred role in decisions about their cancer diagnosis and treatment, and the 
role they have actually taken in treatment decisions.
20
 Roles are classified as fully active (‘I 
prefer to make the decision about what treatment I receive’), active-collaborative role (‘I 
prefer to make the decision about my treatment after seriously considering my doctor’s 
opinion’), collaborative role (‘I prefer that my doctor and I share responsibility in deciding 
which treatment is best for me’), passive-collaborative (‘I prefer that the doctor makes the 
final decision about what treatment will be used, but seriously considers my opinion’) or fully 
passive (‘I prefer to leave all decisions regarding treatment to my doctor’).  
Questions on treatment expectations were adapted from a study by Weeks et al. for patients with 
advanced lung and colorectal cancers.
24
 Patients were asked to indicate how likely they thought 
that chemotherapy would improve survival, cure their cancer and improve problems caused by 
cancer. Response options for included ‘very likely’, ‘somewhat likely’, ‘a little likely’, ‘not 
likely at all’ or ‘don’t know’.  
The four-item Decisional Conflict Scale (‘SURE’) was used to measure the level of 
uncertainty over the decision to receive chemotherapy.
33
 The ‘SURE’ acronym represents the 
four items; ‘Sure of myself’, ‘Understand information’, ‘Risk-benefit ratio’ and 





Patient characteristics and treatment expectations were summarised using descriptive statistics. 
The EORTC–QLQ-C30 global QoL score was calculated using EORTC scoring guidelines; a 
higher score indicates better QoL.
32
 Using the mean score and a clinically relevant difference of 
10 points, we categorised scores into low, medium and high global QoL.
34
  
Responses to items of the quality-quantity questionnaire were summarised using mean and 
standard deviation (SD). For each patient the total score for all four items of each domain (LoL 
or QoL) was calculated and the minimum score (4) was subtracted, the total was then divided by 
the maximum score; for example a score of 3 (midpoint answer) for all 4 questions, produces 
the following calculation: (12-4)/(20-4) = 0.50 (midpoint overall score). A higher score 
indicates greater preference for that domain.  
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Preferred role and actual role in treatment decisions (control preferences) were summarised 
using proportions. Patients were then categorised into three groups; active (fully active or 
active-collaborative), collaborative, or passive (passive-collaborative or fully passive). 
Differences between control preferences (preferred role) and actual role were calculated and 
dichotomised into ‘concordant’ or ‘discordant’.  
The sum of the four items from the ‘SURE’ Decisional Conflict Scale, answer options yes 
(score 1) or no (score 0) was calculated.
33




The chi-squared test was used to determine associations between participant characteristics, 
preferences for QoL vs. LoL (or equal priority), decisional control preferences, expectations 
about curability, and decisional conflict. Fisher’s exact test was used where observed cell 
count was 5 and p-values of 0.05 were considered statistically significant.  Adjusted 
standardized residuals (+/- 2.0), were used to identify cells contributing to significant results. 
Multiple logistic regression analysis was performed to determine factors associated with 
preference for QoL vs. LoL and beliefs about curability.  
Missing data 
Participants who completed online questionnaires online (n=127) had no missing data. 
Missing answers for patients completing paper questionnaires (n=10) were reported where 
applicable, and only available data were analysed.   
Results 
One hundred and thirty-seven patients completed the baseline questionnaire (Table 1). The 
median age of patients was 62 (27-79) years and gender distribution was even (male: n= 68, 
female: n=69). Seventy two patients were recruited in the UK and 65 patients in the NL Most 
patients were Caucasians (n=115, 84%). One third of patients described themselves as religious 
(n=45, 33%). Patients were commonly married or in a relationship (n=114, 83%), and most were 
cohabiting (n=119, 87%). A minority of patients had children aged 18 years (n=30, 22%). 
Participants were well-educated (n=110, 80%: college, diploma, vocational qualification or 
higher) and almost half (n=67, 49%) were currently employed (full/part-time or on sick-leave).  
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Footnotes: * BAME: Black, Asian and Minority Ethnic ** Interval between diagnosis of metastatic STS 
and questionnaire completion.  *** UPS: undifferentiated pleomorphic sarcoma.  
150542-Younger_BNW.indd   54 28-04-2021   20:07
PREFERENCES AND EXPECTATIONS OF ADVANCED STS PATIENTS 
55 
 
Most patients had metastatic disease (n=125, 91%) and 12 patients (9%) had locally-advanced 
disease. Over half of patients had a >6 month interval between diagnosis of advanced STS and 
study participation (n=78, 57%). The most common histological subtypes were leiomyosarcoma 
(n=40, 29%), liposarcoma (n=30, 22%) and undifferentiated pleomorphic sarcoma (n=17, 12%). 
Patients generally had an ECOG PS of 0 (n=46, 34%) or 1 (n=75, 55%). A small number had 
ECOG PS 2 (n=7, 5%), and PS was not recorded for 9 patients.  
The mean EORTC-QLQ-C30 global QoL score of participants was 68.3 (standard deviation 
20.3). One quarter of patients (n=34, 25%) had low global QoL (score 0-58.3), 49 patients 
(36%) had medium global QoL (score >58.3-78.3) and 53 patients (39%) had high global QoL 
(score >78.3-100).  
Preferences for quality of life versus length of life 
Scores for items of the quality quantity questionnaire (QQQ) are demonstrated in Table 2. The 
statement which evoked the strongest agreement was: ‘If I reached a point during treatment at 
which I felt like giving up, I would probably manage to find the strength to continue’ (mean 
score: 3.80, SD 1.03). Mean scores of >3 (indicating agreement) for most items demonstrated 
that patients generally felt that both LoL and QoL were important outcomes. Overall a slightly 
higher proportion of patients placed greater importance on LoL (n=66, 48%) than those who felt 
QoL was more important (n=56, 41%). A minority of patients rated LoL and QoL equally 
(n=12, 9%). Overall preference could not be calculated for three patients (2%) with one or more 
missing items.  
Decisional control preferences 
Preferred role in decisions about treatment (control preferences) was most commonly 
collaborative (n=59, 44%), active-collaborative (n=35, 26%) or passive-collaborative (n=25, 
19%) (Figure 1). A minority preferred a fully active role (n=10, 7%), fully passive role (n=6, 
4%), or did not respond (n=2). Actual roles in decisions about treatment were similar to 
preferred roles; most commonly collaborative (n=54, 39%), active-collaborative (n=38, 28%) or 
passive-collaborative (n=29, 21%). A smaller number reported a fully active role (n=8, 6%) or 
fully passive role (n=8, 6%).  
Actual role in treatment decisions was generally concordant with preferred role (n=104, 76%). 
Discordance was identified for 33 patients (24%), most commonly patients who preferred a 
collaborative role but had an active-collaborative role in actual treatment decisions (n=9).  




Table 2: Quality quantity questionnaire 
Questions relating to preference for quantity [length] of life (LoL) Mean SD 
If a treatment could prolong my life, I would always accept it, 
whatever the side effects might be. 
3.5 1.15 
If I reached a point during treatment at which I felt like giving up, I 
would probably manage to find the strength to continue. 
3.80 1.03 
I would always accept a hard to tolerate treatment, even if the chance 
of it prolonging my life was as little as one percent. 
2.88 1.18 
In order to live a bit longer, I would clutch at any straw. 3.31 1.25 
Questions relating to preference for quality of life (QoL)   
If a life-prolonging treatment would prevent me from leading a 
normal life, then I would rather not have it. 
3.33 0.95 
A moment might come at which I would say “I have done my best, 
this is the limit”. 
3.50 1.01 
If I had to endure six months of intensive treatment in order to live for 
an extra half year, then I wouldn’t bother. 
2.89 1.05 
I can imagine some side effects being so bad that I would refuse the 
treatment, even if that meant a shorter life. 
3.20 0.97 
Footnote: Scores range from 1 to 5, with 1 indicating strong disagreement and 5 indicating strong 
agreement 
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Very likely Somewhat likely A little likely Not likely at all Don't know
Treatment expectations 
Figure 2 demonstrates overall expectations about treatment. Most patients indicated that 
chemotherapy was at least ‘a little likely’ to help them to live longer (n=121, 88%) and two-
thirds of patients thought that chemotherapy would help with cancer-related problems (n=92, 
67%). A significant proportion of patients indicated that cure was ‘not likely at all’ (n=80, 
58%), however over one quarter of patients indicated that chemotherapy was a least ‘a little 
likely’ to be curative (n=37, 27%). Of note, the majority of patients had incurable disease, 
however in a minority of cases (n=9) the possibility of local (radical) approaches upon 
volumetric response to chemotherapy was discussed.   











One third of patients experienced decisional conflict (n=45, 33%); four patients (3%) had 
extremely high decisional conflict (score 4). Decisional conflict was not associated with 
participant characteristics (socio-demographic, clinical, QoL or country of recruitment).  
Association between patient characteristics, preferences and expectations.  
Table 3 demonstrates associations between patient characteristics, preferred role and actual role 
in treatment decisions. Females were significantly more likely to prefer a collaborative role 
compared to males (55% vs. 32%), while males were more likely to prefer a passive role 




compared to females (31% vs. 15%); p=0.016. Patients with an ECOG performance status of 2 
were significantly more likely to prefer an active role in treatment decisions (p=0.042) than 
patients with a better PS (ECOG 0 or ECOG 1), but there was no association between global 
QoL and preferred role. A higher proportion of Dutch participants preferred an active role 
compared to UK participants (43% vs. 24%), whereas UK participants preferred a collaborative 
role (49% vs. 39%); however this did not reach statistical significance; p=0.066. Examining this 
association further, using the original five preferred roles, Dutch patients were significantly 
more likely to prefer a ‘fully active’ role than UK patients (14% vs. 1%; p=0.043). Similar 
patterns were observed in actual treatment decisions; Dutch patients and those with ECOG PS 2 
were significantly more likely to have an active role, while female patients were more likely to 
have a collaborative role compared to males (Table 3). Discordance between preferred and 
actual roles was not related to participant characteristics, or priorities towards QoL vs. LoL.  
Table 4 demonstrates associations between patient characteristics, preferences for QoL vs. LoL 
and views about whether treatment could be curative. Younger patients aged <40 years were 
significantly more likely to prioritise extended LoL than older patients (p=0.001). Conversely, 
almost two-thirds of older patients (aged 65 years) indicated that QoL was more important 
(n=27, 50 %), or equally as important (n=8, 15%) as LoL. Patients with children aged 18 years 
more commonly prioritised LoL than those without (67% vs. 44%), however this difference was 
not statistically significant (p=0.093). Patients who indicated that treatment could be curative 
were significantly more likely to prioritise LoL compared to those who indicated there was no 
chance of cure (78% vs. 39%;  p<0.001). Patients who prioritised QoL were significantly more 
likely to experience decisional conflict than patients prioritising LoL, or with equal preferences 
(p=0.049). Multiple logistic regression demonstrated that age (p=0.020), beliefs about 
curability (p=0.001) and decisional conflict (p=0.024) remained significantly associated with 
preference for QoL vs. LoL.  
Indication that chemotherapy could potentially be curative was significantly more likely among 
patients from Black, Asian and minority ethnic (BAME) backgrounds compared to Caucasians 
(50% vs. 23%; p=0.016). Patients who described themselves as religious were also more likely 
to indicate that there was some chance of cure vs. those who were not religious (38% vs. 22%), 
however this did not reach statistical significance (p=0.066). Exploring further, patients from 
Black, Asian and minority ethnic backgrounds were significantly more likely to describe 
themselves as religious than those of Caucasian ethnicity (BAME: 13 of 22 patients [59%] 
vs. Caucasians: 32 of 115 patients [28%]; p=0.006). Patients who thought there was no chance 
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of cure were more likely to prefer an active role in treatment decisions compared to those who 
thought cure was possible (87% vs. 13%; p=0.008). Multiple logistic regression demonstrated 
that ethnicity (p=0.025) and preferred role in decisions (p=0.004) remained significantly 

























Table 3: Associations between participant characteristics and control preferences.  
 Actual Role  Preferred role  
Participant 
characteristics 
 Active     Collaborative   Passive 
   n (%)           n (%)           n (%) 
 
p-value 
  Active      Collaborative    Passive 
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Table 4: Factors associated with attitudes towards QoL vs. LoL and beliefs about curability.  
 


















































































































































































































Time since diagnosis 
<= 6 months  




































































































Belief chance of cure 











































































To our knowledge this is the first prospective study evaluating the preferences and expectations 
of patients with advanced STS starting palliative first-line chemotherapy. Inclination towards 
extended LoL was slightly more common than preference for QoL; however patients generally 
indicated that both of these outcomes were important. Younger patients prioritised LoL, whereas 
many older patients felt that QoL was at least equally important. Decisional conflict was highest 
among patients who prioritised QoL, indicating uncertainty about the potential impact of 
chemotherapy on QoL. The majority of patients preferred a collaborative role in treatment 
decisions, and actual roles in treatment decisions were largely concordant with preferred roles. 
Preferred and actual roles in treatment decisions were related to gender, country of recruitment 
and performance status. Most patients considered that that chemotherapy would extend life, and 
around one quarter of patients indicated that chemotherapy could be curative. Patients who 
indicated that cure was possible were more likely to be from BAME backgrounds; conceivably 
due to different coping strategies, such as religious beliefs. 
Patient preferences are important throughout the disease trajectory, however, they are 
particularly pertinent in the setting of advanced STS when prognosis is short. Eliciting 
preferences may be challenging, but this can improve communication and satisfaction with 
informed decision-making.
35,36
 Studies among patients with other advanced cancers, have 
reported variable attitudes towards the trade-off between LoL and QoL, however, younger age 
has consistently been associated with preference for LoL.
11,37–40
 Our study demonstrated that 
younger patients with advanced STS were much more likely than older patients to place 
increased importance on living longer. It is probable that younger patients may have 
expectations about their future life, feel responsibility towards dependent children and may 
desire to continue working to provide family income, whereas older patients may have greater 
acceptance of the inevitability of death. Intensive treatment is more common among younger 
patients with cancer, which may be driven by the injustice of death at a young age.
41,42
  
Many participants considered QoL to be more important than LoL, and two-thirds of elderly 
patients (aged 65 years) indicated that QoL was at least equally as important as LoL. This 
finding is particularly important for designing clinical trials in advanced STS, where QoL could 
be considered as a (co)primary or composite endpoint.
43
 Patients who prioritised QoL were 
more likely to acknowledge that cure was not possible and more commonly experienced 
decisional conflict. This uncertainty may be due to concern about the adverse effects of 
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chemotherapy, limited available data on the impact of chemotherapy on QoL and perception that 
the decision to receive chemotherapy is not aligned with individual priorities. Although our 
study focused on patients starting first-line chemotherapy, others have shown that QoL may 
become more important further along disease trajectory.
39,44
 Although baseline global QoL was 
not associated with preference for QoL versus LoL, priorities may change with disease 
progression; follow-up HOLISTIC study data will be informative on this question. 
Shared decision-making is acknowledged to be an integral component of patient-centred care. 
Consistent with previous studies of patients with advanced cancers, the majority of patients 
desired a collaborative role in treatment decisions.
45–48
 Preferred role and actual roles in 
decisions varied according to patient gender, performance status and country of recruitment. The 
majority of females preferred an active or collaborative role in decisions, whereas more men 
than women preferred a passive role. Others have reported variable findings concerning the 
impact of gender on preferred role in treatment decisions.
18,19,47,49
 Patients with poor 
performance status (PS 2) were more likely to prefer an active role than those with a better 
performance status. Previous research had indicated that patients with an incurable disease 
tend to desire greater involvement in decisions further along their disease trajectory.
29–31
 
Dutch patients tended to prefer a more active role in treatment decisions compared to UK 
patients. An international study of 1,490 patients with advanced cancers also found country of 
origin was associated with preferred role in decisions.
46
  
All patients in our study had made the decision to receive chemotherapy and the majority 
thought that chemotherapy would extend survival. Studies have shown that patients with 
advanced cancer are likely to choose a treatment if they believe that the treatment will improve 
their prognosis.
50–55
 People with cancer may also be more willing to accept intensive treatments 
than people without cancer, even if there is  a very low chance of benefit, and at the expense of 
adverse consequences.
53,56
 This finding is conceivably related to altered attitudes when faced 
with a life-limiting condition.
53,56
 While the true impact of chemotherapy on survival for patients 
with advanced STS is not certain, survival has improved over recent decades with the 




Studies have consistently shown high levels of discordance between patient perceptions of 
outcomes and physician estimates of prognosis, with patients tending to overestimate survival 
and benefits of treatment.
58
 Patients with advanced STS generally thought that cure was not 




possible, however around one quarter of patients indicated that cure was a little likely, while 
others were not sure. The possibility of local (radical) approaches upon response to 
chemotherapy was discussed with a minority of patients. Patients from BAME backgrounds 
were more likely to indicate that chemotherapy could potentially be curative and were more 
likely to describe themselves as religious than Caucasians. Religious beliefs have previously 
been associated with belief about curability and a positive approach to coping in patients with 
other cancers (breast, prostate).
60,61
 Other ethnic differences in coping strategies, such as 
distraction and denial, have also been described.
62,63
 
Confidence in specialists, maintaining hope and optimism may also be an important coping 
strategy for patients.
64,65
 Tension between realism and hope is challenging, however it is 
possible to build trust, maintain hope and set realistic goals in the setting of incurable cancer.
66,67
 
Realistic aims may include improvement in symptoms, disease stability, extension of life, and 
reaching personal milestones such as important family occasions.
68
  
Studies have shown that the majority of patients with incurable metastatic cancer desire realistic 
communication including accurate disclosure of prognosis.
66,69
 Demographic, psychological and 
disease-related factors have been shown to influence preferred degree of disclosure.
66
 An 
individualised approach can allow patients control over the extent and delivery of the 
information provided.
69
 Tools to elicit patients preferences and attitudes towards treatment and 
decision making are not currently used for patients with advanced STS, however computer 
based assessment of patient values, goals and communication preferences has been shown to 
have a positive impact on communication and satisfaction with decision-making among patients 
with other metastatic cancers.
70
 Early assessment of preferences could also facilitate appropriate 




Participants were generally well-educated. The HOLISTIC study did not assess the 
preferences and expectations of patients receiving best supportive care. Around one quarter 
of patients are not able to start palliative chemotherapy, for example those with poor 
performance status or with histological subtypes that are not chemosensitive.  Patients who 
decline chemotherapy may prioritise maintaining QoL and are not willing to accept potential 
adverse consequences of chemotherapy. Treatment preferences were assessed prior to starting 
chemotherapy, however views and priorities may be different after starting chemotherapy. 
Follow-up HOLISTIC study data, including decisional regret, will provide insight into this 
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question. We did not ask patients or physicians to provide estimates of prognosis, however this 
could be evaluated in a future study. For example, the surprise question,  ‘Would I be surprised 





This study demonstrates significant heterogeneity in the preferences and expectations of patients 
with advanced STS, supporting a personalised approach to decisions about palliative treatments. 
Age-specific differences in attitudes towards quality of life and length of life should be 
considered when discussing the goals of palliative chemotherapy. Considering personal 
priorities, values, cultural and ethnic backgrounds, will optimise communication and enhance 
patient-centered care.   Further studies are needed to determine the optimal approach to assess 
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Purpose: Soft tissue sarcomas (STS) account for 8% of all cancers in adolescents and young 
adults (AYAs). Metastatic STS contribute significantly to disease-related mortality in this age 
group; however data are limited due to under-representation in clinical trials. 
Methods: AYAs aged 18-39 years, diagnosed with metastatic STS between 1990 and 2012 
were identified from The Royal Marsden Hospital database. Outcomes of interest were 
clinical characteristics, treatment patterns, overall survival (OS) and prognostic factors.  
Results: Overall 455 patients were included. Median age at diagnosis of metastatic STS was 
33 years (interquartile range [IQR] 27-37 years). The most common histological subtypes 
were leiomyosarcoma (n=68, 15%), synovial sarcoma (n=68, 15%), Ewing sarcoma (n=44, 
10%) and rhabdomyosarcoma (n=35, 8%). Treatments included systemic therapy (n=395, 
87%; median 2 lines [IQR 1-3]; clinical trial n=93, 22%), radiotherapy (n=297, 66%), 
metastasectomy (n=191, 43%). Median duration between last chemotherapy regimen and 
death was 4.6 months (IQR 2-10). Median OS was 19.2 months (95% confidence interval 
[CI]: 15.8-22.2); 5-year OS was 16%. Of common subtypes, patients with 
rhabdomyosarcoma had the worst OS (8.8 months; 95% CI 7.9-11.4). Adverse prognostic 
factors included male gender, synchronous metastases, bone or liver metastases, first-line 
polychemotherapy and no metastasectomy.  
Conclusion: Outcomes were variable; patients with supposed chemosensitive subtypes had 
particularly poor survival. The diverse behaviour of STS in AYAs highlights the need for 
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Soft tissue sarcomas (STS) are rare, heterogeneous tumours that can arise in patients of any 
age.
1 
Although STS account for 1-2% of all adult cancers, STS are proportionally more 
common in adolescents and young adults (AYAs), comprising 8% of cancer diagnoses in this 
age group.
2
 Definitions of AYAs vary, however, the U.S. National Cancer Institute and 
European Network for Cancer in Children and Adolescents have accepted the range 15-39 
years.
3
 Cancer is the leading cause of disease-related death in AYAs in high income 
countries, and STS contribute substantially to mortality and loss of life years.
4
  
The distribution of STS histological subtypes varies across the age spectrum. 
Rhabdomyosarcoma predominately occurs in children (typically embryonal subtype), 
however, can also arise in AYA (more commonly alveolar subtype).
5
 Ewing sarcoma of the 
bone has a peak incidence in adolescence, whereas extraosseous Ewing sarcoma is more 
commonly seen in young adults.
6
 Synovial sarcoma, epithelioid sarcoma and alveolar soft 
part sarcoma typically occur in young adults.
5
 STS classically affecting older adults, such as 
undifferentiated pleomorphic sarcoma (UPS), are also seen in patients in the upper age range 
of the AYA group.
5,7
  
Many STS demonstrate an aggressive phenotype, and approximately half of all patients with 
initially localized (intermediate- or high-grade) STS will develop metastatic disease.  
Previous research has described the epidemiology, biology and outcomes of AYAs with 
certain STS histological subtypes, however data on the treatment and survival of AYAs with 
metastatic STS are limited.
3-15
 AYAs with sarcoma are under-represented in clinical trials due 
to multiple factors including the separation between paediatric and adult care.
11
 Furthermore, 
when AYA are included within clinical trials, subgroup analysis of their outcomes are not 
routinely performed and data are therefore not distinguishable from the whole trial 
population.
11
 Observational studies can therefore provide informative data on the natural 




The Royal Marsden Hospital (RMH) Sarcoma Unit is one of the largest STS units in Europe. 
The RMH Sarcoma Unit is led by adult oncologists, and predominately treats patients aged 
18 years and older. Younger patients (aged <18 years) are treated in the Paediatric Unit, 
based at a different site, or referred to specialist units for teenagers and adolescents. The 




objectives of this study were to describe clinical characteristics, treatment patterns, 
prognostic factors and clinical outcomes of adolescents and young adults (AYA), aged 18-39 
years at diagnosis, treated for metastatic STS in the RMH Sarcoma Unit. These data will help 
guide the development of age-specific services, inform strategies for research and assist the 
design of future clinical trials. 
Materials and Methods  
AYAs, aged 18-39 years, diagnosed with STS and treated at RMH for metastatic STS 
between 1st January 1990 and 31st December 2012 were identified from the prospectively 
maintained Sarcoma Unit database. Data collected from electronic patient records included 
patient characteristics (e.g. gender), date of diagnosis of STS, anatomical site and size of 
primary tumour, histological subtype and grading (Fédération Nationale des Centres de Lutte 
Contre le Cancer [FNCLCC] criteria), number and location of metastases at first diagnosis of 
metastatic disease.  
All cases were reviewed by an expert STS pathologist. Molecular assays were chosen based 
on morphology and immunohistochemistry. Reverse-transcription-polymerase chain reaction 
(PCR), fluorescence in situ hybridization (FISH) and additional PCR tests for the family of 
tumours with EWSR1-CREB1 and EWSR1-ATF1 fusion transcripts were performed where 
appropriate.  
Three time periods were defined according to year of diagnosis of metastatic STS; 1990–
1997, 1998–2005 and 2006-2012. Synchronous disease was defined as metastases within 3 
months of STS diagnosis. Metachronous disease was defined as metastases more than 3 
months after STS diagnosis. 
Treatments included primary surgery, metastasectomy, radiotherapy, isolated limb perfusion, 
radiofrequency ablation, systemic therapies (chemotherapy, targeted drugs, endocrine 
therapies and phase I drugs) and stem cell transplant. Systemic therapies received, number of 
treatment lines and best radiological response (Response Evaluation Criteria In Solid 
Tumours [RECIST] criteria version 1.1 where available) were recorded. Date of death, or last 
follow up, was defined at the cut-off date of 1st October 2017 to ensure five-years of follow-
up data.  
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The primary endpoint was median overall survival (OS), defined from date of diagnosis of 
metastatic STS to the date of death, and censored at last follow-up. Secondary endpoints were 
median OS according to time period of metastatic STS diagnosis (defined above), median OS 
according to histological subtype and prognostic factors for OS. Additional measures 
included description of patient characteristics, treatment patterns and systemic therapy 
response rates. Categorical variables were summarised using frequencies and percentages, 
and continuous variables reported using median and interquartile range (IQR) and 95% 
confidence intervals (95% CI) for survival data. The effects of socio-demographic and 
clinical factors on OS were analysed using the chi-squared (2) test. Multivariate Cox 
regression was used to identify significant prognostic factors for OS. 
Results 
Patient characteristics  
Four hundred and fifty-five AYAs diagnosed with STS aged 18-39 years were included in the 
analysis (Table 1). 
Table 1. Patient Characteristics. 






Site of primary tumour 
Extremity 
Retroperitoneum 
Intra-abdominal & pelvic 
Gynaecological 
Intra-thoracic 











































































† ‘Other’ histological subtypes are demonstrated in Figures 1a and 1b. 
‡ Number of sites of metastases at first diagnosis of metastatic disease. 
 
Figure 1 demonstrates the median age at diagnosis according to STS histological subtype. 
One-third of patients presented with synchronous metastases and two-thirds developed 
metastatic disease after a median duration of 16 months (IQR 7-32). Median age at diagnosis 
of metastatic STS was 33 (IQR 27-37) years. The extremity was the most common site of 
primary disease (n=189, 42%) and median primary tumour size was 9 cm (range 0.6-57cm). 
Half of STS were classified as histological grade 3 (n=184, 53%).  Patients with 22 
histological subtypes were treated; highest frequency leiomyosarcoma (n=68, 15%; uterine 
leiomyosarcoma: n=20, ‘non-uterine’ leiomyosarcoma: n=48); synovial sarcoma (n=68, 
15%); Ewing sarcoma (n=44, 10%); rhabdomyosarcoma (n=35, 8%; alveolar: n=22, 
embryonal: n=9, pleomorphic/not otherwise specified: n=4); liposarcoma (n=35, 8%; myxoid 
n=26, ‘non-myxoid’ n=9); malignant peripheral nerve sheath tumour (MPNST; n=33, 7%); 
UPS (formerly MFH; n=25, 5%). At first metastatic diagnosis, most patients had one site of 
distant spread (n=306, 67%); commonly pulmonary metastases (n=268, 59%). 
Seventeen patients (4%) had a history of a previous malignancy and 67 patients (15%) had a 
family history of cancer affecting a first or second degree relative. One patient had Li-
Fraumeni syndrome. Details of family history were not available for two-thirds of patients 
(n=301, 66%).  
All patients with alveolar rhabdomyosarcoma and molecular analysis (n=9) had the PAX3-
FOXO1 fusion gene (formerly PAX3-FKHR). Thirteen patients with MPNST (39%) had an 
NF-1 mutation (20 patients with available data). 
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Acronyms: ASPS: alveolar soft part sarcoma; DSRCT: desmoplastic small round cell tumour; 
MPNST: malignant peripheral nerve sheath tumour; EHE: epithelioid 
haemangioendothelioma; ESS: endometrial stromal sarcoma; SFT: solitary fibrous tumours; 
Sarcoma NOS: sarcoma not otherwise specified; LGFMS: low grade fibromyoid sarcoma; 
IMT: inflammatory myofibroblastic tumour; UPS: undifferentiated pleomorphic sarcoma; 
EMC: extraskeletal myxoid chondrosarcoma. 
 
Treatment patterns  
Three hundred and twenty-two patients (71%) had surgical resection of the primary tumour 
and 191 patients (42%) had at least one metastasectomy (Table 2).  Two-thirds of patients 
received radiotherapy (n=297, 66%). The majority of patients were treated with systemic 
therapy (n=395, 87%). Patients received a median of two lines of systemic therapy (range 1-
8). Anthracycline-based chemotherapy was the most common first-line treatment (n=211, 
46%); doxorubicin plus ifosfamide (n=86) or single agent doxorubicin (n=82) (Table 3). 
Ninety-three patients (22%) participated in a clinical trial; 16 patients (4%) received a phase I 
or II trial drug as first-line systemic therapy and 14 patients (3%) took part in more than one 
clinical trial.  


























Age at Diagnosis According to Histology Subtype




















































































































































































Acronyms: LMS: leiomyosarcoma; SS: synovial sarcoma; Ewing: Ewing sarcoma; RMS: 
rhabdomyosarcoma; LIPO: liposarcoma; MPNST: malignant peripheral nerve sheath tumour; UPS: 
undifferentiated pleomorphic sarcoma. 
 
The majority of radiological responses occurred in the first-line setting (complete response 
[CR] n=6, partial response [PR] n=89; overall response rate 27%) (Figure 2). The response 
rate to second-line treatment was 13% (CR: n=2, PR n=26). Treatment responses (CR or PR) 
beyond second-line of treatment were uncommon (3rd-line: n=7, 4th-line: n=8, 5th-line or 
beyond: n=0). Around one third of patients who received first-, second- and third-line 
systemic treatment had stable disease at best response (first-line: n=100, 31%; second-line: 
n=68, 31%; third-line: n=39, 36%). 
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Table 3. Systemic therapy received according to treatment line. 
Systemic therapy name  1st line (n) 2nd line (n) 3rd line (n) 4th line (n) 5th line (n) 
Doxorubicin 82 16 5 3 0 
Ifosfamide 30 46 12 4 3 
Doxorubicin+Ifosfamide 86 14 3 0 0 
Trabectedin 6 25 22 13 3 
Gemcitabine+Docetaxel 10 11 9 6 2 
Caelyx 7 7 7 5 2 
VIDE 8 0 0 0 0 
VAC 11 4 0 1 0 
IVAD 10 4 1 0 0 
IVA  3 5 0 0 0 
Cisplatin+etoposide 9 9 2 0 0 
Ifosfamide+etoposide 6 8 2 3 0 
Etoposide 9 11 5 4 1 
Pazopanib 2 6 6 4 1 
Paclitaxel 9 3 0 0 0 
Phase 1 drugs 16 28 12 8 1 
Other Dox/Caelyx based regimen 8 3 2 0 0 
Other Ifosfamide  based regimen 6 1 0 0 0 
Other Doxorubicin (or caelyx)+Ifosfamide based regimen 10 0 1 0 0 
Other polychemotherapy regimen 20 11 12 2 1 
Other single agent 13 17 11 5 4 
Endocrine therapy 5 8 3 4 2 
Stem cell regimen 0 2 3 0 1 
Acronyms: VIDE: vincristine, ifosfamide, doxorubicin, etoposide; VAC: vincristine, 
actinomycin D, cyclophosphamide; IVAD: ifosfamide, vincristine, doxorubicin; IVA: 
ifosfamide, vincristine, actinomycin .D.  































Line of systemic therapy









The median duration between starting the last systemic treatment and death was 4.6 months 
(IQR 2-10); 32 patients started within 1 month of death (7%) and 119 patients started within 
3 months of death (26%) (Table 4). Date of last chemotherapy cycle before death was 
available for 299 patients (66%); 62 patients received their last chemotherapy cycle within 30 
days of death (21%) and a further 66 patients (22%) received their last chemotherapy cycle 
between 30 and 60 days of death. 
Table 4. Duration between starting last systemic therapy regimen and death. 
Time (months) N (%) Cumulative total (%) 
Less than one month   32 (7) 32 (7) 
1-1.99   49 (11) 81 (18) 
2-2.99 38 (8) 119 (26) 
3-3.99 28 (6) 147 (32) 
4-4.99 18 (4) 165 (36) 
>4.99 158 (35) 323 (71)  
Footnote: Percentages are expressed as proportion of whole patient group (n=455). 
Overall survival  
Median OS was 19.2 months (95% CI: 15.8 – 22.0). The 5-year OS rate was 19%. There was 
no significant difference in median OS according to time period of diagnosis (p=0.89). 
Median OS for the most common STS subtypes; leiomyosarcoma  20.1 months (95% CI 
14.0-31.8) (uterine leiomyosarcoma: 28.1 months [95% CI 15.0-82.3], ‘non-uterine’ 
leiomyosarcoma 15.0 months [95% CI 11.3-31.8]); synovial sarcoma 19.5 months (95% CI 
14.3-28.9); Ewing sarcoma 13.4 (95% CI 8.9-25.2); rhabdomyosarcoma 8.8 months (95% CI 
7.9-11.4); MPNST 12.9 months (95% CI 9.1-22.8); myxoid liposarcoma 40.3 months (95% 
CI 28.4-60.9) (non-myxoid liposarcoma 64.4 months [95% CI 3.5-82.7]); UPS 11.2 months 
(95% CI 7.9-22.0) and ‘other’ subtypes 21.6 months (95% CI 16.0-27.2). Figure 3 shows 
median OS according to all histological subtypes. Patients with history of a previous 
malignancy (n=17) had a median OS of 8.6 months (95% CI 4.8-14.0).  
On multivariate analysis (Table 5), adverse factors for OS were male gender (hazard ratio 
[HR] 1.4 [95%CI 1.1 – 1.8]), synchronous metastases at diagnosis (HR 1.9 [95%CI 1.4– 
2.5]), bone or liver metastases (bone: HR 1.7 [95%CI 1.2– 2.4]; liver: HR 1.5 [95%CI 1.0 – 
2.2]), polychemotherapy as first-line systemic treatment (HR 1.4 [95%CI 1.1-1.8]), no 
surgery for primary tumour (HR 1.4 [95%CI 1.0 – 1.9]) and no metastasectomy (HR 2.4 
[95%CI 1.8 – 3.1]) 
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Table 5. Cox Multivariate model 
Covariate p-value HR (95% CI) 
Sex   
Female    






1.41(1.12 – 1.77) 
Metastatic disease  
Metachronous 
























1.48(1.04 – 2.11) 
Polychemotherapy 1
st


























2.35(1.81 – 3.05) 
 





This study describes treatment patterns and clinical outcomes of a large group of AYAs with 
metastatic STS treated at a specialist sarcoma unit. Overall survival was poor, although 
slightly better than the accepted prognosis for adult patients with metastatic STS treated in 
clinical practice (12-18 months).
17
 Patients with tumours regarded as chemosensitive, such as 
rhabdomyosarcoma and Ewing sarcoma, had particularly poor survival. Other histological 
subtypes demonstrated relatively indolent behaviour. Multimodality treatment was common 
and systemic treatment was frequently started within the last four months of life, emphasising 
the wish of patients or oncologists to treat, although a limited impact of palliative 
chemotherapy on survival.  
Rhabdomyosarcomas in AYAs were most commonly of alveolar or embryonal ‘paediatric’ 
subtypes. Although these tumours are typically sensitive to chemotherapy, survival was 
remarkably poor in these patients. Previous studies have also demonstrated that AYA with 
rhabdomyosarcoma have poor outcomes compared to children.
18,19
 This has been attributed to 
unfavourable clinical features (e.g. alveolar subtype, nodal infiltration, metastases at 
presentation), biological differences (e.g. multidrug resistance proteins) and under-treatment 
compared to intensive paediatric protocols.
5,19
  
The majority of AYA with rhabdomyosarcoma had an alveolar subtype (63%), and all of 
those with molecular analysis had expression of the PAX3-FOXO1 fusion gene. Alveolar 
subtype and expression of the PAX3-FOXO1 fusion gene are features associated with an 
aggressive phenotype and poor outcomes.
18
  
AYAs often present with larger, more invasive tumours due to late patient presentation and 
delayed recognition by healthcare professionals.
5,9
 Strategies to improve early diagnosis are 
not unjustified, however the intrinsically aggressive behaviour of rhabdomyosarcomas may 
prevail over any impact of diagnostic delay on survival.
20
 Where possible, patients at our 
institution received treatment within dose-dense protocols; predominately IVA (ifosfamide, 
vincristine, dactinomycin) or VAC (vincristine, dactinomycin, cyclophosphamide). Where 
dose intensity was reduced, this was due to tolerability or delayed bone marrow recovery 
rather than due to older age of the patients. Inadequate treatment intensity was not believed to 
be an important contributory factor for the poor outcomes of patients at RMH. Further 
understanding of underlying biology is needed to rationalise treatment protocols and develop 
more effective treatments. 
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Considering other common STS subtypes, AYAs with metastatic Ewing sarcoma, MPNST 
and UPS had poor survival. Outcomes of AYAs with metastatic Ewing sarcoma (skeletal and 
extra-skeletal) are acknowledged to be worse than for paediatric patients with the same 
histological subtypes; it is uncertain whether older age is an independent adverse prognostic 
factor, or whether older age carries a risk of other unfavourable factors such as primary 
metastatic disease and poor response to primary chemotherapy.
21-23
  
More than a third of AYAs with MPNST had an NF-1 mutation, which is associated with 
worse prognosis compared to sporadic MPNST.
10,24
 Patients with MPNST respond relatively 
poorly to chemotherapy and those arising in the setting of NF-1 mutations may have inferior 
response rates.
25,26
 Loss of the NF-1 protein leads to activation of the RAS signalling 
pathway, however therapeutic attempts to target RAS signalling and downstream pathways 
have had disappointing results.
27
 Clinical trials evaluating multi-agent strategies (such as 
MEK and mTOR inhibitors) are on-going and results are awaited.  
Survival of AYAs with metastatic UPS was similar to adults with metastatic UPS treated in 
clinical practice, as reported by the French Sarcoma Group, (AYA: 10.8 months vs. adults: 
11.2 months).
17 
Survival of AYAs with metastatic leiomyosarcoma was also in line adults 
with metastatic leiomyosarcoma in the French Sarcoma Group study (AYA: 20.1 months vs. 
adults: 19.4 months).
17
 Interpretation of a subgroup analysis of patients with uterine versus 
‘non-uterine’ leiomyosarcoma was limited by large confidence intervals. Previous studies 
have reported no significant differences in the outcomes of patients with advanced or 




Survival of AYAs with metastatic synovial sarcoma was similar to adults with synovial 
sarcoma in the French Sarcoma Group ‘METASARC’ observational study (AYA: 19.5 
months vs. adults: 19.7 months).
31
 Others have reported a better prognosis for AYA with 
metastatic synovial sarcoma compared to adults
.32,33 
Despite similar histological features, 
characteristic t(X;18) translocation and fusion transcripts, adults with synovial sarcoma have 
worse outcomes compared to children.
34 
Greater chromosomal instability in adults is 
associated with inferior metastatic outcomes, however mechanisms leading to chromosomal 
complexity are not well understood.
35
 Furthermore, chromosomal instability does not predict 
response to chemotherapy.
36
 Future research may identify genomic alterations which are 
involved in response to treatment and could be targeted with novel or existing agents.
36
  




The majority of AYAs with liposarcoma had a ‘myxoid’ variant, characterized by a 
t(12:16)(q13;p11) translocation, resulting in the formation of a FUS-CHOP fusion 
oncoprotein (rarer  aberrations include t(12;22)(q13;a12) resulting in DDIT3-EWSR1 fusion 
protein).
37
 AYAs with myxoid liposarcoma had a favourable outcome compared to many 
other STS subtypes, explained by the disease biology and sensitivity both to chemotherapy 
and radiotherapy. Myxoid liposarcomas are particularly sensitive to trabectedin, attributable 
to inhibition of gene transcription (affecting production of the aforementioned fusion 
oncoproteins), key cellular processes and modulation of the tumour microenvironment.
38,39
 
Trabectedin was not widely available during the study period, however the pivotal 
randomized phase III trial of trabectedin versus dacarbazine for patients with metastatic 
liposarcoma or leiomyosarcoma (after failure of conventional chemotherapy) demonstrated 
that trabectedin is particularly effective in patients with liposarcomas (myxoid, pleomorphic 
and dedifferentiated subtypes) and leiomyosarcomas.
40
 Trabectedin has also shown activity 
and clinical benefit in many other STS subtypes and it is probable the outcomes of AYAs 
with metastatic STS have improved since Trabectedin was approved in the United Kingdom 
in 2010 (National Institute of Clinical Excellence).
41,42,43 
Consistent with previous studies, poor prognostic factors for survival included male gender, 
synchronous metastases at diagnosis, liver metastases or bone metastases.
31,44,45 
Inferior 
outcomes for male patients may be due to faster clearance of the Doxorubicin metabolite 
(doxorubicinol).
46 
First-line polychemotherapy was associated with poor survival, after 
adjusting for known prognostic factors. This contrasts with the METASARC study of adults 
with metastatic STS, which found that polychemotherapy was associated with better 
outcomes.
31
 It is probable that AYA with intrinsically aggressive tumours were preferentially 
treated with polychemotherapy, and would have had a poor outcome irrespective of 
treatment. 
Surgical resection of the primary tumour was associated with favourable outcome, and 
primarily represents patients with metachronous metastatic disease who had primary surgery 
before developing metastases. A small number of patients had palliative surgery to the 
primary site after developing metastases, such as limb amputation for intractable symptoms. 
Metastasectomy was also associated with improved survival after accounting for known 
prognostic factors. Better outcomes in these patients are likely to be attributable, in part, to 
the more indolent biological behaviour of tumours which are selected for metastasectomy, 
and limited number of metastases in these cases (i.e. oligometastatic disease).The 
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METASARC study reported similar rates of loco-regional surgery in adults with metastatic 
STS (adults: 39% vs. AYA: 42%).
31
 
One-fifth of AYAs participated in a clinical trial, which is slightly higher than overall rates of 
clinical participation in adults with cancer; estimated to be less than 5%.
11,47,48
  This may be 
because RMH is a tertiary referral centre and the Sarcoma Unit is closely linked to the drug 
development unit (DDU). AYAs may be more likely to participate in clinical trials at the 
DDU as they are less likely to have medical comorbidities that may preclude study entry. 
Patients who participated in a clinical trial as first-line systemic treatment for metastatic STS 
included patients who were treated within international phase III randomized trials, patients 
who entered phase I or II trials because no effective conventional treatments were available at 
that time (e.g. alveolar soft part sarcoma or clear cell sarcoma) or patients who had already 
received adjuvant chemotherapy with doxorubicin and ifosfamide. Patients who took part in 
clinical trials at later stages of their treatment trajectory (phase I or II trials) were those who 
had progressed through several lines of standard chemotherapy and had limited treatment 
options.  Recently there have been several subtype specific trials including AYA patients, 
such as a phase II trial with the EZH2 inhibitor (tazemetostat) for patients with advanced 
epithelioid sarcoma, and a placebo-controlled randomized phase II study with cediranib for 
patients with metastatic alveolar soft part sarcoma (CASPS).
49,50
 
A large proportion of AYA patients received chemotherapy in the last months of life. High-
intensity end-of-life care is common in AYAs with cancer, and inherent risks include 
hospitalisation, intensive care unit (ICU) admission and intubation.
51-53
 Patients receiving 
active treatment are less likely to have palliative care involvement, which is essential for 
symptom control, advance care planning and decisions surrounding stopping anti-cancer 
treatments. Very few patients received no active treatment and were managed with best 
supportive care; this contrasts with studies of older patients in whom frailty and comorbid 
conditions are important considerations.
31,54
   
Very few radiological responses were seen beyond second-line systemic therapy; however a 
third of patients attained stable disease with third-line treatment. Similarly, the METASARC 
study reported limited benefit of systemic therapy beyond the second-line setting (except 
leiomyosarcoma), with a median time to next treatment of 2-3 months.
31
 The absence of 
disease progression, not only tumour shrinkage, has been shown to have a favourable impact 
on disease control and survival.
55
 Research into the impact of disease stability on health-




related quality of life may be valuable for patients making challenging treatment decisions 
towards the end of their life.  
Patients with a history of previous malignancy had significantly worse OS compared to the 
overall group. This is consistent with the known adverse impact of a second primary 
malignancy on survival compared with a primary neoplasm in patients of the same age 
group.
56
 Younger age at diagnosis of STS is associated with a higher chance of inherited 
susceptibility; however, family history was not available for two-thirds of patients.
57
 
Recognising patients with inherited genetic defects can guide therapeutic decision making, 




Missing data were common, particularly for patients treated prior to the introduction of 
electronic patient records in 1997. Documentation of family history was limited; attention to 
this topic has become more prominent over the years with advances in genomic technology 
and development of systemic therapies that target specific genetic aberrations in patients with 
cancer.
58
 Selection bias was inherent in our patient sample; patients referred to RMH often 
have challenging disease and have exhausted standard treatment options at local centres. 
Time periods defined were arbitrary as they did not reflect any significant change in 
treatment paradigm. 
Conclusions 
Survival of AYAs with metastatic STS varied according to histological subtype. Patients with 
tumours that are typically sensitive to chemotherapy had particularly poor outcomes. This 
demonstrates that tumour biology plays an important role in the outcomes of patients in this 
age group. Most patients had multimodal treatment and many received chemotherapy in the 
last few months of life, representing a high-intensity treatment approach. Further research 
into the underlying biological mechanisms and clinical trials that consider age and 
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Table 1: Number of metastasectomies received by patients with common histological 
subtypes. 
 
Histology 1 2 3 4 >4 unknown  
Leiomyosarcoma 20 6 2 1 1 2 
Synovial sarcoma 20 7 4 0 0 0 
Ewing sarcoma 7 1 0 1 0 1 
Rhabdomyosarcoma 1 0 0 0 0 1 
Liposarcoma 12 6 3 2 2 0 
MPNST 5 5 0 0 0 0 
UPS 8 1 1 1 3 0 
Acronyms: MPNST -  malignant peripheral nerve sheath tumour; UPS – undifferentiated pleomorphic 
sarcoma.  
Table 2: Median overall survival in patients with common histological subtypes treated with 

















 line Doxorubicin 
 




 line Doxorubicin+ 
Ifosfamide 
Median OS (95% CI) 
months  
Leiomyosarcoma 18 19 15.0 (6.2 – 31.8) 14.5 (11.3 – 65.0) 
Synovial sarcoma 10 23 13.7 (4.7 – 35.5) 19.5 (10.7 – 35.1) 
Liposarcoma 
 
12 4 29.9 (25.6 –NR) 
 
40.3 (27.4 – NR) 
MPNST 
 
7 9 5.8 (0.9 – 38.6) 
 
26.1 (10.9 – 52.5) 
UPS 6 11 8.6 (2.6 – NR) 13.6 (7.9 -35.1) 
 
Acronyms: MPNST -  malignant peripheral nerve sheath tumour; UPS – undifferentiated pleomorphic 
sarcoma. (N.B. Ewing and rhabdomyosarcoma were not included due to their different treatment 
protocols). 
Table 3: Number of participants in clinical trials according to line of systemic treatment. 
Line of systemic 
treatment 
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Background: Almost half of patients diagnosed with soft tissue sarcoma (STS) are older 
than 65 years, however, the outcomes of elderly patients with metastatic disease are not well-
described.  
Patients and Methods: An elderly cohort of patients aged 65 years was extracted from the 
European Organization for Research and Treatment of Cancer (EORTC) Soft Tissue and 
Bone Sarcoma Group database of patients treated with first-line chemotherapy for advanced 
STS within 12 EORTC clinical trials. End points were overall survival (OS), progression-free 
survival (PFS) and response rate (RR).  
Results: Of 2,810 participants in EORTC trials, there were 348 elderly patients (12.4%, 
median 68 years; interquartile range [IQR] 67-70; maximum 84 years) and 2,462 patients 
aged <65 years (median 49 years; IQR 39-57).  Most elderly patients had performance status 
of 0 (n=134; 39%) or 1 (n=177; 51%). Leiomyosarcoma (n=130; 37%) was the most common 
histological subtype. Lung metastases were present in 181 patients (52%) and liver 
metastases in 63 patients (18%). Overall, 126 patients (36%) received doxorubicin, 114 
patients (33%) doxorubicin-ifosfamide, 43 patients (12%) epirubicin, 39 patients (11%) 
trabectedin and 26 patients (7%) ifosfamide. Overall RR was 14.9% (n=52), median PFS was 
3.5 months (95% confidence interval [CI], 2.7-4.3) and median OS was 10.8 months (95% 
CI, 9.43-11.83). In patients aged <65 years overall RR was 20.3% (n=501), median OS was 
12.3 months (95% CI, 11.9-12.9) and median PFS was 4.3 months (95% CI, 3.9-4.6).  
Conclusion: Elderly patients with metastatic STS treated with first-line chemotherapy were 
largely underrepresented in these EORTC STS trials. Their outcomes were only slightly 
worse than those of younger patients. Novel trials with broader eligibility criteria are needed 
for elderly patients. These should incorporate geriatric assessments and measurements of age-
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Global life expectancy is increasing annually. In 2015, the World Health Organisation 
(WHO) estimated that this figure reached 71.4 years, exceeding 82 years in twelve countries.
1
 
Cancer is predominantly a disease of the elderly due to the cumulative acquisition of genetic 
abnormalities and lifetime exposure to carcinogens.
2
 Currently more than 60% of all cancer 
diagnoses and 70% of cancer-related deaths occur in patients aged >65 years.
3 
In view of the 
ageing population, it is widely acknowledged that the incidence of cancer will continue to 
rise significantly in the years to come.
3
 The challenges of treating elderly cancer patients are 
multifactorial. Physiological changes associated with ageing, comorbid medical conditions, 
psychosocial factors, functional and nutritional status and polypharmacy are several key 
issues which require careful consideration in elderly cancer patients.
4
 The interaction of these 
factors is complex, and their influence on cancer biology, treatment tolerance, compliance, 




Currently a multidisciplinary approach is 
recommended, however it is undeniable that new guidelines specifically for elderly cancer 
patients are urgently needed.
2 
Despite the large number of elderly patients with cancer, they are often disproportionally 
under-represented in clinical research trials.
5
 Strict exclusion criteria, attrition (mortality, 





Data from studies in younger patients are often extrapolated in order to aid clinical 
decision-making in elderly patients. Outcomes for elderly patients in clinical trials are not 
routinely distinguished from all data, thus limiting evidence-based decision making in clinical 
practice. Furthermore, dose reductions are frequently implemented in elderly ‘frail’ patients, 
without clear evidence of treatment efficacy at lower dose levels.
3
  
Soft tissue sarcomas (STS) are rare, heterogeneous tumors that account for approximately 1% 
of all adult solid malignancies.
7 
Approximately half of patients with localised, high-grade 
tumours will eventually develop metastatic disease.
8
 Cytotoxic chemotherapy, usually an 
anthracycline-based regimen, has been the mainstay of treatment since the 1970s.
9 
Median 
overall survival for patients with advanced soft tissue sarcoma is around 12-19 months.
10-13 
STS are common in elderly patients aged ≥65+ years, with an age-adjusted incidence of 11.3 
cases per 100,000 population compared with 2.3 cases per 100,000 in those aged <65 years.
14
 
Although approximately 40-50% of all patients diagnosed with STS are aged >65 years, the 
median age of patients in prospective first-line chemotherapy trials for advanced STS ranges 






 The objective of this study is to examine outcomes of elderly patients 
treated with first-line chemotherapy within European Organization for Research and 
Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials. 
Patients and Methods 
Patient sample 
The EORTC-STBSG database comprises 3,711 patients treated with first-line chemotherapy 
in 15 EORTC advanced STS trials. In this analysis, patients with gastrointestinal stromal 
tumours (GIST), those who had received prior (adjuvant or palliative) chemotherapy, and 
patients for whom age or time to treatment failure (discontinuation of treatment for any 
reason, including disease progression, toxicity or death) was missing were excluded. 
Furthermore, we wished to focus on outcomes with currently used chemotherapy schedules 
and consequently patients treated with cyclophosphamide, vincristine, adriamycin, 
dacarbazine (CYVADIC), ifosfamide 12mg/m
2
, or brostallicin were not included in this 
analysis. Therefore, 2,810 patients from 13 trials were used for the descriptive part of this 
report. Elderly patients were defined as those aged at least 65 years. The randomised trial of 
doxorubicin versus doxorubicin plus ifosfamide (EORTC 62012) had an upper age range of 
60 years (oldest patient 63 years), and therefore patients in this trial did not contribute to the 
elderly subgroup. From the remaining 12 studies, 348 elderly patients were identified 
(Appendix: Summary of EORTC-STBSG clinical trials in this analysis and elderly patients 
per protocol). Ethical approval was not required for this analysis.  
Endpoints 
Endpoints for this analysis were overall survival (OS), progression free survival (PFS) and 
response to chemotherapy. PFS was defined as the time interval between the date of 
randomisation, or the date of prospective registration in the non-randomised trials, and the 
date of first report of progression or death, whichever came first. Patients who were alive and 
without progressive disease at the last follow-up date were censored. OS was computed from 
the date of randomisation (in randomised trials) or the date of prospective registration (in 
non-randomised trials) to the date of death. Patients who were alive at the last follow up date 
were censored. Response to chemotherapy was evaluated in all trials using WHO response 
criteria or RECIST, and categorised as complete response, partial response, stable disease, or 
progressive disease.  
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The variables included in the study were demographic data, histological subtype of sarcoma, 
and the extent of the disease at the time of inclusion in the trials and the assigned treatment. 
The demographic variables include age and performance status (PS) before the start of 
chemotherapy. PS was measured on the WHO scale (except for two trials in which it was 
retrospectively converted from Karnosky scale to the WHO scale). As few patients had PS 3, 
PS 2 and 3 were combined in the same category, named as PS 2+. Variables related to the 
history of sarcoma were prior radiotherapy and prior surgery which had three categories; no 
surgery, partial surgery (including palliative surgery and other) and total surgery. For study 
62012, data about primary surgery was not collected; therefore the variable was missing for 
all the patients of that trial. Histopathological grade estimated by a panel of reference 
pathologists was preferred over the use of local diagnosis to ensure the consistency and 
homogeneity of the database. Similarly, the reviewed histopathological cell type was 
preferred over the local diagnosis.  












), ifosfamide alone (ifosfamide 5 mg/m
2
, ifosfamide 3mg/ m
2
 [days 1-3],  
ifosfamide 9 mg/m
2
 [continuous infusion over 72 hours]), the combination of doxorubicin 
and ifosfamide (doxorubicin 50mg/m
2
 - ifosfamide 5 mg/m
2





, doxorubicin 75 mg/m
2
 - ifosfamide 10 mg/m
2
) and trabectedin (1.3 
mg/m² [3 hour infusion] or 1.5 mg/m² [24 hour infusion]). 
Statistical methodology 
All baseline variables are described. The categorical data are summarized by frequencies and 
percentages, and the continuous covariates are summarized by median, interquartile range 
and the overall range. The overall and progression free survival were estimated by the 
Kaplan–Meier method. Medians are provided with corresponding 95% Confidence Intervals 
(CI). Response to chemotherapy is summarized as a percentage with corresponding 95% CI.  
Results 
A total of 348 elderly patients with advanced STS who entered in EORTC first-line 
chemotherapy clinical trials between 1980 and 2012 were identified for this analysis.  




Patient Characteristics  
The median age of elderly patients was 68 years (IQR 67-71), with a maximum of 84 years 
(Table 1). Most patients had a performance status (PS) of 0 (n=134, 38.5%) or 1 (n=177, 
50.9%). A small number of patients had a PS of 2+ (n=32, 9.2%). Histopathological grade 
was most commonly grade 3 (n=89, 25.6%) or grade 2 (n= 71, 20.4%); however, data 
regarding tumour grade were ‘missing’ for almost half of patients (n=155, 44.5%). The most 
frequent histological subtypes were leiomyosarcoma (n=130, 37.4%), malignant fibrous 
histiocytoma (MFH) or undifferentiated pleomorphic sarcoma (UPS; n=55, 15.8%) and 
liposarcoma (n=30, 8.6%). Of note, MFH is no longer part of the currently used 
nomenclature and has been reclassified as UPS. There were 43 patients (12.3%) with 
unclassified or missing histological subtype. Overall, 167 patients (48%) had involvement of 
the primary site of disease, more than half of patients had pulmonary metastases (n=181, 
52.0%), 63 patients (18.1%) had liver metastases, 24 patients (6.9%) bone metastases, and 
139 patients (39.9%) with metastases at other sites.   
Table 1: Patient  
Characteristics 
Age category  
Total (n=2810) < 65 yrs. (n=2462) ≥65 yrs. (n=348) 
Performance status   n (%)                                                                                                   n (%)                                                                                                    n (%)                       
0 1122 (45.6)                                                                                         134 (38.5)                                     1256 (44.7)
1 1127 (45.8)                                                                                         177 (50.9)                                         1304 (46.4)
2+  187 (7.6)                                        32 (9.2)                                                                                           219 (7.8)
Missing   26 (1.1)                                                                                          5 (1.4)                                          31 (1.1)
Treatment*                                                                                                                                                                                                         
DOX 75  843 (34.2)                                   113 (32.5)                                                                                         956 (34.0)          
Caelyx   34 (1.4)                                                                                          13 (3.7)                                                                                          47 (1.7)
EPI 75   81 (3.3)                                                                                          17 (4.9)                                    98 (3.5)
EPI 3*50   89 (3.6)                                                                                19 (5.5)                                                                                          108 (3.8)
EPI 1*150  102 (4.1)                         7 (2.0)                                                                                          109 (3.9)                                                                            
IFO 5   43 (1.7)                                                                                          9 (2.6)                                          52 (1.9)
IFO 3*3  134 (5.4)                                                                                          13 (3.7) 147 (5.2)
IFO 9 continu   98 (4.0)                                                                          4 (1.1)                                                         102 (3.6)           
DOX 50-IFO 5  533 (21.6)                                                                                         78 (22.4)                                          611 (21.7)               
DOX 75-IFO 5  234 (9.5)                                                                                          36 (10.3)                                         270 (9.6)
DOX 75-IFO 10  220 (8.9)                                                                                          0 (0.0)                             220 (7.8)
Trabectedin   51 (2.1)                                                                      39 (11.2)                                                                                         90 (3.2)           
Histological Grading                                                                                                                                                                                                         
1  213 (8.7)                                                                                          33 (9.5) 246 (8.8)
2  703 (28.6)                                                                                         71 (20.4)                                          774 (27.5)
3  841 (34.2)                                                                                         89 (25.6)                                          930 (33.1)
Missing  705 (28.6)                                                                                         155 (44.5)                                                                                        860 (30.6)
Histological Cell Type                                                                                                                                                                                                         
MFH/UPS**  239 (9.7)                                                                                          55 (15.8)                                          294 (10.5)
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Leiomyosarcoma  741 (30.1)                                                                                         130 (37.4)                                                                                 871 (31.0)
Liposarcoma  242 (9.8)                                                                                          30 (8.6)                                         272 (9.7)
Synovial sarcoma  254 (10.3)                          11 (3.2)                                                                                           265 (9.4)                            
Fibrosarcoma   74 (3.0)                                                                                          12 (3.4)                                                                                          86 (3.1)       
Rhabdomyosarcoma   56 (2.3)                                                                                          3 (0.9)                                          59 (2.1)
Angiosarcoma   78 (3.2)                              12 (3.4)                                                                                          90 (3.2)                                                                                    
MPNST***  127 (5.2)                                                                                          7 (2.0)                                                                                          134 (4.8)               
Miscellaneous  398 (16.2)                                                                                         45 (12.9)                  443 (15.8)
Unclassified  160 (6.5)                                                                                          21 (6.0)                                         181 (6.4)
Missing   93 (3.8)                                   22 (6.3)                                                                                           115 (4.1)
Prior Surgery                                                                                                                                                                                                                
No  213 (8.7)                                                                                          20 (5.7)                                         233 (8.3)
Partial  474 (19.3)                                  65 (18.7)                                                                                          539 (19.2)
Total  482 (19.6)                                                                                         69 (19.8)                                          551 (19.6)
Missing 1293 (52.5)                                                                                         194 (55.7) 1487 (52.9)
Prior radiotherapy                                                                                                                                                                                            
No 1677 (68.1)                                                                                         201 (57.8)                                         1878 (66.8)
Yes  675 (27.4)                                                                                         71 (20.4)                                          746 (26.5)
Missing  110 (4.5)                                                                                          76 (21.8)                                         186 (6.6)
Site (s) of Disease 
involvement 
   
Primary site involved 1076 (43.7)                                                                                         167 (48.0)                                         1243 (44.2)
Bone metastases  252 (10.2)                                                                                         24 (6.9)                                          276 (9.8)
Liver metastases  420 (17.1)                         63 (18.1)                                                                                          483 (17.2)                            
Lung metastases 1417 (57.6)                                                                                         181 (52.0)                                         1598 (56.9)
Other metastases 1003 (40.7)                                                                                         139 (39.9)   1142 (40.6)
* DOX 75 (doxorubicin 75mg/m2), Caelyx (caelyx 35mg/m2), EPI 75 (epirubicin 75mg/m2) EPI 3*50 
(epirubicin 50mg/m
2 
[days 1-3]),  EPI 1*150 (epirubicin 150mg/m
2
), IFO 5 (ifosfamide 5 mg/m
2
), 
IFO 3*3 (ifosfamide 3mg/ m2 [days 1-3]) IFO 9 continu (ifosfamide 9 mg/m2 [continuous infusion 
over 72 hours])) DOX 50-IFO 5 (doxorubicin 50mg/m
2
 - ifosfamide 5 mg/m
2
), DOX 75-IFO 5 
(doxorubicin 75 mg/m2 - ifosfamide 5 mg/m2) DOX 75 – IFO 10 (doxorubicin 75 mg/m2 - ifosfamide 
10 mg/m
2
), TRAB (1.3 mg/m², 3 hrs infusion or 1.5 mg/m², 24 hrs infusion). 
**MFH/UPS –Malignant fibrous histiocytoma (now reclassified as undifferentiated pleomorphic 
sarcoma) 
*** MPNST – Malignant peripheral nerve sheath tumour 
 
Prior surgical details were missing for more than half of patients (n=194, 55.7%), however, of the 
remaining 154 patients with available data, 65 patients had received previous partial surgery, and 69 
patients previous total surgery. Prior radiotherapy details were missing for 76 patients (21.8%), 
however, out of the remaining 272 patients, 71 patients (26%) had received prior radiotherapy.  
Overall, 126 (36%) patients were treated with first-line single-agent doxorubicin, 114 patients (33%) 
with combination doxorubicin and ifosfamide, 43 patients (12%) with epirubicin, 39 patients (11%) 
with trabectedin and 26 (7%) with single-agent ifosfamide.  
 





The median follow-up time for elderly patients who were still alive at the time of analysis 
was 9.5 months (IQR 6-25).  Of note, the median follow-up time for patients treated with 
trabectedin who were still alive at the time of the clinical cut-off date was considerably 
shorter than for the other treatment groups (trabectedin, 6.7 months [IQR 5.8-9.2], 
doxorubicin + ifosfamide, 24 months [IQR 7-38], doxorubicin alone, 14 months (IQR 5.5-
29), epirubicin, 24 months [IQR 8-43] and ifosfamide alone, 4 months [IQR 3.5-16]). At the 
time of their respective analyses, 84 patients (24.1%) were alive and 264 patients (75.9%) 
were deceased.  
Response Rates  
In total, 48 patients (13.8%) had a partial response and 4 patients (1.1%) had complete 
response (Table 2). There were 127 patients (36.5%) with stable disease as best response and 
115 patients (33.0%) with progressive disease. Response was not evaluable for 49 patients 
(14.1%). Radiological responses were primarily seen in patients treated with single-agent 
doxorubicin (n=22) or combination doxorubicin plus ifosfamide (n=21). 



























Complete Response    1 (0.8)                                                                                            3 (2.6)                                                            0 (0.0)                                      0 (0.0) 0 (0.0)                                                                       4 (1.1)
Partial Response   21 (16.7)                                                                                          18 (15.8)                                                             2 (4.7)                2 (7.7)                                                          5 (12.8)                                        48 (13.8)
Stable Disease   41 (32.5)                                                                                          36 (31.6)                                                              22 (51.2)                         8 (30.8)            20 (51.3)                                                                       127 (36.5)
Progressive Disease   49 38.9)                                                                                         33 (28.9)                           15 (34.9)      10 (38.5)                                                 13 (33.3)                                       115 (33.0)
Not evaluable 14 (11.1)                                                                                         24 (21.1)                                                           4 (9.3)                                      6 (23.1)                                      1 (2.6)                                                                 49 (14.1)
Survival status                                                                                                                                                                                                                                                                                 
Alive   29 (23.0)                                                                                          18 (15.8)                                                             6 (14.0)                   5 (19.2)                                                         26 (66.7)                          84 (24.1)
Dead   97 (77.0)                                                                                          96 (84.2)                                                              37 (86.0)                           21 (80.8) 13 (33.3)                                                                       264 (75.9)
PFS status*                                                                                                                                                                                                                                                                                       
Censored    5 (4.0)                                                                                            9 (7.9)                                                            3 (7.0)                                      0 (0.0) 0 (0.0)                                                                       17 (4.9)
Event  121 (96.0)                                                                                         105 (92.1)                                                              40 (93.0)                  26 (100.0)                                                         39 (100.0)                                                    331 (95.1)
*Progression Free Survival Status.  
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Overall Survival  
Median OS was 10.8 months (95% CI 9.4-11.8) (Table 3); for single agent doxorubicin, 9.8 
months (95% CI 7.4-11.5); doxorubicin plus ifosfamide, 12.1 months (95% CI 9.6-14.9); 
epirubicin, 9.9 months (95% CI 5.9-11.8); single-agent ifosfamide, 9.7 months (95% CI 2.9-
14.4); and trabectedin, 17.3 months (95% CI 9.4-17.3). Due to the shorter follow-up in the 
trabectedin group there is some overestimation of overall survival in this group as compared 
to the other treatment groups. The median OS across treatment groups at 3, 6 and 12 months 
respectively were 82.6%, 69.2% and 44.0%. Kaplan-Meier OS curves for all patients and 
according to treatment received are available as supplementary material.  
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32.5 (14.8, 51.6) 







60.6 (37.0, 77.7) 







44.0 (38.3, 49.5) 
*Number of events observed 
Progression Free Survival  
The median PFS was 3.48 months (95% CI 2.76-4.27) (Table 4); doxorubicin, 3.1 months 
(95% CI 2.1-4.1); doxorubicin plus ifosfamide 5.2 months (95% CI 3.1-6.4); epirubicin 3.8 
months (95% CI 1.4-6.2); fifosfamide alone 2.2 months (95% CI 1.4-3.8); and trabectedin 2.8 
months (95% CI 1.6 – 5.8).  
Older Elderly Patients (aged ≥75 years)  
There were 31 patients aged ≥75 years. Their median survival was 10.1 months (95% CI 4.8-
13.0) and their median PFS was 3.4 months (95% CI 1.4 – 5.5).  
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*Number of observed events.  
Comparison of Elderly (65 years) and Younger Patients (<65 years)  
There were 2,462 patients aged <65 years, who were treated in 13 EORTC-STBSG trials of 
the same chemotherapy regimens described above. The median age of these patients was 49 
years (IQR, 39-57). Median follow-up was 46 months (IQR, 29-72). 
Patient characteristics are summarised in Table 1. In patients aged <65 years, a higher 
proportion were PS 0 compared with elderly patients (45.6% vs. 38.5%), however, in both 
age groups the majority of patients were either PS 0 or 1 (91.4% younger vs. 89.4% elderly).  
In patients aged <65 years, tumours were most commonly histopathological grade 3 (34.2%) 
or grade 2 (28.6%); however tumour grading was missing for 705 patients (28.6%). As 
observed in elderly patients, the most common histological cell type in patients aged <65 
years was leiomyosarcoma (n=741, 30.1%). The second most frequent histological subtype in 
younger patients was synovial sarcoma (n=254, 10.3%); only reported in 11 elderly patients 
(3.2%). UPS (MFH) was proportionally less common in patients aged <65 years compared 
with the elderly patient group (9.7% vs. 15.8%).  The frequency of liposarcoma was similar 
in both age groups (9.8% vs. 8.5%).  
The lung was the most common site of metastases in patients aged <65 years (57.6%). Liver 
metastases were present with similar frequency in younger and elderly patients (17.1% vs. 
18.1%). A slightly higher proportion of younger patients had bone metastases compared with 
elderly patients (10.2% vs. 6.9%). Rates of prior partial surgery (19.3%) and total surgery 
(19.6%) in younger patients were almost identical to elderly patients. As seen in the elderly 
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patient group, very few patients had received prior radiotherapy; 20.4% younger vs. 26.5% 
elderly patients. 
Treatments received by patients aged <65 years (younger) were compared with treatments 
received by elderly patients; doxorubicin (36% younger vs. 36% elderly), doxorubicin plus 
ifosfamide (40% younger vs. 33% elderly), epirubicin (11% younger vs. 12% elderly), 
ifosfamide alone (11% younger vs. 7% elderly), trabectedin (2% younger vs. 11% elderly).  
In patients aged <65 years, 424 patients (17.2%) achieved a partial response and 77 patients 
(3.1%) a complete response. There were 974 patients (39.6%) with stable disease, 784 
patients (31.8%) with progressive disease and 203 patients (8%) for whom disease was not 
evaluable. Therefore, compared with elderly patients, younger patients (<65 years) had a 
slightly higher radiological response rates (20.3% vs. 14.9%). Radiological responses in 
younger patients were primarily seen in those treated with combination doxorubicin plus 
ifosfamide (n=227, 23.0%). Table 5 summarises radiological responses in younger versus 
older patients according to treatment received. 
























Doxorubicin  (n=78) (n=19) (n=153) (n=392) (n=361) (n=1003) 
< 65 yrs. 64 (7.3) 18 (2.1) 132 (15.1) 351 (40.0) 312 (35.6) 877 
≥65 yrs. 14 (11.1) 1 (0.8) 21 (16.7) 41 (32.5) 49 (38.9) 126 
Doxorubicin + 
ifosfamide 
(n=111) (n=51) (n=245) (n=426) (n=268) (n=1101) 
< 65 yrs. 87 (8.8) 48 (4.9) 227 (23.0) 390 (39.5) 235 (23.8) 987 
≥ 65 yrs. 24 (21.1) 3 (2.6) 18 (15.8) 36 (31.6) 33 (28.9) 114 
Epirubicin (n=22) (n=10) (n=35) (n=122) (n=126) (n=315) 
< 65 yrs. 18 (6.6) 10 (3.7) 33 (12.1) 100 (36.8) 111 (40.8) 272 
≥65 yrs. 4 (9.3) 0 (0.0) 2 (4.7) 22 (51.2) 15 (34.9) 43 
Ifosfamide alone (n=39) (n=0) (n=31) (n=117) (n=114) (n=301) 
< 65 yrs. 33 (12.0) 0 (0.0) 29 (10.5) 109 (39.6) 104 (37.8) 275 
≥ 65 yrs. 6 (23.1) 0 (0.0) 2 (7.7) 8 (30.8) 10 (38.5) 26 
Trabectedin (n=2) (n=1) (n=8) (n=44) (n=35) (n=90) 
< 65 yrs. 1 (2.0) 1 (2.0) 3 (5.9) 24 (47.1) 22 (43.1) 51 
≥65 yrs. 1 (2.6) 0 (0.0) 5 (12.8) 20 (51.3) 13 (33.3) 39 
*CR- complete response, PR- partial response, NC – no change (stable), PD – progressive disease.  
 




Median overall survival (OS) was better in younger patients (<65 years) compared with 
elderly patients (65 years); median OS 12.3 months (95% CI 11.9 – 12.9) vs. median OS of 
10.8 months (95% CI 9.4-11.8) in elderly patients (Table 6). Younger patients had a slightly 
better median progression free survival compared with elderly patients: median PFS 4.3 
months (95% CI 3.9-4.3) compared to 3.5 months (95% CI 2.8–4.3) for elderly patients 
(Table 7).  





Median (95% CI) 
(Months) 
% at 6 months 
(95% CI) 
All treatments     
< 65 yrs. 2462 1997 12.32 (11.86, 12.85) 77.2 (75.5, 78.8) 
>= 65 yrs. 348 264 10.78 (9.43, 11.83) 69.2 (64.0, 73.9) 
Doxorubicin alone     
< 65 yrs. 877 700 11.79 (10.48, 12.71) 74.6 (71.6, 77.4) 
>= 65 yrs. 126 97 9.76 (7.36, 11.50) 62.9 (53.6, 70.8) 
Doxorubicin + 
ifosfamide 
    
< 65 yrs. 987 824 13.24 (12.42, 14.16) 82.1 (79.5, 84.4) 
>= 65 yrs. 114 96 12.06 (9.59, 14.88) 79.5 (70.8, 85.9) 
Epirubicin     
< 65 yrs. 272 229 11.17 (9.63, 12.16) 72.1 (66.3, 77.0) 
>= 65 yrs. 43 37 9.86 (5.88, 11.79) 64.8 (48.5, 77.1) 
Ifosfamide alone     
< 65 yrs. 275 231 11.14 (10.22, 12.62) 72.3 (66.5, 77.2) 
>= 65 yrs. 26 21 9.72 (2.86, 14.39) 55.6 (34.0, 72.7) 
Trabectedin     
< 65 yrs. 51 13 Not reached 81.6 (67.6, 90.0) 
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Median (95% CI) 
(Months) 
% at 6 months 
(95% CI) 
All treatments     
< 65 yrs. 2462 2318 4.27 (3.94, 4.57) 41.0 (39.0, 42.9) 
>= 65 yrs. 348 331 3.48 (2.76, 4.27) 34.5 (29.6, 39.6) 
Doxorubicin alone     
< 65 yrs. 877 827 3.65 (3.22, 4.17) 36.0 (32.8, 39.2) 
>= 65 yrs. 126 121 3.12 (2.07, 4.14) 28.8 (21.2, 36.9) 
Doxorubicin + 
ifosfamide 
    
< 65 yrs. 987 921 6.18 (5.62, 6.60) 51.2 (48.0, 54.3) 
>= 65 yrs. 114 105 5.22 (3.09, 6.41) 44.2 (34.9, 53.1) 
Epirubicin     
< 65 yrs. 272 253 2.89 (2.33, 3.42) 33.5 (27.9, 39.1) 
>= 65 yrs. 43 40 3.84 (1.41, 6.21) 41.0 (26.2, 55.2) 
Ifosfamide alone     
< 65 yrs. 275 266 2.76 (2.43, 3.09) 28.0 (22.8, 33.4) 
>= 65 yrs. 26 26 2.18 (1.38, 3.81) 15.4 (4.8, 31.5) 
Trabectedin     
< 65 yrs. 51 51 2.99 (1.54, 6.14) 37.3 (24.3, 50.2) 

















Although almost half of patients diagnosed with STS are aged >65 years, elderly patients 
only represented 12% of participants in EORTC clinical trials of first-line chemotherapy for 
advanced STS.
15
 Furthermore, the median age of elderly in these studies was 68 years, which 
is relatively low. This is concordant with previous studies which have shown that elderly 
cancer patients account for less than one quarter of all participants in clinical trials.
18
  
As expected, most elderly patients had a performance status of 0 or 1 as a result of strict 
eligibility criteria required for clinical trials. Good performance status (0 or 1) is an 
independent predictive factor for overall survival.
19
 Lung and liver metastases were present 
with similar frequency in elderly and younger patients. Liver metastases are associated with 
poor response rates and worse overall survival in advanced STS treated with anthracyclines.
19
 
Although tumours were most commonly histopathological grade 3, a significant proportion of 
tumours in elderly and younger patients were grade 2. Given that histopathological grade 
predicts development of metastases in adult STS, and all patients had advanced disease, a 
higher proportion of grade 3 tumours were anticipated.
8
 It is conceivable that patients with 
rapidly progressive grade 3 tumours were excluded due to frailty. The high number of grade 2 
tumours is also noteworthy given that low histological grade is associated with lower 
response rates in advanced STS patients treated with anthracycline chemotherapy and 
improved overall survival.
19,20
 Histological subtypes differed according to age group; 
synovial sarcomas were more common in young patients, and UPS (formerly MFH) was 
more frequent among elderly patients. Synovial sarcoma is associated with improved survival 
in advanced STS patients treated with anthracyclines and longer PFS in those treated with 
ifosfamide-containing regimens.
19,20
 Conversely, UPS is associated with reduced overall 
survival in patients treated with anthracyclines.
19
  
A minority of patients in this analysis had received prior radiotherapy. This is unexpected 
given that pre-or post-operative radiotherapy is now recommended for the majority of 
patients with intermediate or high-grade tumours.
21
 These results may reflect inaccurate data 




Overall, elderly patients had shorter overall survival than younger patients. There was also a 
trend towards shorter progression free survival and lower response rates. Despite favourable 
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baseline characteristics, these results demonstrate that older age (65 years) is an adverse 
prognostic factor for patients with advanced STS treated with first-line chemotherapy. In 
reality, the heterogeneity of an unselected elderly STS population encountered in clinical 
practice is not directly comparable with these patients. A previous single-institution, 
retrospective review of 120 elderly advanced STS (excluding GIST) patients treated with 
first-line chemotherapy, most commonly single-agent doxorubicin (60%), described a slightly 
better RR of 20%, however, OS was 6.5 months (95% CI 4.7-8.3).
23 
Another mono-
institutional study of 134 elderly patients with advanced soft tissue sarcomas (primary scalp, 
trunk, girdles and extremities only) reported median OS of 7.3 months.
24
 In this study, one 
quarter of patients had PS 2 (n=33, 25%). In addition, 40% of cases were high grade UPS 
(formerly MFH) or angiosarcomas and these tumours were associated with worse prognosis 
<6 months.
24
 Another retrospective study evaluated 197 advanced STS patients aged ≥75 
years and reported a median PFS of 4 months (95% CI, 2.9-5.1) and OS of 10.9 months (95% 
CI, 8.3-13.5), however baseline characteristics were undistinguishable from patients 
receiving best supportive care.
25
 In this study, age ≥80 years, PS≥2 and number of metastatic 
sites were independent prognostic variables for OS.
25
 The majority of patients received an 




Doxorubicin has been standard first-line chemotherapy for advanced STS since the 1970s; 
however, side-effects include myelosuppression, mucositis and cardiotoxicity. Empirical dose 
reductions are often used in patients who are frail or have pre-existing comorbidities such as 
renal dysfunction, due to the risk of severe toxicity and hospitalisation. Previous studies have 
demonstrated a dose-response relationship with optimal anti-tumour activity at doses of 
≥60mg/m
2
 (administered every three weeks) and reduced efficacy at lower levels.
26,27
 Older 
patients may therefore be disadvantaged due to suboptimal treatment.  
The combination of doxorubicin and ifosfamide has been shown to provide higher response 
rates, however no improvement in overall survival and at the cost of increased toxicity.
21
 In 
EORTC STBSG clinical trials 62842, 62851, 62883 and 62903 trials, 114 elderly patients 
were treated with combination therapy (doxorubicin+ifosfamide). These patients had a 
median OS of 12 months (95% CI 9.59-14.88) and PFS 5 months (95% CI 3.09-6.41). There 
is often a misconception that elderly patients do not tolerate chemotherapy; however these 




results demonstrate that even doublet chemotherapy can be used effectively in carefully 
selected patients 
We observed that radiological responses were mainly seen in elderly patients treated with 
doxorubicin or doxorubicin plus ifosfamide. It is probable that these patients were potentially 
the more ‘fit’ elderly patients who were considered to be suitable for clinical trials of these 
more toxic chemotherapy drugs. In addition, two-thirds of all elderly patients were treated 
with these chemotherapy regimens and therefore more responses may be anticipated in a 
larger group. The higher overall response rate in younger patients may be at least partly 
explained by greater proportion of patients aged <65 years who received combination 




Determining which patients will tolerate chemotherapy is challenging. The ability of 
physicians to predict chemotherapy induced toxicity has been evaluated in patients with lung 
cancer.
28
 This group found that severe toxicity and successful completion of treatment were 
equally likely in patients who were deemed eligible for treatment.
28   
They suggested that 
more detailed geriatric assessments are needed in order to predict those patients who are at 
risk of toxicity.
28
 The effectiveness of such tools have been tested in other tumour groups. 
The mini-mental state examination (MMSE) and instrumental activities of daily living 
(IADL) were predictive of toxicity in elderly, metastatic colorectal cancer patients.
29
 
Comprehensive geriatric assessment (CGA) has been used in metastatic breast cancer patients 
(aged ≥65 years) to predict grade 3-4 toxicity.
30
   The International Society of Geriatric 
Oncology consensus has determined the G8 assessment as the most robust, 
predictive/prognostic tool for outcome measures in elderly patients.
31
 The EORTC-STBSG is 
now routinely incorporating the G8 assessment tool in their clinical trials. 
Participants in research studies must be representative the population of interest.
5
 With an 
ageing population, there is increasing need for clinical trials which are designed to assess the 
optimal pharmacotherapeutic strategies for elderly patients. The feasibility of metronomic 
oral cyclophosphamide with prednisolone was evaluated in a group of 26 elderly patients 
(aged 66-88 years); the toxicity profile was favourable, the response rate was 26.9% and 
median PFS was 6.8 months.
32
 Other trials include the EPAZ phase II non-inferiority trial of 
pazopanib (800mg once daily) vs. doxorubicin (75 mg/m
2
) as first-line therapy for patients 
aged 60 years with advanced STS (n=120) and the E-TRAB study in elderly patients (aged 
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>60 years), treated with first-line Trabectedin and considered unsuitable for anthracycline-
based chemotherapy (n=110).
33,34
 The E-TRAB study will analyse quality of life and patient- 
reported outcome data in addition to overall survival.
34
  
The challenge is to design trials which are not only for ‘elite’ older patients but consider the 
heterogeneity of older patients. Although the median overall survival was inferior for elderly 
patients, response rates were similar, suggesting that elderly patients can derive benefit from 
standard chemotherapy regimens which are routinely prescribed for younger patients. 
Although the patients described in this report were of good performance status, our data can 
provide a benchmark for designing future trials. Study designs should also consider tools 
which can accurately assess potential toxicity of treatments and enable stratification of 
patients. These trials should be done within a multidisciplinary team, including geriatricians 
and trained nursing staff to provide adequate support for patients. Given the marginal survival 
benefit of chemotherapy in advanced STS, clinical trials should also incorporate health-
related quality of life assessments as study endpoints. This data will enhance clinical decision 
making and enable clinicians to provide a holistic, evidence-based approach to the care of 
elderly patients.  
Although there were few patients in these EORTC-STBSG clinical trials aged 75 years, 
their outcomes were similar to those aged 65 years. It is probable that these patients were 
highly selected older elderly individuals in order to meet eligibility criteria for these clinical 
trials. In a real-life setting the METASARC observational study (n=2,165) reported that 
patients aged 75 years (n=279) were significantly less likely to receive any systemic 
treatment for metastatic disease and more likely to be offered best supportive care than those 
aged <75 years.
35
 This French group attributed this finding to the general reluctance of 
oncologists to prescribe anthracyclines to elderly patients in view of potential haematological 
and cardio-toxic effects these drugs in older patients with functional decline or co-morbid 
medical conditions.
35
  The complex association of cellular senescence, ageing and cancer is 
outside the scope of this paper. 
Limitations 
The clinical trials in this EORTC-STBSG database were not designed to evaluate age-related 
differences in chemotherapy outcomes; therefore p-values are not presented in order to avoid 
over-interpretation the data. Selection bias due to the favourable baseline characteristics of 
clinical trial patients means that these results may not reflect outcomes in clinical practice. 




No details were available on treatments received on progression of disease. However, due to 
the limited availability of effective second- or third-line treatment options, it is likely that all 
patients will have received similar treatments. In addition, this database contains historical 
data from patients recruited in clinical trials from the 1980s and therefore results may be 
influenced by differences in concomitant standards of care.    
Conclusion 
Elderly patients with advanced STS have slightly worse outcomes than younger patients 
when treated with first-line chemotherapy within clinical trials. In light of the ageing 
population, there is increasing need to design studies which specifically evaluate treatments 
in elderly patients, not only those with favourable characteristics. The results of this analysis 
can help in the design of future trials, incorporating geriatric tools to stratify patients and 
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Background: More than half of patients with soft tissue sarcoma (STS) are aged 65 years 
(older), however contemporary data on the efficacy/safety of anthracycline chemotherapy in 
older patients with STS are lacking.  
Methods: SARC021 randomized patients to receive first-line doxorubicin or doxorubicin 
plus evofosfamide. The main aim of this study was to compare the outcome and safety of 
first-line anthracycline-based therapy in older patients compared with those <65years. IRB 
approval was obtained at all participating sites and this research meets requirements for 
protection of human subjects. 
Results: Of 640 patients, 209 (33%) were older, with a median age 70 (range 65-89) years. 
The median overall survival (OS) was 16.7 months (95% CI 13.2-20.0) in older patients 
compared to 20.1 months (95% CI 16.9-23.2) in those aged <65years (n=431), HR 1.21 (95% 
CI 0.99-1.48), p=0.057. The median progression-free survival (PFS) in older patients was 6.3 
months (95% CI 5.8-7.2) compared to 6.0 (95% CI: 5.1-6.4) in those <65 years, HR 0.86 
(95% CI 0.70-1.05), p=0.14. Older patients had significantly more hematological (n=141 
[67%] vs. n=208 [48%], p<0.0001), non-hematological (n=131 [63%] vs. n=215 [50%], 
p=0.0097) and Grade 3 adverse events (n=178 [85%] versus n=299 [69%], p=0.0002), 
compared to younger patients. Older patients (n=30, 14%) more commonly stopped treatment 
due to adverse events than younger patients (n=22, 5%), p=0.0001.  
Conclusions: The efficacy of first-line anthracycline-based chemotherapy did not differ 
significantly between older and younger advanced sarcoma patients. Significantly more of the 
older patients stopped chemotherapy due to adverse events. These results provide a 
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Soft tissue sarcomas (STS) are rare, heterogeneous tumours of mesenchymal origin, that 
account for approximately 1-2% of all adult cancers.
1 
 Almost half of STS are diagnosed in 
older patients aged 65 years, with the highest incidence in patients aged 75 years. There 
are 13.5 new cases per 100,000 per year in the United States.
2,3
 Advancing age is a risk factor 
for the development of STS and an independent adverse prognostic factor for survival in the 
metastatic setting.
1,4–8 
Older patients are often diagnosed with higher-grade, higher-stage 
tumours, and under-treatment is believed to contribute to worse survival.
6–8
 Older patients 
with STS are under-represented in clinical trials; a recent analysis of 12 EORTC first-line 
chemotherapy trials found that only 12% (n=348) of participants were aged 65 years.9 In 
view of the ageing global population, contemporary, prospective data on the outcomes of 
older patients with STS are needed to inform clinical practice.   
Anthracycline-based schedules are the mainstay of treatment for advanced STS (either as 
single agent or in combination). Systemic therapies are used cautiously in older patients due 
to their toxicity; for example, advancing age is a risk factor for anthracycline-associated 




SARC021 was a randomized phase III trial of single-agent doxorubicin versus doxorubicin 




The main aim of this study was to compare the outcome and toxicity of first-line 
anthracycline-based chemotherapy in older (65 years) and younger patients with advanced 
sarcomas. Secondary aims included a comparison of the efficacy and safety of doxorubicin 
and doxorubicin plus evofosfamide (DE) in older patients and an evaluation of patients 75 
years of age treated within the trial.  
Materials and Methods 
 
In this study, older patients were defined as those aged 65 years or older. A retrospective 
analysis of the SARC021 clinical trial database was performed to identify older patients and 
those aged <65 years. Patient demographics, clinical details and prior treatments were 
collected for analysis. Response was defined according to Response Evaluation Criteria In 




Solid Tumours (RECIST) version 1.1. Adverse events (AEs) were grouped into four 
categories (haematological, non-haematological, cardiac, and Grade 3 AEs) and graded 
according to National Cancer Institute Common Terminology Criteria for Adverse Events 
version 4.0. Cardiac function was assessed using either multi-gated radionuclide angiography 
(MUGA) or echocardiogram, and electrocardiogram (ECG), at baseline, after completion of 
four cycles and at termination of doxorubicin. A cardiac AE was defined as a drop in left 
ventricular ejection fraction (LVEF) of 10% from baseline resulting in a LVEF of <55%, an 
absolute LVEF of 45%, or a 20% decline in LVEF at any level.  
Quality of life (QoL) assessments were performed at screening, on Day 1 of each cycle (pre-
dose), at termination of treatment and every 3 months during follow-up. QoL assessments 
were completed by patients only. Two QoL instruments were administered, the EuroQoL-five 
dimension-five response level tool (EQ-5D-5L) incorporating 5 items (mobility, self-care, 
usual activities, pain/discomfort and anxiety/depression) scored 1 (‘no problem’) to 5 
(‘extreme problems’) and a 20-cm visual analog scale tool, the EuroQoL- visual acuity scale 
(EQ-VAS) (scored 0 ‘the worse health you can imagine’ to 100 ‘the best health you can 
imagine’).  
Descriptive statistics were used to compare baseline characteristics of older patients with 
those aged <65 years. Kaplan-Meier curves were used to summarise progression-free (PFS) 
and overall survival (OS) of older patients and those aged <65 years with p-value calculated 
from log-rank test. Response rates were compared between the two age groups using Fisher’s 
exact test. Cox models were used to generate HRs and we also tested for interaction between 
treatment arm and age group. Comparison of AEs between older patients and those <65 years 
of age was similar to the analysis for older patients, but instead of treatment, age ≥65 was 
included as the covariable of interest in the analysis. We described the number of cycles 
administered for older patients and those <65 years of age and number of patients who 
stopped therapy due to AEs. Finally, 65 years is an arbitrary threshold for defining status. To 
determine how sensitive the results are to this value, we also did an analysis of patients over 
75 years of age, defined as ‘much older’. 
Within the group of older patients, OS, PFS and response rate (RR) were compared between 
those treated with doxorubicin versus DE. Kaplan-Meier curves were used to summarize OS 
and PFS, with p-value calculated using the log-rank test. Univariable Cox-proportional 
hazards models were used to estimate hazard ratios, with corresponding 95% confidence 
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intervals. Multivariable models included treatment arm, age, and all factors significant at the 
0.05 level in univariable analyses. Response rates of older patients between the two treatment 
arms were compared using Fisher’s exact test. Univariable logistic regression models were 
used to estimate hazard ratios, with corresponding 95% confidence intervals. Multivariable 
models included arm, age, and all factors significant at the 0.05 level in univariable analyses.  
IRB approval was obtained at all participating sites and this research meets requirements for 
protection of human subjects. 
Results 
 
The primary analysis of the SARC021 trial showed no significant difference in OS (HR 1·06, 
95% CI 0·88–1·29), or PFS (HR 0·85, 95% CI 0·70–1·03) between patients treated with 
doxorubicin and DE (as previously published).
12
  
Of 640 participants in the SARC021 trial, there were 209 patients aged 65 years (33%) and 
431 patients (67%) aged <65 years. Baseline characteristics are summarized in Table 1. The 
median age of older patients at baseline was 70 (range 65-89) years, and the median follow-
up was 16.5 months. Patients aged <65 years commonly had a baseline ECOG performance 
status (PS) of 0, whereas older patients more frequently had PS of 1 (p=0.001). 
Leiomyosarcoma was the most common histological subtype in both age groups and 
undifferentiated pleomorphic sarcoma was more frequent in older patients (p=0.006). Older 













Table 1: Characteristics of trial population 
 Patients < 65 
years (n=431) 
Patients  65 
years (n=209) 
p-value 













Hispanic or Latino 













































































































There was no statistically significant difference in median OS between patients aged <65 
years (20.1 months, 95% CI 16.9-23.2) and older patients (16.7 months, 95% CI 13.2-20.0), 
HR = 1.21 (95% CI 0.99-1.48), p=0.057 (Figure 1). No significant difference in median PFS 
was observed between patients aged <65 years (6.0 months, 95% CI 5.1-6.4) compared to 
older patients (6.3 months, 95% CI 5.8-7.2), HR=0.86 (95% CI 0.70-1.05), p=0.14 (Figure 2).  
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Fig 1: OS older patients aged 65 years vs. patients aged <65 years
 
Fig 2: PFS older patients aged 65 years vs. patients aged <65 years 
 
 
No significant difference in response rate was observed between those <65 years (n=103, 
24%) compared to older patients (n=46, 22%), p=0.60. On multivariable analysis (Tables 2 
and 3), PS of 1 or 2 was associated with significantly worse OS than PS 0 (HR 1.92 [1.57- 
2.32], p<0.001) and significantly worse PFS (HR 1.47 [1.20-1.79], p<0.001). Patients with 
pleomorphic sarcoma had significantly worse OS compared to those with leiomyosarcoma 
(HR 1.61 [1.18-2.20], p=0.002), as did ‘other’ subtypes compared to leiomyosarcoma (HR 
1.65 [1.31-2.08], p<0.001). 




Table 2. Overall Survival: Cox Proportional Hazard Regression 
 
Table 3: Progression Free Survival: Cox Proportional Hazard Regression 
 Univariable Multivariable 
 HR (95% CI) p value HR (95% CI) p value 
Age >= 65 0.86 (0.70-1.05) 0.140 0.78 (0.63-0.96) 0.020 
Doxorubicin plus Evofosfamide (vs. 
Dox alone) 
0.86 (0.71-1.04) 0.128 0.84 (0.70-1.02) 0.086 
ECOG 1 or 2 (vs. ECOG 0) 1.38 (1.14-1.67) 0.001 1.47(1.2-1.79) <0.001 
Continuous (vs. bolus) 0.89 (0.67-1.18) 0.433   
Locally advanced (vs. distant 
metastatic) 
0.92 (0.7-1.22) 0.562 
  
Prior radiation (vs. no) 0.9 (0.74-1.1) 0.296   
Histology (vs. Leiomyosarcoma)*     
Liposarcoma 0.81 (0.61-1.07) 0.139   
Pleomorphic sarcoma/malignant 
fibrous histocytoma 
1.12 (0.89-1.41) 0.322 
  
Other 1.14 (0.84-1.57) 0.398   
Gender male (vs. female) 1.18 (0.97-1.42) 0.094   
* Likelihood ratio test p value = 0.98, therefore not included in multivariable analysis  
 
 
 Univariable Multivariable 
 HR (95% CI) p value HR (95% CI) p value 
Age >= 65 1.21 (0.99-1.48) 0.057 1.08 (0.87-1.31) 0.515 
Doxorubicin plus Evofosfamide 
(vs. Dox alone) 
1.08 (0.89-1.3) 0.451 1.11 (0.92-1.34) 0.293 
ECOG 1 or 2 (vs. ECOG 0) 2.02 (1.66-2.44) <0.001 1.92 (1.57-2.33) <0.001 
Continuous (vs. bolus) 0.85 (0.64-1.14) 0.291   
Locally advanced (vs. distant 
metastatic) 
0.92 (0.7-1.21) 0.539   
Prior radiation (vs. No) 0.92 (0.75-1.12) 0.380   
Histology (vs. Leiomyosarcoma)*     
Liposarcoma 1.15 (0.86-1.55) 0.345 1.12 (0.83-1.50) 0.457 
Pleomorphic sarcoma/malignant 
fibrous histocytoma 
1.68 (1.23-2.29) 0.001 1.61 (1.18-2.20) 0.002 
Other 1.76 (1.4-2.22) <0.001 1.65 (1.31-2.08) <0.001 
Gender male (vs. female) 1.12 (0.93-1.36) 0.235   
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As shown in Table 4, haematological (anaemia, neutropenia, thrombocytopenia) and non-
haematological (fatigue, reduced appetite, diarrhoea) AEs were significantly more common 
in older patients. There were 494 patients with at least one follow-up echocardiogram. There 
was no significant difference in cardiotoxicity between those <65 years (n=35, 8%) and older 
patients (n=20, 20%), p=0.60.  Dexrazoxane was administered to 22 patients <65 years and 
12 in the older age group. Two of these patients experienced cardiotoxicity (both <65 years). 
AEs of Grade 3 were significantly more common in older patients (p=0.0002). The most 
common Grade 3 AE was anaemia (<65 years: n=125 [30%], older: n=83 [40%]) and most 
frequent Grade 4 AE was neutropenia (<65 years: n=55 [13%], older: n=47 [23%]). 
Table 4: Adverse events (all grades): patients <65 years versus older patients 
 
 Patients < 65 
years (n=431) 
















































Both age groups received a median of 6 cycles (range 0-6). In those <65 years, 154 (36%) 
underwent dose reductions compared to 93 (44%) in the older age group, p=0.700. 
Significantly more of the older patients (n=30, 14%) stopped therapy due to AEs compared to 
those <65 years (n=22, 5%), p=0.0001. Baseline ECOG performance status (PS) of 1 or 2 
was associated with significantly greater hematologic AEs compared to PS 0 (OR 1.68 [1.22-
2.33]; p=0.002) and remained significant in multivariable analysis after accounting for age 
and treatment arm (OR 1.55 [1.11-2.17], p=0.010). Patient age 65 years was also associated 
with significantly more hematologic AEs compared with age <65 years (OR 2.07 [1.47-2.95], 
p<0.001), and remained significant in multivariable analysis after accounting for ECOG 
performance status and treatment arm (OR 1.95 [1.38-2.80], p<0.001).  
On univariable analysis, factors associated with higher non-haematological AE were age 65 
years (OR 1.57 [1.12-2.21]; p=0.01), DE combination treatment (OR 1.67 [1.22-2.31], 
p=0.02), baseline PS 1 or 2 (OR 2.00 [1.44-2.78], p<0.001) and prior radiation (OR 1.48 




[1.06-2.07], p=0.021). On multivariable analysis, DE combination treatment arm, ECOG PS 
of 1 or 2 and prior radiation remained independently associated with non-haematological AEs 
(p=0.001, p<0.001 and p=0.015 respectively), however older age was no longer associated 
with non-haematological AEs when controlling for these variables (p=0.072). Baseline PS of 
1 or 2 was associated with significantly more Grade 3 AEs than PS 0, HR 1.93 (1.30-2.89), 
p=0.001.  
In patients aged <65 years, QoL data were available for 127 patients (29%) at baseline and 
131 patients (30%) at study termination. For older patients, QOL data were available at 
baseline in 61 (29%) and 57 (27%) at study termination. Patients aged <65 years had a 
significantly higher (worse) mean anxiety/depression score (2.04, SD 0.98) at baseline 
compared with older patients (1.62, SD 0.78), p=0.004. Older patients had numerically higher 
(worse) mean mobility score (1.82, SD 1.14) at termination of the study compared to <65 
years (1.5, SD 0.78), p=0.063. There were no differences in EQ-VAS scores between patients 
aged <65 years and older patients.  
The comparison of 103 older patients treated with doxorubicin and 106 treated with DE, 
demonstrated that the baseline characteristics were well-balanced between the arms (Table 5).  
Table 5: Characteristics of patients per treatment arm 
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There was no significant difference in median OS between the doxorubicin (17.0 months, 
95%CI: 12.9-20.6) and the DE arm (16.2 months, 95%CI: 11.5-23.0), HR 1.08 (0.89-1.3), 
p=0.45. There was no significant difference in median PFS between the doxorubicin (6.1 
months, 95%CI: 4.7-7.2) and the DE arm (6.5 months, 95% CI 4.9-8.2), HR 1.08 (0.89-1.3) 
and p=0.45 (Figure 3). 
Figure 3: PFS in older patients treated with doxorubicin vs. doxorubicin + evofosfamide 
 
There was no significant difference in response rate between the doxorubicin (19, 18%) and 
the DE arm (27, 25%), p=0.22. As shown in Table 6, haematological AEs occurred with 
similar frequency in both treatment arms. Non-haematological AEs were more common in 
the DE arm (p=0.0014). The most frequent non-haematological AEs were fatigue, nausea, 




stomatitis and constipation. There was no significant difference in cardiac AEs between the 
doxorubicin (8, 8%) and DE arm 12 (11%), p=0.40. Grade 3 and 4 AEs occurred in 85 
patients (83%) in the doxorubicin arm and 93 (88%) in the DE arm, p=0.37. Significantly 
more patients treated with DE (58, 55%) had a dose reduction compared to doxorubicin (35, 
34%), p=0.003.  




















































Thirty-nine patients aged 75 years participated in the SARC021 trial (Dox n=19, DE n=20), 
and 30 of these patients were deceased at the time of analysis. The median OS of ‘much 
older’ patients was 16.7 months (95%CI: 7.5-23.0) and the median PFS was 4.4 months 
(95%CI: 2.8-6.5).  There was no significant difference in median OS and PFS between ‘much 
older’ patients treated with doxorubicin and DE. Nine of these 39 patients had a radiological 
response (doxorubicin n=5, DE n=4, p=0.72). Five patients discontinued treatment due to 
toxicity (doxorubicin n=1, DE n=4).   
Discussion 
 
This SARC021 sub-analysis demonstrated no significant difference in median OS, PFS and 
response rate between older patients and patients aged <65 years. However, older participants 
experienced significantly more haematological and grade 3 AEs, and were more likely to 
stop treatment early. Our study also showed no significant difference in median OS, PFS and 
response rate between older patients treated with doxorubicin compared with doxorubicin 
plus evofosfamide, however, non-haematological AEs were significantly more common in 
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the combination arm. There are few contemporary data regarding the safety and efficacy of 
first-line anthracycline-based therapy in advanced soft tissue sarcomas. The available studies 
are of historic cohorts and do not represent current diagnostic classification and salvage 
systemic therapy schedules.
9,13
 Furthermore, compared to previous studies, our study is 
strengthened by central pathology review and consistent treatment within a prospective 
clinical trial. 
Physiological changes associated with ageing can impact pharmacokinetic and 
pharmacodynamic properties leading to an increased risk of toxicity.
14–16
 Many physicians 
are cautious to use combination chemotherapy in older patients despite several solid tumour 
trials showing that doublet chemotherapy can be used safely in carefully selected patients.
17–
19
 Predicting which patients are at greater risk of toxicity is challenging due to significant 
inter-individual variability.
13–16 
The G8 (Geriatric 8) assessment screening tool is currently 
recommended by the Society of Geriatric Oncology (SIOG) to identify patients who require 
comprehensive geriatric assessment (CGA).
20
 Management of high-risk patients by a 
geriatrician-led multidisciplinary team can improve tolerance to chemotherapy, although 
provision may be limited by costs and resources.
21
 Anaemia and neutropenia were the most 
commonly reported grade 3 and 4 AEs respectively. High rates of haematological AEs in 
older patients are likely to reflect depleted bone marrow reserves.
16
  
Older patients have been under-represented in clinical trials. One third of patients in 
SARC021 were older, which provided an opportunity to better understand outcomes and 
toxicity in comparison with patients aged <65 years. More clinical trials specifically for older 
patients are needed, such as the EPAZ phase II randomized trial of pazopanib versus 
doxorubicin as first-line treatment for older patients (60 years) with advanced STS.22,23  The 
median age of patients in the EPAZ trial was 71 (range 60-88) years.
24
 Pazopanib was non-
inferior to doxorubicin in terms of median PFS (4.4 versus 5.3 months) and OS (12.3 versus 
14.3 months respectively).
24
 AEs were typical for known side effects. The EPAZ doxorubicin 
arm (n=39) had slightly lower median PFS and OS compared to older patients in our study. A 
recent study of older patients treated within the randomized phase III trial of trabectedin 
versus dacarbazine in pre-treated liposarcoma and leiomyosarcoma, demonstrated the safety 
and efficacy of trabectedin in patients over the age of 65 years.
25
 Consequently, there is 
evidence to support the use of palliative systemic therapies in older patients with metastatic 
sarcomas. 




Comprehensive QOL assessments should be incorporated as endpoints in trials, as patient-
reported outcomes are a vital component of evaluation of the net clinical benefit of a 
treatment. Older patients may consider QOL as more important than survival, compared with 
younger patients.
26
  Although QOL analysis in SARC021 did not identify significant 
differences between younger and older patients, EQ-5D-5L contains five questions and EQ-
VAS only one measurement, which may not adequately assess the complex interplay of STS 
and its treatment on all aspects of daily functioning. Only patients with a good PS were 
enrolled into SARC021, which may not represent the older population in clinical practice. 
Very few patients completed QOL assessments and interpretation of these data are limited.  
Conclusion 
This study provides a contemporary benchmark of first-line anthracycline-based therapy in 
older patients with advanced soft tissue sarcoma. Our data show that anthracycline-based 
chemotherapy appears to be effective in older patients. However, the increased rates of AEs 
in older patients highlight the need for less toxic treatments and optimization of supportive 
care. Future studies should incorporate geriatric assessment tools and evaluate whether 
alternative drugs or schedules can be safely and effectively used in this population. Greater 
attention should be given to QOL, in order to guide interpretation of treatment efficacy and 
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Background: Sarcomas are rare, heterogeneous tumours affecting patients of any age. 
Previous surveys describe that sarcoma patients report a significantly worse experience than 
those with common cancers. Consequently, Sarcoma UK conducted a national survey and 
these data were examined for age- and tumour-related differences in patients’ experiences.  
Methods: Patients were randomly selected from respondents to National Cancer Patient 
Experience Surveys (n=900). Differences between patient groups according to age 
(Adolescent Young Adult [AYA] 18-39 years, middle-aged 40-64 years, elderly 65+years) 
and tumour type (soft-tissue [STS] vs. bone) were analysed with t-tests or chi-square tests.  
Results: Survey response rate was 62% (n=558; STS 75%, bone sarcoma 25%). Delay in 
diagnosis was reported; 27% patients (n=150) waited >3 months and initial symptoms were 
incorrectly interpreted; AYA STS patients were significantly more likely to be treated for 
another condition, or advised that their symptoms were not serious, than older STS patients. 
Clinical trial participation was low (6%, n=35). Symptom burden was high, most commonly 
daytime fatigue (48%, n=277) and pain (44%, n=248). AYAs were significantly more likely 
to report most side-effects and post-treatment concerns than older patients. Elderly patients 
were more satisfied with the information and emotional support provided than younger 
patients, however were significantly less likely to be referred to rehabilitation services. 
Conclusions: This study identifies significant age-related differences in the sarcoma patient 
journey, which are not only related to variation in tumour-types. These results provide 
rationale for adopting an age-specific approach to the management of sarcoma patients in 
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Sarcomas are rare and heterogeneous tumours of mesenchymal origin, which account for 




In 2010, the incidence of sarcomas in 
the United Kingdom (UK) was 3,829 (3,298 soft tissue, 531 bone).
2
 Sarcomas can affect 
patients of any age and occur at almost any anatomical site. Moreover, there are at least 70 
histological subtypes and therefore research is often limited by small patient numbers.
1 
Diagnosis is often delayed due to a lack of public awareness of the symptoms of sarcoma, 
coupled with limited experience among healthcare professionals.
3
 Delay may allow the 
development of advanced disease, which is not amenable to curative surgical resection.
1
 In 
addition, many sarcomas demonstrate an aggressive phenotype and around half of patients 
with high grade tumours will eventually develop incurable disease.
4,5
 Despite improvements 
in the prognosis of many other solid malignancies and certain sarcoma subtypes, the five-year 




Patients with sarcoma often have multiple complex symptoms.
7
 Burden of symptoms has 
been shown to have a negative impact on health-related quality of life (HRQoL) in cancer 
patients.
8,9
 Patient-reported outcomes (PROs) including HRQoL are increasingly recognised 
as key components of patient-centred care and decision-making.
10
 PROs reflect how patients 
feel and function in relation to a disease, and its treatment, without interpretation by others, 
including healthcare professionals. PROs enable unique insight into the effectiveness of care 
from the patient perspective, which has particular relevance in an era of scarce resources and 
rising treatment-costs.
11
 In addition, patient self-report can itself improve symptom 
management, communication, HRQoL and satisfaction with care.
12,13
 
In view of the diversity of sarcoma histotypes across the age-spectrum and specific 
developmental issues an age-stratified approach to the overall management of sarcomas 
seems appropriate from both the patients’ and health care professionals’ perspective. 
Paediatric patients most commonly develop rhabdomyosarcoma, whereas adolescent and 
young adults (AYA) acquire synovial sarcoma, Ewing sarcoma, osteosarcoma, desmoplastic 
small round cell tumor, clear cell sarcoma, alveolar soft part sarcoma, epithelioid sarcomas 
and malignant peripheral nerve sheath tumours.
14,15
 Many of these patients require intensive, 
multimodal treatment, including chemotherapy, and may face potential long-term side-
effects.
11
 AYA sarcoma patients also encounter additional psychosocial challenges including 
changes in body-image and relationships, as well as issues with fertility, higher education, 
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gaining employment and financial difficulties.
14,15
 Adult sarcoma patients most commonly 
develop undifferentiated sarcomas, gastrointestinal stromal tumours, leiomyosarcomas and 
liposarcomas requiring surgery, often radiotherapy and on indication chemotherapy.
11
 Unlike 
younger patients, elderly patients often receive less aggressive treatments possibly due to 
medical co-morbidities; a factor associated with increased mortality.
16 
It is also 
acknowledged that elderly patients are disproportionally under-represented in clinical 
research trials.
17
 Overall, the treatment of sarcoma patients is often burdensome due to bulky 
tumours, and at times may be challenging due to anatomic locations such as the head and 
neck.  
 
In 2014, the UK National Cancer Patient Experience Survey (NCPES) identified that patients 
with rare cancers, including sarcomas, described a significantly poorer experience of care 
than those with common cancers.
18
 They were less likely to feel that they were seen in a 
timely manner, among other negative findings.
18
 Following these results, Sarcoma UK (the 
largest sarcoma-specific cancer charity in the UK) commissioned and funded a national 
survey to gain additional insight into the sarcoma patient journey. The Sarcoma UK data 
were used in the present study to examine age-related differences in the sarcoma patient 
journey. Understanding the age-specific patient experience before, during and after treatment 
is essential in order to develop patient-centered services, which incorporate biomedical and 
psychosocial needs with existing clinical knowledge.  
Methods 
Patients 
This study was a cross-sectional survey of adult sarcoma patients (aged 18 years and older) in 
England. Patients were identified from respondents to the NCPES 2012-14, who indicated 
willingness to be contacted for future questionnaires. The NCPES is an annual survey 
commissioned by the National Health Service in England. The NCPES is sent to all patients 
with cancer who have been discharged after an inpatient or day-case admission (over a 
specified three-month period) from one of the acute and specialist NHS trusts in England that 
provide adult cancer services. Public Health England have reported high concurrence 
between NCPES respondents and a newly diagnosed cancer population-based dataset, with 
regard to age, sex, ethnicity and deprivation, however NCPES has slight over-representation 
of patients aged 51-75 years and of white ethnicity: reflecting known bias in survey 
responders.
19
 Patients with tumour types which are more likely to be treated as an outpatient 
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 The NCPES does not collect data on date of diagnosis or stage of 
disease. The flow diagram below demonstrates how the patient sample was selected for the 
Sarcoma UK patient survey.  Deceased patients, duplicated patients or those without a 
validated address were identified and excluded from the study. Preference was given to those 
patients who participated in the most recent NCPES: 2014 (n=452), 2013 (n=343), 2012 
(n=105). Patients were approached independent of their stage of disease, which was not 
identified for this survey. The final sample size was 900.   

















Ethical approval was not required for this secondary study as the NCPES is underpinned by 




Agreed to future 
questionnaires 
n=1740  







completed >1 NCPES 
(duplicates) 
n=92 
Living patients with 
validated address 
n=1092 
Deceased patients or 
no validated address 
n=556 
Final sample after 
further screen 
n=900 
Deceased or from 
NCPES 2012/2013* 
n=192 
Respondents to the 
Sarcoma UK survey 
n=558 
Did not respond to 
Sarcoma UK survey 
n=342 
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adult cancer services. Annual approval for NCPES is reviewed by the The Ethics and 
Confidentiality Committee of the National Information Governance Board. Patient consent 
was implicit through completion of the Sarcoma UK questionnaire. Patients were advised that 
they could withdraw the information that they had provided in the questionnaire upon 
request, up to the point at which personal details were removed and data was analysed.  
Materials 
Questionnaires were designed by Quality Health, an independent agency approved by the 
Care Quality Commission specialising in national patient surveys, in conjunction with 
Sarcoma UK, patient advocates and sarcoma clinicians. The questionnaire aimed to provide a 
comprehensive overview of the sarcoma patient experience and focused on three areas of the 
patient journey: diagnosis, treatment and post-treatment. Questionnaires were dispatched to 
patients by post and two reminders sent to non-respondents as necessary within the 12-week 
period. Fieldwork was undertaken between January-March 2015. Questionnaires were 
returned by post to Quality Health for analysis. 
Statistical analysis  
Patients who completed the questionnaire were grouped by tumour-type (STS or bone 
sarcoma) and age (AYA, 18-39 years; middle-aged, 40-64 years; and elderly, 65+years). 
Certain questions were not applicable to all participants and therefore missing data for these 
questions was assumed to be ‘missing not at random’ (e.g. question 28 ‘If you had a bone 
sarcoma were you given information from the Bone Cancer Research trust?’)  For other 
questions only available data were analysed. Descriptive statistics were used to describe the 
study sample. For continuous variables, mean values and standard deviations are presented. 
Categorical variables are represented by numbers and percentages and chi-square tests were 
conducted to detect differences between tumour-type and age groups. Adjusted residual 
values were calculated to identify significant differences with a significance level of α=0.05. 
All data analysis was performed using IBM SPSS 22.0. 
Results 
Patient characteristics (Table 1) 
Of the 900 patients invited, 558 patients completed the survey (response rate 62%): 418 STS 
(75%) and 140 bone sarcoma (25%). Response rates for STS patients and bone sarcoma 
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patients were equal (62%). Mean age of respondents was 64.1 years (SD 14, range 18-96). 
There were 46 AYA (bone sarcoma, n=23, STS n=23), 285 middle-aged (bone sarcoma, 
n=78, STS n=207) and 227 elderly patients (bone sarcoma n=39, STS n=188). Response rate 
varied according to age: AYA 60%, middle-aged 82% and elderly 48%. Gender distribution 
was almost equal (male n= 274, 49%, female n=284, 51%). ‘Lower limb’ was the most 
common primary site of disease in both STS and bone sarcoma patients (total n=177, 32%). 
The total number of patients treated with surgery was 502 (90%), radiotherapy (n=246 
patients, 44.1%) and chemotherapy (n=201, 36.0%). AYA patients (STS and bone sarcoma) 
were significantly more likely to have been treated with chemotherapy than middle-aged and 
elderly patients (80% AYA vs. 40% middle-aged vs. 22% elderly: p<0.001).
 
Most patients 
had three-monthly (n=232, 45.4%) or 6 monthly (n=109, 21.3%) follow-up.   
Diagnosis  
The most common presenting symptom overall was a ‘painless lump’ (n=229, 41%). Elderly 
STS patients were more likely to present with a painless lump than AYA and middle-aged 
patients (p=0.038). In contrast, bone pain was most common in bone sarcoma patients (n=44, 
31%) and was a more common presenting symptom in AYA bone sarcoma patients than 
other bone sarcoma age groups (p=0.011).  
Almost half of patients (n=251, 48%) presented to a medical professional within 4 weeks of 
first developing symptoms, however, more than a quarter waited >3 months (n=150, 27%) 
and one in ten >1 year (n=54, 10%) before seeking medical advice. Presentation was more 
likely to be delayed in bone sarcoma than STS patients (p=0.047). There were no age-related 
differences in time to presentation. 
Most patients sought advice from their General Practitioner (GP) (n=447, 80%) about their 
symptoms. Within this cohort of patients, GPs referred 324 patients (72%) either for further 
investigations, to a hospital specialist or immediately admitted to hospital. An incorrect 
interpretation of symptoms and subsequent advice was given to 123 patients (28%). This 
included those treated for another condition (n=42, 8.6%), those who were told that their 
symptoms were not serious but to return if they persisted (n=41, 8.4%) and those who were 
not advised to return if symptoms persisted (n=40, 8.1%). Elderly bone sarcoma patients 
(n=21, 87.5%) were significantly more likely to be referred for investigation than younger 
patients while AYA bone sarcoma patients were more frequently treated for another 
condition or advised their symptoms were not serious (n=10, 50%; p=0.021). Elderly STS 
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patients (n=123, 78.3%) were also more likely to be referred and AYA STS patients more 
likely to be treated for another condition or advised that their symptoms were not serious 
(n=8, 53.3%; p=0.001) 
Approximately one fifth of patients presented to the Emergency Department (n=121, 22%). 
Similarly, of those seen in the Emergency Department, 91 patients (75%) were referred for 
further investigation and 30 patients (25%) were treated for another condition or advised their 
symptoms were not serious. No significant age-related differences were identified in bone 
sarcoma patients. However, in STS patients, the elderly were more likely to be further 
investigated than younger patients and AYA and middle-aged patients were more commonly 
treated for another condition or told their symptoms were not serious (p=0.020)  
Overall, 104 patients (20%) were told that they may have a sarcoma when first presenting 
with symptoms. This was significantly more likely in elderly bone sarcoma patients (n=15, 
45.5%) compared to AYA (n=2, 9.1%) and middle-aged (n=10, 14.3%) bone sarcoma 
patients (p=0.003), and in elderly STS patients (n=49, 27.7%) compared to AYA (n=4, 
17.4%) and middle-aged (n=24, 12.1%) STS patients (p=0.001). 
Treatment  
Most patients (n=475, 87%) reported that they were treated by a specialist sarcoma team and had a 
clinical nurse specialist (n=407, 76%). Patients were often treated at more than one hospital (n=368, 
66%). Most patients “did not mind” travelling for surgical treatment (n=451, 89%) and almost half 
(n=260, 49%) journeyed at least 20 miles for an operation. Patients who were treated with 
chemotherapy and/or radiotherapy in addition to surgery often had to travel to a different hospital for 
this treatment (n=209, 62%). AYA bone sarcoma patients (n=17, 85%) were significantly more likely 
to attend another hospital for these additional treatments (p<0.001) and to be treated at more than 
three hospitals (p=0.033) than older bone sarcoma patients.  
One third of patients (n=158, 30%) were offered participation in a clinical trial, of whom a small 
number participated (n=35, 22%). Consequently, 6% of all participants were involved in a clinical 
trial. AYA bone sarcoma patients were more likely to be offered (n=13, 57%; p=0.013) and to 
participate (n=12, 52%; p=0.004) in a clinical trial compared to middle-aged and elderly bone 
sarcoma patients. There were no significant age-related differences in clinical trial accrual among the 
STS patients.  
Most patients (n=472, 87%) felt that they were given sufficient information to make informed 
decisions about their care. Almost half of patients were provided with a complete written treatment 
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plan (n=237, 48%). Elderly patients (bone sarcoma n=39, STS n=188) were more likely to report 
satisfaction with the information given than AYA and middle-aged patients (bone sarcoma p<0.001, 
STS p=0.049).  
Most patients (n=441, 81%,) were given adequate emotional support from hospital staff, however 40 
patients (7%) would have preferred more support and 64 patients (12%) did not feel that this was 
necessary. Elderly bone sarcoma patients (n=33, 85%; p=0.006) and elderly STS (n=115, 64%; 
p=0.003) were more likely to report sufficient emotional support than AYA (n=12, 52%) and middle-
aged (n=39, 51%) bone sarcoma patients, and AYA (n=9, 41%) and middle-aged (n=100, 49%) STS 
patients.  
The most common symptoms and side effects of treatment were daytime fatigue (n=277, 47.7%) and 
pain (n=248, 44.4%). Pain was the symptom with the greatest impact on patients’ lives (n=92, 25%). 
AYA bone sarcoma and STS patients were significantly more likely to recall side effects of treatment 
than middle-aged and elderly patients. Middle-aged patients were also more likely to report side 
effects than elderly patients in STS and bone sarcoma groups (Figures 2a and 2b) 
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Figure 2a. Percentage of bone sarcoma patients with symptoms or side-effects according 














Figure 2b. Percentage of soft tissue sarcoma patients with symptoms or side-effects 
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Support and follow-up  
Most patients felt that follow-up information was very clear (n=428, 85%) and knew how to 
contact the sarcoma team for information (n=482, 89%). Patients were most likely to be 
referred to physiotherapy after treatment (n=184, 33%). Referral was significantly more 
likely in AYA and middle-aged bone sarcoma patients than elderly bone sarcoma patients 
(p=0.030). Similarly, AYA STS patients were more commonly referred for physiotherapy 
than older patients (p=0.030). Rehabilitation services were helpful for 176 patients (48%), 
however 105 patients (29%) found minimal benefit and 49 patients (13%) not useful at all. 
No age-specific differences were observed. 
One quarter of patients (n=133, 24%) were aware of Sarcoma UK and given a Sarcoma UK 
toolkit (n=104, 19%).  A minority of patients were told about generic (n=134, 28%) or 
sarcoma-specific (n=92, 18%) local support groups. Patients used online national UK charity 
websites including Macmillan (n=231, 48%) and Cancer Research UK (CRUK) (n=108, 
22%). AYA and middle-aged bone sarcoma patients were significantly more likely to use 
Macmillan (p<0.001) and CRUK (p=0.003) websites than elderly bone sarcoma patients. 
AYA STS patients were more likely to use Macmillan and Sarcoma UK than older patients 
(p<0.001). Middle-aged bone sarcoma patients were more likely to use Sarcoma UK than 
elderly (p=0.032).  
Fear of cancer recurrence was the most common post-treatment concern (n=398, 72%).  
Many post-treatment concerns were more common in AYA (bone sarcoma and STS patients) 
compared with middle-aged and elderly patients. Middle-aged patients also reported more 
worries than elderly patients (Figure 3: Post-treatment concerns). Worry about ‘cancer 
coming back’ was significantly more common among AYA and middle-aged patients 
compared with elderly patients (AYA 80%, middle-aged 76%, elderly 64%, p=0.005). AYA 
and middle-aged patients were more likely to report worries about ‘coping with side effects 
of treatment’ (AYA 37%, middle-aged 30%, elderly 18%, p=0.001). AYA were the most 
likely group to have worries about coping with disability caused by surgery (AYA 48%, 
middle-aged 32%, elderly 20%, p<0.001). Worries about family and friends were most 
commonly reported by AYA and middle-aged patients (AYA 46%, middle-aged 37%, elderly 
17%, p<0.001). Worries about ‘loss of control of my life’, the ‘possibility of dying’ and 
financial concerns were also more common in AYA and middle-aged patients compared with 
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elderly patients. There were no other statistically significant differences in worries between 
age-groups.  

















































To our knowledge, this is the first large-scale study of the sarcoma patient journey from the 
patient perspective. In accordance with current UK guidelines, the majority of patients were 





Delay in patient presentation was observed in the diagnostic trajectory.  We found that 27% 
of patients presented more than three months after first noting symptoms and 10% of patients 
waited more than one year before seeking advice for their symptoms. Patient age was not 
associated with time to presentation. Our findings are consistent with a previous UK survey 
of almost 2,000 cancer patients, which found that 21% of sarcoma patients (n=127) delayed 
>3 months from symptom-onset to first presentation, and was not associated with patient 
age.
22
 Patient delay in other malignancies varied from 8.5% (breast) to 47.8% (prostate).
22
 
Almost three-quarters of participants in this study were referred for further evaluation by 
their GP or emergency department doctor, after seeking advice for their symptoms. 
Approximately one quarter of patients who presented to a medical practitioner with 
symptoms reported that they were treated for another condition or advised that their 
symptoms were not serious. AYA patients were more likely to be treated for another 
condition or advised that their symptoms were not serious, whereas elderly patients were 
more likely to be referred for further evaluation. Previous data has also demonstrated that 
AYA cancer patients are significantly more likely to have seen their GP 3 times before 
referral than older patients.
23
 This may be due to low clinical suspicion of cancer in this age 
group and may lead to delay in diagnosis. Overall, given the low incidence of sarcomas, 
professionals may only encounter one case in their career.
24
 In addition, only approximately 
one in 100 soft tissue lumps are malignant, leading to low clinical suspicion.
24
 Previous 
research has shown that patients with sarcomas are more likely to have seen their GP >2 
times before referral to hospital (41%) compared to others malignancies, such as breast 8% 
and skin 10% cancer.
18
 They are also less likely to be referred by the ‘Two Week Wait’ 
(TWW) system, which ensures that patients with suspected cancer are seen within two weeks 
(10% bone sarcoma, 12% STS vs. 25% all cancers).
25
 Patients with central nervous system 
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We found that one fifth of patients presented with first symptoms to the ED but this was not 
associated with patient age. The high number of emergency presentations is particularly 
concerning as this is associated with more advanced disease and significantly lower survival 
rates in patients with other cancers, even when adjusted for stage of disease at diagnosis.
25-27
 
A previous UK study demonstrated that 18.6% of sarcomas and 23% of all cancers were 
diagnosed through ‘emergency presentation’ between 2006 and 2008.
25
 This study also found 
that bone sarcoma patients aged <10 or >80 years, and STS patients aged <19 or >80, were 
more likely to present to ED.
25
 Although we did not find this association, our survey did not 
include paediatric patients and our sample size was considerably smaller (558 vs. 8956 
patients).
25
 Others have also found that emergency presentation is more common in elderly 
cancer patients, which may itself contribute to increased mortality.
26
 Emergency presentation 
may be unavoidable due to tumour-related factors, however research indicates that many 
patients have had consultations within 12 months of diagnosis. This indicates that there may 
be opportunities to reduce the number of emergency cancer presentations.
27
  
UK cancer survival figures are significantly lower than most European countries, a finding 
that has been attributed to late stage diagnosis.
28
  In the UK a relatively high number of 
patients present to the ED before diagnosis.
27
 The UK Royal College of Emergency Medicine 
(RCEM) and The Patients Association reported that patients often attended ED because they 
felt unable to access timely help elsewhere and perceived that they would be able to access 
immediate diagnostic investigations and specialist opinion.
29
 This included patients with 
symptoms which had been present for days or even weeks, who were offered a GP 
appointment the same day however still chose to attend ED instead. For lung cancer this has 
been exemplified by a study of eight European countries. In this study an emergency route to 
lung cancer diagnosis was most likely in the UK and Portugal, and least common in The 
Netherlands.
30
 Disparities in routes to diagnosis may influence outcomes for UK cancer 
patients compared with their European counterparts. 
Treatment 
In accordance with findings of the NCPES, less than one third of patients (30%) were offered 
the opportunity to participate in a clinical trial.
18
 AYA bone sarcoma patients were 
significantly more likely to be involved in a clinical trial than all other groups. These findings 
reflect the availability of clinical trials enrolling patients at the time of the survey, which 
included large international trials for bone sarcoma and few trials for first presentation of 




STS.  It is internationally acknowledged that there are significant age inequalities in clinical 
trial accrual among cancer patients. Previous studies have demonstrated that AYA cancer 
patients overall are less commonly enrolled in clinical trials than paediatric and adult 
patients.
31
 Lack of involvement in research trials is believed to be responsible for slower 
progress in survival outcomes for AYA cancer patients.
31,32
 Older patients are also often 
disproportionally underrepresented in clinical research trials despite an increasing incidence 
of sarcomas with advancing age.
33
  
Comparable with other cancers, many sarcoma patients reported a high burden of symptoms 
and side-effects of treatment, most commonly daytime fatigue.
34
 Notably, almost all 
symptoms and side effects of treatment occurred with increased frequency among AYA 
patients, however AYAs were significantly more likely to have been treated with 
chemotherapy than older patients. A large study of patients with advanced cancer also found 
that increasing age was associated with lower reporting of symptoms, however this 
association has not been replicated in all studies.
35
 Older patients may report less symptoms 
due to physiological changes associated with ageing, lower levels of physical activity, less 
work-related and social activities compared with younger patients, and possibly a more 
tolerant attitude toward illness.
35,36
 Elderly patients were significantly more satisfied with the 
information and emotional support provided than younger patients. This is consistent with 
research demonstrating a paternalistic attitude of older patients, who report higher levels of 




The majority of post-treatment concerns were most common in AYA patients. AYAs who are 
diagnosed with cancer are suddenly faced with existential questions during a critical phase in 
their life.
32
 While their siblings and peers are progressing forward with education and 
relationships, their own journey is suddenly and unexpectedly altered.
32
 The AYA-HOPE 
study also found a high prevalence of unmet psychosocial needs and reduced HRQoL in 
AYA cancer survivors compared with an age and sex matched population.
38
 Studies of 
multiple myeloma and lymphoma patients have also demonstrated that the elderly are less 
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Despite the growing body of evidence that early diagnosis improves survival in many 
common cancers, the impact in sarcomas has not been clearly established and may be limited 
to certain subtypes.
24,41-43
 The intrinsically aggressive disease biology of some sarcomas may 
override any potential influence of delay on survival outcomes.
32
 Nonetheless, it would seem 
rational to strive toward early diagnosis for those in whom early treatment may improve 
outcome. Additionally, delayed diagnosis can cause psychological distress and may lead to 
tumour growth with reduced potential for curative localised surgery. Public awareness 
campaigns for common cancers are well established. Strategies to improve awareness of 
‘alarm’ symptoms of sarcomas, such as a lump larger than a ‘golf ball’, increasing size >5cm, 
deep to the fascia, or persistent deep bone pain have recently been introduced to public 
awareness programs.
44,45
 Medical professionals must also be aware that sarcomas can affect 
AYAs and thus avoid delayed referral in this age group.  Unlike care for paediatric patients, 
which is often centralized and protocol-driven, AYAs often fall between services for 
paediatric and adult patients.
46
 AYAs also encounter unique developmental challenges and it 
is unquestionable that an age-specific approach is required for these patients.
47
  
The high symptom-burden must be addressed, particularly for AYAs and those who have 
received intensive treatment. Early integration of specialist symptom control teams can 
improve HRQoL, satisfaction with care and reduce rates of depression in cancer patients.
48
 In 
addition, this intervention has demonstrated a survival benefit in metastatic non-small-cell 
lung cancer patients.
49
 Pain screening and early referral to a pain treatment protocol has been 
successful in head and neck cancer patients.
50 
Based on results from this survey, it is probable 
that a multidisciplinary, symptom-oriented approach would be also beneficial for the sarcoma 
population.  
Elderly patients with bone sarcoma were uncommonly involved in research and overall were 
less likely to be referred to rehabilitation services. Although physical and cognitive problems 
may require optimisation, it is vital that chronological age is not a barrier to involvement in 




Limitations of this study include the lack of patient details, such as race or ethnicity, 
geographic location of participants, disease stage and interval from diagnosis to participation 




in the study.  Patients with localised disease encounter very different challenges to those with 
advanced disease, and consequently, the lack of data regarding disease stage means that it is 
not clear whether this sample is truly representative of the general sarcoma population. 
Additionally, the NCPES only includes patients who were discharged from hospital following 
a day-case or inpatient admission. This means that patients with certain sarcoma subtypes, 
such as endometrial stromal sarcoma or gastro-intestinal stromal tumour (GIST), who are 
more commonly treated as an outpatient with oral therapy would not have been invited to 
participate in the NCPES and thus are likely to be under-represented in the Sarcoma UK 
patient survey.   
Age-based comparisons were limited due to the small sample size of the group of AYA 
patients (n=46), however statistical analysis was used to identify true differences across the 
age groups.  The response rate was higher in middle-aged patients than AYA or elderly 
patients: reflecting a known bias in survey respondents. Survivorship bias was introduced by 
selection of patients who participated in NCPES from 2012-2014, which means they will 
have survived at least one year since diagnosis. These patients are likely to have a better 
prognosis than an unselected population of sarcoma patients. This study did not use 
internationally a validated questionnaire, however was designed by sarcoma patients and 
experts in a similar format to previous NCPES in order that patients were familiar with the 
terminology used. The meaning of a ‘clinical trial’ was open to interpretation by the patient 
and therefore participation rates should be interpreted with caution. As with all patient 
surveys, it is possible that recall bias had an influence on our results. The perspective of the 
healthcare professional (e.g. GP) was not surveyed and therefore all results are based on the 
patient’s perception of their individual experience.  
Conclusions 
In this study, describing the largest sarcoma patient survey to date, we identified significant 
age-related differences in the sarcoma patient journey. AYA patients appear more vulnerable 
to incorrect diagnosis, a high burden of treatment related side effects and post-treatment 
psychological concerns. Elderly patients reported less trial participation and were less likely 
to be referred to rehabilitation services. Overall, the burden of disease was felt high. Despite 
the general focus of physicians and researchers on the anatomic and histological 
heterogeneity of sarcomas, from a patient perspective attention should also be paid to the 
differences in age-related aspects of diagnosis, treatment, trial access and survivorship. The 
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findings suggest a rationale for integrating an age-stratified approach to the general 
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Dit proefschrift bevat twee delen. Het eerste deel betreft de kwaliteit van leven, voorkeuren 
en verwachtingen van patiënten met een uitgezaaide en/of lokaal onbehandelbare vorm van 
wekedelensarcoom die behandeld (gaan) worden met palliatieve chemotherapie en beschrijft 
hoe de resultaten van de zogenaamde HOLISTIC studie gebruikt kunnen worden om 
gepersonaliseerde zorg voor deze patiëntengroep te bevorderen. Het tweede deel gaat over 
leeftijdsspecifieke klinische uitkomsten van patiënten met een uitgezaaide en/of lokaal 
onbehandelbare vorm van wekedelensarcoom en op leeftijd toegespitste ervaringen van 
patiënten met zowel wekedelen- als botsarcomen 
Hoofdstuk 1 geeft een algemene inleiding op het proefschrift, waarbij met name aandacht 
wordt besteed aan de epidemiologie van sarcomen, de bestaande focus van gepersonaliseerde 
zorg, patiënt gerapporteerde uitkomsten en leeftijdsspecifieke aspecten. 
Sarcomen vormen een zeldzame groep van mesenchymale tumoren van bot en weke delen, 
die op alle leeftijden overal in het lichaam voor kunnen komen. Er zijn zeer veel 
verschillende subtypes die variabele tumorbiologie en klinisch gedrag hebben. Het succes van 
behandeling wordt vaak voornamelijk beoordeeld aan de hand van overlevingscijfers. In dit 
proefschrift komen echter nadrukkelijk ook andere uitkomsten en aspecten van zorg aan de 
orde.  
Deel 1 Kwaliteit van leven  
Patiënt gerapporteerde uitkomstmaten, en in het bijzonder kwaliteit van leven, worden 
toenemend gezien als van onschatbare waarde voor zorg waarbij de patiënt centraal staat. 
Bovendien dragen ze bij aan klinische besluitvorming en het maken van beleid in de zorg. 
Van oudsher hebben klinische studies zich, voor wat betreft het meten van effectiviteit van 
een behandeling, gefocust op radiologisch respons en (progressievrije) overleving, terwijl 
kwaliteit van leven niet gestructureerd werd gemeten. Patiënten met een uitgezaaide vorm 
van wekedelensarcoom hebben een scala aan vaak complexe symptomen en een slechte 
prognose, maar er is een gebrek aan literatuur op het gebied van kwaliteit van leven in deze 
patiëntengroep. 
Om hier meer over te weten te komen hebben wij de HOLISTIC studie opgezet en 
uitgevoerd. 




Hoofdstuk 2 beschrijft het protocol van de HOLISTIC studie (ClinicalTrials.gov: 
NCT03621332); een prospectieve observationele cohort studie waarin kwaliteit van leven 
wordt gemeten bij patiënten die starten met palliatieve chemotherapie voor een 
gemetastaseerd en/of lokaal niet meer curatief te behandelen wekedelensarcoom. Patiënten 
die mee konden doen moesten 18 jaar of ouder zijn en werden geselecteerd in sarcomen 
centra in Nederland en Engeland. Patiënten werden geïncludeerd voor de start van eerste of 
derdelijns chemotherapie.  Vragenlijsten werden ingevuld via PROFIEL. PROFIEL is de 
vertaling van PROFILES wat staat voor Patient-Reported Outcomes Following Initial 
treatment and Long term Evaluation of Survivorship. De PROFIEL registratie is in 2008 in 
Nederland opgezet om de fysieke en psychosociale gevolgen van kanker en de behandeling 
ervan te onderzoeken in patiënten met kanker of die kanker hebben gehad. Deelnemers in de 
HOLISTIC studie werd gevraagd om vragenlijsten in te vullen voor start van de 
chemotherapie en voorafgaand aan iedere kuur en iedere 2-3 maanden na afloop van de 
behandeling. Vragenlijsten die werden voorgelegd betroffen onderwerpen als kwantiteit 
versus kwaliteit van leven, een schaal die keuzestress mat, een die zich toelegde op 
voorkeuren van controle bij het nemen van beslissingen, een kanker specifieke kwaliteit van 
leven vragenlijst en vragen over de financiële gevolgen van het hebben van kanker. Het 
eerste doel van HOLISTIC studie was om te bepalen hoe de kwaliteit van leven verandert van 
patiënten die starten met eerstelijns palliatieve chemotherapie vanaf start van behandeling tot 
het moment dat er 4 kuren chemotherapie zijn gegeven. De uitkomst van de studie is voor dit 
eerste doel nog niet bekend en zal later worden bestudeerd. Een andere groep wordt gevormd 
door patiënten die met derdelijns chemotherapie startten. Ook bij hen werd de kwaliteit van 
leven tijdens behandeling gemeten. Vaak is van derdelijns chemotherapie veel minder winst 
te verwachten en het is belangrijk te weten hoe patiënten een dergelijke behandeling ervaren 
en of niet alleen de winst in overleving anders is dan na de eerstelijns behandeling maar ook 
de impact van de behandeling verschilt. Een belangrijke observatie was dat de HOLISTIC 
studie aantoonde dat het mogelijk is om elektronisch patiënt gerapporteerde uitkomsten te 
meten tijdens palliatieve chemotherapie voor behandeling van gemetastaseerde 
wekedelensarcomen, dit te doen in twee landen en met participatie van patiënten van alle 
leeftijden boven de 18 jaar. 
Deelnemers aan de HOLISTIC studie werden geïncludeerd tussen februari 2018 en maart 
2021. Bevindingen van de deelnemers voor start van de studie zijn beschreven in hoofdstuk 
3. In totaal vulden 137 patiënten de vragenlijsten in, 72 in Engeland en 65 in Nederland. 




Patiënten hadden een mediane leeftijd van 62 (27-79) jaar. Hoewel zowel kwaliteit als lengte 
van het leven als belangrijk werden beoordeeld als behandeldoel van de palliatieve 
chemotherapie was er een kleine meerderheid die lengte van leven belangrijker vond.  In lijn 
met eerdere bevindingen in de literatuur in patiënten met gemetastaseerde ziekte vond de 
jongere groep (tot en met 39 jaar) lengte van leven belangrijker en twee derde van de ouderen 
(65 jaar en ouder) gaven aan dat kwaliteit van leven op zijn minst even belangrijk was als 
duur van het leven. Deze bevindingen ondersteunen de keuze van co-primaire eindpunten in 
klinische studies bij patiënten met wekedelensarcomen, in het bijzonder in oudere patiënten, 
waarin naast response of (ziektevrije-)overleving ook kwaliteit van leven wordt 
meegenomen. Het is in elk geval belangrijk om al vroeg met de individuele patiënt te 
bespreken waar zijn prioriteiten liggen om de behandeldoelen hierop aan te kunnen laten 
sluiten. 
 Zogenaamde keuzestress (om wel of niet te starten met palliatieve chemotherapie) was het 
meest aanwezig bij patiënten die kwaliteit van leven belangrijker vonden dan duur van het 
leven (hoofdstuk 3). Een van de belangrijkste factoren die ten grondslag liggen aan 
keuzestress is het ontbreken van kennis van risico’s en voordelen van de chemotherapie. 
Keuzestress om wel of geen chemotherapie te starten bij patiënten met gemetastaseerde weke 
delen sarcomen is mogelijk deels het gevolg van het ontbreken van informatie over wat een 
dergelijke behandeling voor impact heeft op de kwaliteit van leven. De resultaten van de 
HOLISTIC studie kunnen hier naar verwachting in tegemoet komen en daarmee hopelijk 
voor toekomstige patiënten de keuzestress verminderen. 
Gezamenlijke besluitvorming wordt beschouwd als beste manier van zorg waarbij de patiënt 
centraal staat. De meerderheid van de patiënten die aan de HOLISTIC studie deelnamen 
prefereerden enige mate van samenwerking in besluiten omtrent behandelingen, terwijl een 
minderheid de voorkeur gaf aan een actieve of juist geheel passieve rol. Nederlandse 
deelnemers hadden significant vaker de voorkeur voor een actieve rol (actief of actief-
samenwerkend) in vergelijking met Engelse deelnemers. Geslacht en klinische conditie 
bepaalden ook de voorkeursrol in besluitvorming. Ook anderen hebben eerder aangetoond dat 
patiënten met een terminale ziekte steeds meer een actieve rol in besluitvorming ten aanzien 
van behandeling namen. Het was geruststellend om te zien dat de gewenste rol in het nemen 
van beslissingen in het algemeen overeenkwam met de wijze waarop de beslissing ten 
aanzien van behandelen in de praktijk was genomen. Eens te meer geven de resultaten van dit 




onderzoek aan dat bij besluitvorming meerdere zaken een rol spelen en een gepersonaliseerde 
benadering bij het spreken over besluiten ten aanzien van dergelijke behandelingen belangrijk 
is. 
In hoofdstuk 3 werden verder verwachtingen ten aanzien van behandeluitkomsten 
onderzocht. De grote meerderheid van patiënten met gemetastaseerde wekedelensarcomen 
die eerstelijns chemotherapie startten, geloofden dat chemotherapie hun leven zou verlengen 
en kanker gerelateerde problemen zou doen verminderen. Hoewel de impact van 
chemotherapie op overleving in deze context niet heel duidelijk is, weten we wel dat de 
mediane overlevingsduur van patiënten met een uitgezaaide vorm van wekedelensarcomen 
over de laatste jaren is verbeterd door een toename in beschikbare behandelingen, 
behandelingen die meer op de histologische subtypes wekedelensarcoom zijn toegespitst en 
betere ondersteunende maatregelen. De meeste deelnemers aan de HOLISTIC studie gaven 
aan dat het doel van de behandeling niet genezing was, maar patiënten met een 
migratieachtergrond gaven significant vaker aan dat genezing op zijn minst enigszins 
mogelijk was. Verschillen in hoop en verwachtingen tussen groepen met een verschillende 
etnische achtergrond zouden te maken kunnen hebben met begrip (niet primair de taal van het 
land sprekend) of verschil in omgaan met deze behandelingen en religieuze overtuigingen.  
Deel 2 Leeftijdsspecifieke aspecten 
Patiënten met alle leeftijden kunnen worden getroffen door een sarcoom en verschillen in 
zowel biologie van de ziekte, behandelingen en psychosociale factoren die een rol spelen bij 
leeftijdsspecifieke zorg. 
Adolescenten en Jongvolwassenen (AYA) 
Hoewel kanker op jonge leeftijd niet veel voorkomt, vormen sarcomen een van de meest 
frequent voorkomende maligniteiten op AYA leeftijd (18-39 jaar bij diagnose). Ongeveer 
10% van de sarcomen komen voor bij kinderen en AYA’s. In vergelijking met andere 
tumoren op AYA leeftijd, zoals schildkliercarcinomen en testistumoren, hebben sarcomen 
een slechte prognose. Ongeveer de helft van de patiënten met hooggradige sarcomen 
ontwikkelen gemetastaseerde ziekte, wat een groot aandeel in de totale sterfte aan kanker op 
AYA leeftijd veroorzaakt. Histologische subtypes die typisch op AYA leeftijd voorkomen, 
zoals alveolair rhabdomyosarcoom en Ewing sarcoom, vragen om een intensive behandeling 




die vaak bestaat uit chemotherapie, bestraling en chirurgie, met korte en lange termijn 
effecten van behandeling.  
In hoofdstuk 4 worden behandelingen en uitkomsten van 455 AYA patiënten (18-39 jaar) met 
uitgezaaide wekedelensarcoom beschreven die behandeld zijn geweest in een gespecialiseerd 
sarcomencentrum (het Royal Marsden ziekenhuis in Londen). Hoewel de overleving met 
mediaan 19 maanden iets beter is dan de beschreven mediane overleving bij alle volwassenen 
met gemetastaseerde weke delen sarcomen, 12-18 maanden, is de uitkomst toch erg slecht en 
gaat dit samen met een groot verlies aan levensjaren. Het maakt ook helder hoe belangrijk 
nieuwe effectieve behandelingen zijn. Patiënten met subtypes wekedelensarcomen die bekend 
staan als chemosensitief, dus gevoelig voor chemotherapie, zoals rhabdomyosarcoom en 
Ewing sarcoom hadden juist opvallend slechtere uitkomsten, terwijl andere subtypes zoals 
alveolair soft part sarcoom, een meer indolent beloop hadden.  In totaal bleken in de hele 
studie patiënten 22 verschillende histologische subtypes wekedelensarcomen te hebben, die 
alle verschillende uitkomsten lieten zien. Dit onderstreept de enorme diversiteit van 
wekedelensarcomen in deze leeftijdsgroep en de noodzaak tot begrip van biologische 
verschillen tussen deze vormen van wekedelensarcomen. 
Een belangrijk deel van deze AYA’s  met een uitgezaaide vorm van wekedelensarcoom kreeg 
chemotherapie in de laatste weken tot maanden voor overlijden. Dit fenomeen is wel meer 
beschreven in AYA’s met kanker. De redenen hiervoor kunnen zijn ingegeven door patiënt, 
familie, maar ook behandelend oncologen. Het gevoel dat een naderend levenseinde op deze 
jonge leeftijd onrechtvaardig is, kan zeker een rol bij spelen bij dit relatief lang actief 
behandelen, zelfs als men weet dat de kans op een zinnige toevoeging van tijd van leven 
beperkt is. Deze bevinding wordt ondersteund door resultaten uit de HOLISTIC studie waarin 
AYA patiënten allen aangaven verlenging van levensduur het allerbelangrijkste te vinden bij 
het starten van palliatieve chemotherapie. Eerder onderzoek heeft aangetoond dat de nadruk 
op levensduur verlenging een gesprek over het naderend levenseinde bemoeilijkt terwijl juist 
deze gesprekken tussen behandelaars en de patiënt zeer belangrijk zijn om overbehandeling te 
voorkomen. Toch blijft ook hier weer een geïndividualiseerde benadering van belang om 
patiënten controle over de hoeveelheid, wijze en het moment van informatieverschaffing te 
geven. 
 





Wereldwijd neemt de levensverwachting toe en neemt het aantal ouderen met kanker ook toe. 
Helaas is deze groep echter zwaar ondervertegenwoordigd in klinische studies, waardoor er 
weinig bewijs is voor de beste behandeling in deze leeftijdsgroep.  Chronologische leeftijd en 
de (mis)perceptie van kwetsbaarheid en verdraagzaamheid van een behandeling leiden vaak 
tot empirische keuze voor doseringen chemotherapie waarbij patiënten makkelijk onder- of 
overbehandeld worden. Hoewel ongeveer de helft van de patiënten met wekedelensarcomen 
ouder dan 65 jaar is, zijn data over de behandeling van patiënten in deze leeftijdsgroep met 
gemetastaseerde wekedelensarcomen zeer schaars. 
In hoofdstuk 5 wordt een gepoolde analyse van 12 klinische studies van de EORTC Soft 
Tissue en Bone Sarcoma Group (STBSG) uitgevoerd om de resultaten van oudere patiënten, 
tenminste 65 jaar, met gemetastaseerd wekedelensarcoom die tussen 1980 en 2012 hebben 
geparticipeerd in studies met eerstelijns chemotherapie te vergelijken met die van patiënten 
jonger dan 65 jaar. Deze analyse toonde aan dat slechts 12% van de deelnemers in deze 
klinische studies ouder was dan 65 jaar waarbij hun mediane leeftijd (slechts) 68 jaar was. 
Wat bemoedigend is in dit opzicht is dat in een meer recente Amerikaanse SARC021 trial 
(2011-2014), die de waarde van standaard doxorubicine versus doxorubicine met 
evofosfamide onderzocht, ongeveer een derde van de patiënten 65 jaar of ouder was met een 
mediane leeftijd van 70 jaar (hoofdstuk 6). In beide studies was de overleving van de 65 plus 
patiënten slechter dan die van de jongere patiënten: 10.8 versus 12.3 maanden in de EORTC 
analyse en 16.7 maanden versus 20.1 maanden in de SARC021 studie. Als we ons realiseren 
dat in het algemeen relatief fitte patiënten aan dergelijke studies meedoen, is het duidelijk dat 
leeftijd op zich een slechte prognostische factor is bij de palliatieve behandeling van 
patiënten met wekedelensarcomen. Wat in de SARC021 studie verder opviel was dat de 
oudere patiëntengroep significant meer bijwerkingen had van de chemotherapie dan de 
jongere groep, met zelfs in 85% van deze groep een CTCAE graad 3 tijdens de behandeling 
(hoofdstuk 6). Gegeven het feit dat veel van de ouderen kwaliteit van leven op zijn minst 
even belangrijk vinden als duur van leven benadrukken deze gegevens de noodzaak van beter 
verdraagbare behandelingen en het verbeteren van ondersteunende maatregelen en zorg. 
Ondanks significant hogere aantallen van bijwerkingen in patiënten van 65 jaar en ouder in 
de SARC021 studie die met combinatie in plaats van met monotherapie waren behandeld, 
werden er geen verschillen in kwaliteit van leven gevonden tussen beide groepen (hoofdstuk 
6). De methodes om kwaliteit van leven in deze studie te meten waren de EQ-5D en de EQ-




VAS wat beide algemene meetinstrumenten zijn met een beperkt aantal items. Bovendien 
vulde maar een kwart van de deelnemers de kwaliteit van leven vragenlijsten bij start van de 
behandeling in wat het lastig maakt deze bevindingen op hun waarde te schatten. Het is 
onduidelijk waarom maar zo weinig patiënten deze vragenlijsten invulden, misschien waren 
er logistieke redenen en/of was er geen tijd om deze vragenlijsten uit te delen tijdens de 
drukte van de kliniek of was er gebrek aan bekendheid met dit soort meetinstrumenten. 
Gezien het feit dat juist ouderen kwaliteit van leven zo belangrijk vinden moet juist het 
invullen van dit soort vragenlijsten meer prioriteit krijgen. De “International Society of 
Quality of Life research (ISOQOL)” heeft richtlijnen gepubliceerd om onderzoekers te 
ondersteunen en te trainen in het ontwerp en de uitvoering en het rapporteren van de 
uitkomsten van klinische studies met door patiënt gerapporteerde uitkomsten. 
In vervolg op eerder studies die leeftijd als focus hadden zijn in hoofdstuk 7 door patiënt 
gerapporteerde ervaringen verder onderzocht. In dit hoofdstuk is gebruik gemaakt van 
gegevens van een onderzoek onder 558 patiënten met bot- en wekedelensarcomen in 
Engeland. Belangrijke leeftijdsspecifieke resultaten werden gevonden. Met name AYA 
patiënten ondervonden vaak een langere route tot uiteindelijke diagnose. Onbekendheid met 
de mogelijkheid van kanker op deze leeftijd kan hier een van de oorzaken zijn. Dit is met 
name belangrijk omdat late diagnosestelling kan leiden tot een meer gevorderd stadium van 
de ziekte en een meer intensieve behandeling (met mogelijk ook meer late effecten) en een 
slechtere prognose. Ook kwam naar voren dat AYA’s meer symptomen hadden en post 
behandeling psychologische zorgen hadden in vergelijking met de middelbare en oudere 
leeftijdsgroep. Dit kan het gevolg zijn van meer intensieve behandelingen die nodig zijn voor 
de subtypes van sarcomen die juist op jongere leeftijd voorkomen en meer angst voor 
terugkeer van ziekte. Ouderen werden minder vaak uitgenodigd voor deelname aan klinische 
studies wat overeenkomt met eerdere bevindingen die in hoofdstuk 5 zijn beschreven over 
lage deelname van oudere patiënten met sarcomen in klinische studies. Ook werden ouderen 
minder vaak voor revalidatie verwezen, terwijl chronologische leeftijd hiervoor geen bezwaar 
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Summary and General Discussion 
This PhD thesis describes the results of two principal projects. The first part concerns the 
quality of life, preferences and expectations of patients with metastatic or locally-advanced 
soft tissue sarcoma commencing treatment with palliative chemotherapy, and how the 
findings of the HOLISTIC study can be used to provide personalised care for this patient 
group. The second part is focused on age-specific outcomes of patients with metastatic or 
locally-advanced soft tissue sarcoma, and age-specific experiences of patients with both soft 
tissue and bone sarcomas.  In this chapter, the main findings of the thesis will be summarised 
and further recommendations for clinical care and future research will be considered.  
Summary  
Chapter 1 provides a general introduction to this thesis, including the epidemiology of 
sarcomas, current focus in personalised medicine, patient-reported outcomes and age-specific 
considerations.  
Part 1: Health-related quality of life  
Patient-reported outcomes (PROs), such as health-related quality of life (HRQoL), are 
increasingly acknowledged to be invaluable for patient-centred care, clinical decision-making 
and informing health policy.
1–3
 Clinical trials have historically focused on radiological 
response, progression-free survival and overall survival as measures of treatment efficacy, 
while HRQoL has not been measured in a structured way. Patients with advanced STS often 
have complex symptoms and a poor prognosis, however there is a paucity of HRQoL 
literature for this group of patients.
4
  
Chapter 2 describes the protocol for the HOLISTIC study (ClinicalTrials.gov: 
NCT03621332); a prospective observational cohort study measuring HRQoL in patients with 
advanced STS treated with palliative chemotherapy. Eligible patients, aged ≥18 years with 
advanced STS were recruited from specialist sarcoma centres in the UK and the Netherlands. 





Questionnaires were completed through the PROFILES (‘Patient-Reported Outcomes 
Following Initial treatment and Long term Evaluation of Survivorship’) registry. The 
PROFILES registry was established in the Netherlands (2008) for the study of the physical 
and psychosocial impact of cancer and its treatment on cancer survivors.
5
 Participants were 
invited to complete questionnaires at baseline, each cycle of chemotherapy, and 2-3 monthly 
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during follow-up. Questionnaires included quality-quantity questionnaire, decisional conflict 
scale, control preferences scale, EORTC-QLQ-C30 and EORTC financial toxicity items. The 
primary aim of the HOLISTIC study is to determine how global HRQoL changes from 
baseline to after four cycles of palliative 1
st





-line chemotherapy were included to explore HRQoL further along their 
treatment trajectory. Importantly this study has demonstrated feasibility of collecting 
electronic patient-reported outcomes (ePROs) in advanced STS patients across the age 
spectrum, and in two countries with different languages. 
Participants for the HOLISTIC study were recruited consecutively between February 2018 
and March 2020. Baseline findings were reported in Chapter 3. One hundred and thirty-
seven participants completed the baseline questionnaire (UK n=72; Netherlands n=65). 
Participants had a median age of 62 (27-79) years. Quality of life and length of life (LoL) 
were both considered to be important treatment outcomes, however patients were slightly 
more likely to prioritise LoL than quality of life. Consistent with previous studies in 
advanced cancer patients, younger patients (39 years) prioritised extended LoL; conceivably 
due to hopes and expectations of life and the injustice of incurable cancer at a young age.
7–11
 
Conversely, two-thirds of elderly patients (aged 65 years) indicated that QoL was at least 
equally as important as LoL. This provides support for (co)primary or composite quality of 
life endpoints in clinical trials for patients with advanced STS - particularly trials for older 
patients.
12
 Early discussion of patient values is needed to ensure decisions are aligned with 
individual priorities.  
Decisional conflict was most common among patients who prioritised quality of life over 
length of life (Chapter 3). One of the key factors contributing to decisional conflict is 
inadequate knowledge and understanding of the risks and benefits of treatment approaches.
13
 
Decisional conflict in advanced STS patients who prioritised quality of life may therefore be 
at least partly due to limited information about the impact of chemotherapy on HRQoL. 
Availability of HOLISTIC study data may reduce decisional conflict, as more information 
about HRQoL during and after chemotherapy may reduce uncertainty about treatment 
choices.  
Shared decision-making is considered the optimal approach for patient-centred care. The 
majority of HOLISTIC study participants desired some degree of a collaborative role in 
treatment decisions, while a minority preferred a fully-active or fully-passive role (Chapter 




3). Dutch participants were significantly more likely to prefer an active role (active or active-
collaborative) compared to UK participants. Gender and performance status also influenced 
preferred roles in decisions. Others have also shown that patients with a terminal illness tend 
to desire more involvement in decisions further along their disease trajectory.
14–16
 
Reassuringly, actual roles in decisions about chemotherapy were generally concordant with 
preferred roles, however these data again demonstrate that individual preferences are 
influenced by multiple factors, highlighting the need for a personalised approach to decision-
making.  
Treatment expectations were explored in Chapter 3. The vast majority of advanced STS 
patients starting palliative 1
st
 line chemotherapy believed that chemotherapy would prolong 
survival and help them with problems caused by their cancer. Although the impact of 
chemotherapy on survival is not certain, median overall survival for patients with advanced 
STS has improved over recent years, due to the availability of new drugs, histological-
subtype tailored approaches and better supportive care.
17,18
  Most HOLISTIC study 
participants indicated cure was not possible, however patients from Black, Asian and 
minority ethnic (BAME) backgrounds were significantly more likely to indicate that cure was 
(at least) a little likely. Different beliefs and hopes in patients from BAME groups may have 




Part 2: Age-specific considerations 
Sarcomas can affect patients across the age spectrum and differences in disease biology, 
treatment and psychosocial factors and should be considered in providing age-specific care.  
Adolescents and Young Adults 
Although cancer occurring at a young age is uncommon, sarcomas are among the most 
prevalent cancers in adolescents and young adults (AYA), and around 10% of sarcomas occur 
in children or AYAs.
21
 Sarcomas generally have an inferior prognosis compared to other 
cancers affecting this age group, such as leukaemias and germ cell tumours.
22
 Approximately 
half of patients with high grade sarcomas will develop metastatic disease, which has a 
significant impact on disease-related mortality in AYA. Histological subtypes commonly 
affecting AYA, such as alveolar rhabdomyosarcoma and Ewing sarcoma, require an intensive 
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multimodality approach including chemotherapy, radiotherapy and surgery; associated with 
short- and long-term adverse consequences.  
In Chapter 4, treatment patterns and outcomes of 455 AYA patients (aged 18-39 years) with 
metastatic STS treated at a specialist sarcoma centre were described. Although the median 
overall survival (19 months) was slightly better than the accepted median survival in adults 
with advanced STS (12-18 months), this represents significant loss of years of life and 
highlights the need for more effective treatments.
23
 Patients with histological subtypes that 
are typically sensitive to chemotherapy in children, such as rhabdomyosarcoma and Ewing 
sarcoma, had particularly poor outcomes. Other histological subtypes, such as alveolar soft 
part sarcoma, demonstrated more indolent behaviour. This study included patients with 
twenty-two distinct STS histological diagnoses, with a wide range of clinical outcomes 
between and within subtypes. This demonstrates the extensive heterogeneity of STS in AYA, 
and the need for greater understanding of the biological differences of STS arising in AYAs 
compared to histologically similar tumours in paediatrics.  
A significant number of AYA patients received chemotherapy in the weeks and short months 
preceding death. High intensity end of life care among AYAs with cancer has been well-
documented.
11,24,25
 Delivery of intensive treatments may also be driven by the injustice of 
advanced cancer at a young age, and a desire or patients, families and oncologists to treat 
despite a limited chance of benefit.
11
 This finding is supported by baseline HOLISTIC study 
findings (Chapter 3), which demonstrated that all patients aged <39 years starting 1
st
 line 
palliative chemotherapy prioritised length of life over quality of life. Previous research has 
shown that preference for LoL over quality of life is associated with less willingness to 
discuss forgoing cancer-specific treatment.
26
 Discussions surrounding prognosis and the risks 
and benefits treatments are necessary to avoid over-treatment towards the end of life, 
however it is important to ensure that an individualised approach is taken to allow patients 




Global increases in life expectancy have had an unprecedented impact on the proportion of 
elderly people in the population. Elderly patients with cancer have historically been under-
represented in clinical trials, resulting in a limited evidence base and extrapolation of data 
from younger patients.
28
 Chronological age and (mis)perception of frailty and tolerability 
often lead to empirical dose reductions resulting in under-treatment or over-treatment of 






 Although almost half of STS are diagnosed in patients aged 65 years, data on 
the outcomes of elderly patients with STS are limited.  
In Chapter 5, a pooled analysis of twelve EORTC-STBSG trials of first-line chemotherapy 
for patients with advanced STS, between 1980 and 2012, was performed to compare the 
outcomes of elderly patients with younger patients within the setting of international clinical 
trials. This analysis demonstrated that elderly patients, defined as aged 65 years, accounted 
for 12% of all trial participants, and had a median age of 68 years. Encouragingly, one third 
of participants in the more recent SARC021 trial (recruitment 2011-2014) were aged 65 
years, and had a slightly older median age of 70 years (Chapter 6). Elderly patients (aged 
65 years) had slightly worse overall survival in both analyses compared to younger patients 
(EORTC-STBSG: elderly 10.8 months vs. 12.3 months patients aged <65 years; SARC021: 
elderly 16.7 months vs. 20.1 months patients aged <65 years) indicating that older age is an 
adverse prognostic factor for survival even in a highly selected group of elderly patients with 
good performance status (ECOG 0 or 1). Importantly, in the SARC021 trial, rates of toxicity 
were significantly higher in elderly patients, with 85% experiencing adverse events of 
CTCAE Grade 3 or higher (Chapter 6). Given that many elderly patients believe that quality 
of life is at least equally as important as length of life, these findings emphasise the need for 
more tolerable treatments and optimisation of supportive care.
32
  
Despite significantly higher rates of adverse events in older patients (aged 65 years) and 
those treated with combination versus single-agent chemotherapy, no significant differences 
in quality of life scores were identified in the SARC021 study (Chapter 6).
33
 Tools used to 
assess quality of life in this study included the EQ-5D and EQ-VAS, which are both generic 
measures with a limited number of items. Furthermore, only one quarter of study participants 
completed questionnaires at baseline, limiting the interpretability of study findings. It is 
uncertain why so few patients took part in these assessments, however this may have been 
due to logistical barriers, failure to prioritise in a busy clinical setting, or lack of familiarity 
with HRQoL measures. In view of the importance of quality of life to many older patients, 
consideration should be given to prioritising these assessments.
32
 The International Society of 
Quality of Life Research (ISOQoL) have published guidelines to support and educate 
researchers with designing, performing and reporting clinical trials which include patient-
reported outcomes.
34,35
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In addition to age-specific outcomes, age-stratified patient-reported experiences were 
explored in Chapter 7. This chapter was based on a cross-sectional survey of 558 patients 
with STS and bone sarcomas in England. Several important age-specific differences were 
identified. In particular, AYA patients were vulnerable to delayed recognition of sarcoma, 
whereas elderly patients were more likely to be referred for specialist evaluation. Given that 
sarcomas are rare cancers, and cancer arising at a young age is uncommon, it is plausible that 
clinical suspicion may be low, however greater awareness of the possibility of sarcomas is 
needed among the public and healthcare professionals.
36
 This is particular important given 
that early diagnosis can reduce morbidity from treatment (e.g. local excision vs. amputation) 
and may improve survival for patients with certain subtypes.
36–38
 There was also significant 
heterogeneity in the most common presenting symptoms according to age and tumour 
subgroup (bone vs. STS), emphasising the complexity of sarcomas and need for education 
and rapid referral pathways to specialists.  
This survey also demonstrated that AYA were significantly more likely to report most 
symptoms and post-treatment psychological concerns compared to middle-aged and elderly 
patients (Chapter 7). This may be due to the intensive treatments used to treat the most 
common histological subtypes occurring in AYA patients. Psychological challenges such as 
fear of cancer recurrence are well documented in young cancer survivors.
39
 Elderly patients 
were less likely to be offered participation in clinical trials, consistent with the findings of 
previous chapters which demonstrated that elderly are under-represented in research studies. 
Referral for rehabilitation was also uncommon in elderly patients, however chronological age 
should not be a barrier to interventions such as physiotherapy which may improve 
functioning and HRQoL.
29
 Elderly were generally more satisfied with their care and 












The studies presented in this thesis are focused on enhancing personalised care for patients 
with sarcomas. The HOLISTIC study is the first study to assess longitudinal HRQoL in 
patients with advanced STS treated with palliative chemotherapy. Heterogeneity in patient 
preferences and expectations were demonstrated, emphasising the importance of an 
individualised approach to treatment discussions. The second part of the thesis focused on 
age-specific differences in outcomes and experiences, highlighting the importance of age-
stratified approach to the care of sarcoma patients.  
Sarcoma-specific patient-reported outcome measures 
One of the challenges with measuring HRQoL is that its meaning is unique to each 
individual.
40
 Many existing patient-reported outcome measures (PROMs) used to measure 
HRQoL consist of a standard list of items, which may not capture all aspects that are 
important to a patient and therefore lack content validity.
40
 Pre-defined clinically meaningful 
differences in scores may not be applicable across all cancer types and subtypes. This issue is 
particularly relevant in sarcomas, due to the heterogeneity of this group of tumours. Sarcomas 
can arise in patients of any age, at almost any anatomical location and there are more 100 
histological subtypes with widely variable clinical behaviour (between and within subtypes). 
It is therefore not surprising that a sarcoma-specific PROM(s) has not yet been developed.  
The EORTC-QLQ-C30 is one of the most commonly used tools to measure HRQoL in 
patients with cancer and was used to collect HRQoL data in the HOLISTIC study. 
Advantages of using the EORTC-QLQ-C30 in HRQoL research include availability of 
translations in more than 100 languages, existing data across multiple cancer types (and 
disease stages) and normative population values as potential comparator groups. Although the 
EORTC-QLQ-C30 includes symptoms that are common in advanced STS patients (e.g. pain, 
fatigue) and frequent chemotherapy toxicities, a recent study reported that changes in 
EORTC-QLQ-C30 scores may not adequately address qualitative descriptions reported by 
advanced STS patients within certain domains, such as loss of independence.
41
  
In order to address the issue of content validity, several groups are investigating whether it is 
possible to develop a sarcoma-specific PROM(s) or whether other innovative approaches are 
needed. The EORTC Soft Tissue and Bone Sarcoma Group in collaboration with the EORTC 
Quality of Life Group (QLG) are currently evaluating this question (ClinicalTrials.gov: 
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NCT04071704). An initial literature review has suggested that patients with localised disease 
may have more heterogeneous issues, whereas there may be more similarities among patients 
with advanced disease (e.g. constitutional symptoms such as fatigue).
42
 Anatomical location-
specific questionnaires were proposed as a potential solution to address symptoms caused by 
the primary tumour, such as the EORTC-EN-24 endometrial carcinoma module for patients 
with gynaecological sarcomas, however this may not be appropriate due to different patient 
characteristics and treatment regimens.   
One option would be to combine a standardised list of items (so-called ‘static’ 
questionnaires) with selected items from item libraries. For example, a recent project for 
patients with haematological malignancies exemplified how literature review and interviews 
(patients and clinicians) could be used to identify conceptual gaps in the EORTC-QLQ-C30, 
and subsequently select supplementary items to enhance content converge for that group of 
patients.
43
 Interviews among sarcoma patients have been held and will be used to develop a 
list of issues affecting patients. This item list will soon be tested with patients and healthcare 
providers in order to identify the most relevant and important issues.  
Electronic patient-reported outcomes in clinical practice 
The HOLISTIC study was designed for research purposes and electronic patient-reported 
outcome (ePRO) data will be analysed at the end of the study. The benefits of ePRO data are 
widely recognised, including convenience, accuracy and potential for large scale data 
collection.
44
 Others have also shown that ePRO data can also be retrieved and interpreted in 
real time. Real-time feedback of ePRO data can allow immediate recognition of toxicities in a 
clinical context.
45
 This is particularly important given that physicians commonly 
underestimate the frequency and severity of adverse events.
46
 This model also has potential to 
advance personalised, patient-centred care, ensuring that the effectiveness of a treatment is 
determined though interpretation of ePRO data alongside traditional clinical data.
47
 
Immediate feedback of ePRO data to patients, such as symptom charts, may also enhance 
adherence with therapy, which may be reflected in improved clinical outcomes.
45,48
 
Electronic PROs can also be used to provide tailored advice and support to patients at home, 
providing reassurance and empowering patients in self-management.
49
 Studies have shown 
numerous other benefits of collecting ePROs, including enhanced communication, greater 
satisfaction with care, improved HRQoL and prolongation of survival.
3,50,51
  Further research 




is needed to determine the best way use of ePROs to improve personalised care for sarcoma 
patients. 
Eliciting patient preferences 
Treatment decisions for patients with advanced STS are often complex. Data from the 
HOLISTIC study demonstrate significant heterogeneity in preferences and priorities of 
patients with advanced STS. Although it is acknowledged that patient values are an important 
aspect of patient-centred care, research suggests that many patients feel that their preferences 
are not assessed, or are discordant with provider interpretation.
52–54
 Eliciting patient 
preferences may be challenging, however previous studies have shown that integration of 
patient values into treatment decisions improves communication, satisfaction and improves 
the quality of care.
10,52,55–57
 However, preferences are not ‘static’ and appraisal of priorities 
across the disease trajectory is necessary to identify change in priorities.
55
 Follow-up data 
from the HOLISTIC study will be informative on how patients’ priorities change throughout 
the treatment trajectory, as well as decisional regret.  
Decision aids have previously been used to prepare patients for making decisions which 
involve a degree of scientific uncertainty.
10,58–60
 Decision-aids, can improve knowledge about 
treatment options (risks and benefits) and may reduce decisional conflict, however they are 
relatively inflexible and there is limited evidence that they improve congruence between 
patient values and their chosen option.
61–63
 A Discrete-Choice Experiment (DCE) is an 
alternative method to elicit preferences, based on the value which patients place on certain 
attributes of therapeutic options.
64,65
 DCEs focus on quantifying the trade-offs that patients 
are willing to accept for a particular benefit, asking participants to choose between pairwise 
comparisons of hypothetical alternatives.
65
  This method may be more representative of real-
life decisions involving a trade-off between characteristics and their levels.
65
 Ivanova et al 
recently carried out a DCE for 76 patients with advanced STS.
66
 Participants were asked to 
choose between hypothetical pairs of treatment profiles, including varying levels of survival, 
response rates, hospitalisation and days to administer treatment.
66
 Results indicated that 
patients preferred a treatment that prolonged their survival while avoiding hospitalisation, 
however this study did not include any HRQoL, functioning, symptom or side-effect 
attributes. Further work is needed to determine an appropriate design for a DCE in patients 
with advanced sarcomas, and evaluate its use in larger patient samples.    
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Personalising treatment discussions and prognosis 
The vast majority of participants in the HOLISTIC study believed that palliative 
chemotherapy would extend survival and around one quarter indicated that chemotherapy 
could be curative. Although physicians expectations were not assessed in the HOLISTIC 
study, discordance between patient and physician expectations of treatment benefits and 
prognosis has been widely reported.
67–71
 Patients’ overestimation of prognosis appears to be 
related to several factors including ineffective communication, unwillingness to acknowledge 
poor prognosis, and lack of agreement between patients and their clinicians.
72,73
  Evidence 
indicates that doctors may be reluctant to discuss treatment goals and prognosis due to 
concerns that this may take away hope, make patients depressed, perception that disclosure is 
not culturally appropriate or because they find such discussions emotionally upsetting.
74
 Yet, 
several studies in advanced cancer patients have shown that realistic discussions about 
prognosis do not cause higher rates of worry, depression or loss of hope, and may reduce 
distress.
26,74–76
 Of note, these studies included predominately White patients in developed 
countries, and may therefore not be generalisable to all cultures. Hope can be maintained 
through setting realistic goals in the setting of incurable disease.
27,77
 Early discussions about 
patient values and the goals of treatment, may also help to guide management decisions and 
facilitate timely advanced care planning; associated with lower rates of ventilation and ICU 
admission, earlier hospice referral and better quality of life.
11,55,75
 Furthermore, although there 
may be ethnic or cultural differences in desire for information, individual views are more 
relevant than broad preferences of a ‘group’ and assumptions should be avoided.
74
 
Patients with advanced STS are generally given an estimated prognosis based on median 
overall survival data and the clinical features of their disease. Patients with unfavourable 
features, such as rapid disease progression, may be advised that life expectancy is likely to be 
shorter than average. Conversely patients with favourable clinical features, such as low grade 
tumours, may anticipate better survival.
78
 Could HRQoL data be used to provide more 
accurate, personalised prognostic estimates? A recent study of almost 7,000 patients with 12 
cancer types, demonstrated that HRQoL (EORTC-QLQ-C30 summary score) was an 
independent prognostic factor for survival.
79
 This study did not include sarcoma patients and 
therefore further research is needed to determine if these findings are applicable in sarcoma 
patients. Integrating individual HRQoL scores with clinical, radiological, molecular and 
genomic data could enable more accurate estimates of prognosis for individual patient. Large 
scale ePRO data collection and incorporation with clinical outcomes, ‘Big Data’, would be 









Sarcomas can develop in patients of any age, however the disease biology and incidence of 
individual histological subtypes varies across the age spectrum. Furthermore, patients 
encounter age-specific psychosocial challenges, which should be considered in the provision 
of holistic patient care. This thesis focused on the age-specific outcomes and experiences of 
adolescents and young adults (AYAs, aged 18-39 years) and elderly patients (aged >65 
years).  
One of the strengths of the AYA study was the high number of histological subtypes 
described. Availability of these subtype-specific outcomes will help to guide more accurate 
prognostic discussions with patients and their families, based on behaviour of histologically 
similar tumours occurring in this age group; a caveat being that outcomes can vary 
significantly between histologically or morphologically similar tumours.
81
 Although 
outcomes were slightly better than accepted median survival in adult patients with metastatic 
STS, our data highlight the need for further research into the biological differences of 
sarcomas occurring in AYAs compared to paediatric patients and older adult patients. This 
will enable development of more effective and more tolerable treatments. Of note, this study 
included AYA patients diagnosed between 1990-2012, which was prior to the development 
and availability of several molecular-targeted therapeutic options for sarcomas. 
The World Health Organisation estimate that there will be nearly 1.5 billion people aged 65 
years by the year 2050.
82
 Older age is a risk factor for development of cancer due to 
cumulative acquisition of genetic anomalies and exposure to carcinogens, and almost half of 
STS are diagnosed in patients aged 65 years.83 The treatment of elderly patients with cancer 
is challenging, due to the complex interplay of physiological changes, comorbidities, 
polypharmacy, functional, nutritional and psychosocial issues, and their influence on disease 
biology, treatment tolerance, compliance and efficacy.
84
 
In view of the increasing elderly population, clinical trials specifically designed for older 
patients or innovative trial designs should be considered.
12,28
 For example an embedded 
study, with geriatric assessments of specific older cohorts, or extended trials, where older 
patients are added as a cohort to superior treatment arm.
28
 Consideration should also be given 
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altered pharmacokinetics of drugs in elderly patients (e.g. renal function and drug clearance), 
less toxic therapeutic options, optimisation of supportive care, hydration and avoidance of 
polypharmacy.
31
 Comprehensive geriatric assessments (CGA) can also be used to identify 
patients at risk of toxicity and poor outcomes, enable tailored interventions, modify and 
optimise oncological treatments.
85–87
 Specifically, The Society of Geriatric Oncology 
recommend evaluation of “functional status, comorbidity, cognition, mental health status, 
fatigue, social status and support, nutrition, and presence of geriatric syndromes.
85
 Research 
also suggests that optimisation of health through geriatrician-led interventions improves 
chemotherapy tolerance, leads to fewer treatment modifications, lower hospital admissions, 
better HRQoL and clinical outcomes.
88,89
 In view of the heterogeneity of sarcomas, and the 
heterogeneity in functional status of elderly patients, assessment of the utility of CGA and 
individualised, tailored interventions in elderly sarcoma patients is needed.  
Two-thirds of elderly participants in the HOLISTIC study indicated that quality of life was 
equally or more important than length of life. The EORTC TOLERANCE trial (collaboration 
between Soft Tissue and Bone Sarcoma Group, Quality of Life Group and Elderly Task 
Force) is a novel trial in development for elderly patients which will assess HRQoL as the 
primary endpoint. In this study, elderly patients are defined as aged 70 years, or aged 65-70 
years with a geriatric assessment score of 14 (impairment requiring comprehensive geriatric 
assessment). The primary objective will be to assess whether physical and role functioning 
differ between the three treatment arms (doxorubicin three-weekly, doxorubicin weekly or 
cyclophosphamide plus prednisolone), in order to demonstrate whether metronomic 
schedules have a lower burden on HRQoL compared to standard treatment.  
Age-specific differences in experiences of care provide further evidence for an age-stratified 
approach for the care of sarcoma patients across the disease trajectory. Although care for 
AYAs in the UK often falls between paediatric and adult services, other countries such as the 
Netherlands have more well-established AYA services.
90
 Initiatives in geriatric oncology 
have predominately occurred in well-developed countries.
91
 International collaboration and 





The HOLISTIC study did not include a comparator group of patients receiving best 
supportive care. Patients with histological subtypes that are not sensitive to chemotherapy, 




and patients who are frail or too unwell to receive treatment are not comparable to patients 
receiving chemotherapy. We therefore did not assess the preferences, priorities and HRQoL 
of patients who do not start chemotherapy and further work is needed to evaluate the 
priorities and HRQoL in this group of patients. Patients who chose not to participate in the 
HOLISTIC may have declined due to higher levels of anxiety, stress or worry about 
treatment. These patients may have been more willing to take part in research at a later stage 
in their treatment pathway. Other modes of capturing the priorities of patients who were not 
included in the HOLISTIC study could also be considered, such as patient interviews or focus 
groups.  
The quality-quantity questionnaire and decisional control preference scale are validated 
scales used to assess preferences for quality versus length of life, and preferences for role in 
treatment decisions, however do not elicit the underlying psychological variables which 
influence preferences. Recognition of values which influence preferences may further 
understanding of why patients feel a certain way, and enhance discussions between patients 
and clinicans.
92
  Satisfaction with decisions and relationship between patients’ preferred and 
actual roles in decisions may be another interesting aspect of care to explore.  
Although expectations of chemotherapy were assessed, patients and clinicians were not asked 
about their views on prognosis. Further research could evaluate whether understanding of 
prognosis in patients with advanced STS is congruent between patient and clinicians. 
Furthermore coping mechanisms used by patients with advanced STS, and the variables 
which influence coping styles may provide insight into the strategies used when faced with a 
life-limiting disease in this patient group.  
‘Real-life’ outcomes of AYAs were reported, however all patients were treated at a specialist 
sarcoma centre in the UK and therefore outcomes may not be generalizable. The majority of 
the patients in this study were also treated prior to development of most current targeted 
therapeutic options, and access was limited in the UK due to lack of funding or 
reimbursement. Conversely, patients referred to specialist centres may have disease which is 
particularly challenging to treat. Elderly patients treated in international randomised 
controlled trials were ‘elite’ older patients with an excellent performance status. Although 
these patients do not represent the known heterogeneity in functional status of elderly 
patients, these data demonstrate progress towards expanding the evidence base for elderly 
patients and the need for broader eligibility criteria.  
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Patient and public involvement 
Patient and public involvement (PPI) in clinical research has gained momentum over recent 
years, often accompanied by the phrase ‘nothing about me, without me’. A number of 
reviews have demonstrated the benefits of engaging patients (e.g. patient empowerment and 
ensuring patient-centered care) and challenges such as logistics, resources (time, cost) and 
limited validated frameworks.
93–96
 This thesis has demonstrated how patient-reported 
outcomes, patient preferences and patients experiences can be used to enhance personalised 
care. However, “a study is not patient centered simply by measuring patient preferences.”
97
 
Involving patients at appropriate stages of research design and development will ensure that 
their priorities are considered and research remains patient-orientated. Integrating patients 
and public contributions with expertise of providers and researchers will optimise the 
relevance and quality of research.
93
 For example, in order to design trials that are appealing to 
older adults, researchers should consider how to incorporate patient priorities into trial design 
and develop relevant outcome measures.   
Sir Roger Wilson is the co-founder of Sarcoma Patients Euronet (SPAEN) and Sarcoma UK 
cancer charity, and is the chair of the EORTC patient panel. As a sarcoma patient and patient 
advocate, he has been instrumental in ensuring that the ‘patient voice’ is heard, and that value 
is found in research.
98
 He believes that patient advocacy and partnership with specialists can 
address many of the challenges in sarcomas, helping to ensure that patients have access to 
information about trials, and involvement in national research programmes.
98
   
The Angiosarcoma Project (ASCproject) was a recent example of how patient-partnered 
research could be used to study a sarcoma subtype with a low incidence.
99
 Patients in the 
ASCproject remotely shared clinical details and biological specimens, enhancing 
understanding of aetiology and enabling identification of potential therapeutic targets.
99
 In 
another novel study, patients with epithelioid haemangioendothelioma (EHE) (incidence 1 
per million/year) were recruited through the Facebook EHE support group to complete 
electronic questionnaires to study HRQoL.
100
 Collaborative efforts and international studies 
are needed to improve knowledge, care and outcomes for patients with sarcomas. These 
innovative patient-centered approaches are examples of how futures studies for patients with 
rare and ultra-rare subtypes of STS can be performed. Encouraging patients to have an active 
voice in research will improve understanding of patient-reported outcomes. Furthermore, 




larger scale analysis of tumour biology may enable more rapid advances in treatment options, 
ultimately aiming to improve clinical outcomes.  
Further research directions  
This thesis has highlighted the need for further HRQoL studies in sarcoma patients, including 
development of more precise sarcoma-specific HRQoL questionnaires. Although there is 
increasing recognition of the importance of PROs in clinical trials and routine clinical 
practice, support for research in this field is not easy to acquire. Given the increasing global 
focus on patient-centred care, it could be considered that funding for these studies and 
implementation in daily clinical practice should be funded by health insurance companies or 
national health services.  
This thesis has considered outcomes and experiences of specific age groups, however other 
vulnerable groups require further study. For example, studies have shown that patients from 
Black, Asian and ethnic minority backgrounds report worse experiences of care and 
inequalities in outcomes are well documented.
19
 Further work is needed to address barriers to 
effective communication in patients from different cultural backgrounds, including 
translation of materials into native languages and consideration to the most appropriate mode 
of information delivery (e.g. printed, online, video).
19
 Due to the rarity of sarcomas, care is 
centralised in expert references centres, which may be geographically distant from patients’ 
homes.
101
 Access to care for patients who are isolated from specialist centres may improve 
through greater provision of telemedicine.
102
 Rapid enforced changes during the COVID-19 
pandemic exemplified how care could be delivered remotely for a high proportion of patients, 
with high acceptability, time and cost saving implications.
102
 This is of particular importance 
to patients who are under-privileged or in lower socioeconomic groups; travel expenses may 
be a significant burden and taking time off work for hospital appointments may not be 
possible.  
Concluding remarks 
In the current era of personalised medicine, the primary emphasis has been on clinical, 
genetic and molecular characteristics, with little attention given to individual patient 
perspectives. In order to enhance personalised care, patient preferences and patient-reported 
outcomes should also be integrated into routine clinical practice. Age-specific differences in 
sarcoma disease biology, and psychosocial issues encountered across the age-spectrum 
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should be considered in order to provide an individualised, holistic approach to care. In order 
to design trials that are appealing to patients, we should engage patients in clinical trial design 
and ensure that outcomes are relevant to patients. The ultimate goal is to deliver high quality 
care for every individual. “Quality is never an accident; it is always the result of high 
intention, sincere effort, intelligent direction and skilful execution; it represents the wise 
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Research Data Management 
This thesis is based on the results of human studies, which were conducted in accordance 
with the principles of the Declaration of Helsinki. The HOLISTIC study (Chapter 2 and 3) 
was approved by the Heath Research Authority and Research Ethics Committee of the United 
Kingdom (REC reference 17/NI/0197) and in the Netherlands at each participating centre 
(Radboud University Medical Centre and UMCG: 2018-4151, Erasmus medical Centre: 
MEC-2018-1101, Leiden University Medical Centre: P18.179 P1a, Antoni van Leeuwenhoek 
hospital: 2018-12-04 18.453). 
Baseline data described in chapter 3 are stored securely on the Royal Marsden Hospital server 
(F:): dept apps/sarcoma unit/ PROFILES UK/ PROFILES CTU/ OPEN research studies/ 
CCR4782/ Study output, under the file name ‘Baseline HOLISTIC data’  
All participants signed an electronic informed consent form which is stored on the 
PROFILES server based on the Netherlands. Patients who completed paper questionnaires 
are stored in the Sarcoma Research offices, room 24. Paper data were entered using the 
PROFILES data entry portal. Privacy of study participants was ensured by providing unique, 
individual subject codes which were stored separately from study data. Data will be saved for 
25 years after termination of the study.  
Chapter 4 was approved as a service evaluation by the Royal Marsden Hospital Committee 
for Clinical Research (SE 670). The patient data for this analysis is stored on the sarcoma unit 
Royal Marsden Hospital server (F:) Dept Apps/Sarcoma Unit/AYA Service Evaluation 
670/AYA metastatic study. Privacy of study participants was ensured by providing unique, 
individual subject codes which were stored separately from study data. Data will be saved for 
25 years after termination of the study. 
Data for Chapter 5 are stored at the Department of Statistics at the EORTC headquarters in 
Belgium. Ethical approval for this sub-analysis was not required.  
Data for Chapter 6 are stored in the Department of Statistical Medicine, Weill Cornell 
Medicine, New York, USA.  Ethical approval for this sub-analysis was not required. 
Data for Chapter 7 are stored on the Royal Marsden Hospital server (F:) Dept Apps/Sarcoma 
Unit/Sarcoma UK age-specific analysis.  All datasets analysed during these studies are 
available from the author on reasonable request.  
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